annual repor johnson johnson continue bring meaningful innovation people world live well healthy life deeply commit dedicated people use product employee community live work shareholder important lose sight cover matt cox type diabete use waterproof animas vibe insulin pump swam english channel relay raise money juvenile diabetes research foundation matt want son jack type diabetes condition need hold life read matts story chairman letter shareholder hroughout annual report year ll read severe economic decline tighten consumer johnson johnson bring meaningful spending health care budget overthecounter otc innovation patient customer make product quality issue mcneil consumer healthcare difference live personal wayfrom recall depuy asr hip system brunhilde wecker recovery stroke company severely test thank new blood clot retrieval removal device manage stretch rely heavily resolve bill hait oncologist vision insight people timeteste business model broad help accelerate approval wholly new treatment base health care decentralize management structure prostate cancer manage long term value set forth credo story remind health care rewarding necessary restructuring business manage endeavor excite future johnson johnson cost structure simplify operation ensure past year navigate steadily efficient use capital longterm benefit patient series significant challenge keep longterm perspective shareholder maintain discipline approach management team employee manage investment growth take critical action preserve core portfolio broadly base business value strength business stay true operating model remain committed retain value turn corner trust patient customer take particularly difficult period responsibility institute new measure year johnson johnson ensure product live celebrate th anniversary high quality standard customer return sale growth launch expect deserve number innovative new product come close moved address unmet health care need turn point headwind patent globe advanced pipeline expiration tough portfolio choice litigation today good industry matter otc product quality issue strengthen product portfolio address leadership position area time continue include immunology oncology surgical william c weldon investments research development chairman board director device emerge market rd equal nearly billion chief executive officer focus scientific innovation maintain past year yield major approval build share key growth market new pharmaceutical product deliver meaningful innovation health care united statesincluding stelara ustekinumab simponi build agile company seize market opportunity golimumab immunology prezista darunavir ve remain committed credo intelence etravirine hiv zytiga abiraterone acetate longheld value enable succeed decade oncology xarelto rivaroxaban cardiovascular disease continue face difficult uncertain emphasis place rd lead exciting macroeconomic condition ongoing investment innovation medical device diagnostic mdd positioned grow increase market leadership consumer platform contact lense electrophysiology important rewarding industry world advanced energy biosurgical oral care skin care deliver sustainable growth shareholder replenish advanced pipeline new technology like fibrin pad hemostasis fiveyear journey compound like canagliflozin diabete bapineuzumab year ago set build strong foundation alzheimer disease sustain track record growth prepare focus financial discipline capital address daunt challenge patent expiration return shareholder form dividend share major drug risperdal risperidone topamax repurchase capital important longterm topiramate product combine peakyear investment strategic alliance acquisition like pfizer sale billion prepare consumer healthcare beijing dabao cosmetics company ltd market issue good line sight consumer business crucell nv elan corporation plc additional development easily foresee pharmaceutical business pende acquisition chairman letter synthes inc mdd business create demand health care population look face period industry develop world aging rapidly consume global change manage proud health care grow old global expansion growth people johnson johnson show ingenuity slow year ago lead grow resiliency tenacity integrity compassion demand health care especially emerge market expect global leader human health care investment continue align market opportunity address unmet medical need cancer result mental health disorder diabete heart disease stroke johnson johnson return deliver operational sale growth rheumatoid arthritis hiv grow adjust earning th consecutive year significant diseasesand market today worldwide sale billion increase percent leadership increase investment gain sale increase operationally percent reflect strength leadership new product launch pharmaceutical business segment steady performance mdd franchise sciencebase g overnment payer regulator health care reform innovation consumer business strong growth evolve world government require emerge market costeffective health care solution approximately percent sale product recognize priority make investment global market share position approximately personalize medicine companion diagnostic percent sale product introduce past especially area oncology antipsychotic year gear well target treatment continue focus financial discipline adjust monitor result efficient product development earning billion adjust earning share regulatory environment represent increase percent percent intense share common goal regulator save life respectively ease people suffer address unmet medical need invest billion rd advance robust pipeline meaningful innovation support strong regulatory business segment environment ensure patient safety enable generate significant free cash flow approximately fast efficient approval potentially lifesave medicine billion maintain aaa credit rating increase treatment dividend shareholder th consecutive year industry trend bring new innovation market solid consistent return shareholder require significant investment access good mind hallmark johnson johnson generate talent adaptability everchange market oneyear total shareholder return nearly percent exceed important company agile standard poor dow jones industrial average collaborative able thrive new business model long timeframe continue compare favorably look complement development index longterm management focus company effort acquisition collaboration help remain solid investment choice decade detail gain new capability provide access technology business segment highlight page product compound accelerate market collaboration alzheimer disease elan pfizer force shape health care hiv gilead sciences inc look ahead major force shape health promising ventures care environment macroeconomic condition role government payer regulator industry trend clearly position growth pose continue challenge inherent overall johnson johnson position address opportunity seize evolve market force opportunitie macroeconomic condition slow economic growth b ecause way deliver meaningful innovation uncertainty financial market high unemployment patient customer pressure health care cost contribute b ecause step take build agile company constraint health care spending dynamic balance demographic trend nd commitment operating model net sale dilute earning share dividend pay share billion dollar dollar dollar johnson johnson annual reportvalue enable consistent track record approach decision patient customer success employee communitie shareholder year offer significant challenge achieve meaningful inno vation commitment credo remain foundation learn path achieve meaningful response provide common set value hold innovation step identify significant unmet approximately employee country need market opportunity believe johnson johnson operating company difference patient responsibility global citizen root credo look area capability insight year innovation philanthropy unique advantage shape opportunity touch life billion people particularly area search inside outside company find late world access basic health care challenge science research address need addition honor recognize united rd use strategic alliance licensing arrangement nation humanitarian year work regard acquisition venture capital investment insight report strong progress inaugural year fiveyear access big breakthrough finally leverage pledge help save improve live million woman breadth resource development supply chain child annually develop country marketing sale bring innovative product market united nations millennium development goal pharmaceutical business follow model proud program drive pursuit well treatment hepatitis c cardiovascular passion employee hundred equally passionate disease hepatitis c infect million people partner world worldwide partner vertex pharmaceuticals inc development telaprevir approve commitment market incivo europe honor privilege serve chief partner bayer healthcare executive officer past year success development launch xarelto prevention deep develop outstanding leader johnson johnson vein thrombosis knee hip replacement surgery reflect selection alex gorsky ceo lead reduce risk stroke systemic embolism patient great company forward effective april date nonvalvular atrial fibrillation annual meeting shareholder decision involve time choose acquisition broaden rigorous thorough formal multiyear process portfolio new capability gain entry new piece alex experience discipline leader market technology not pipeline rein company turbulent time health care case revive se device innovative promising time johnson johnson product help save mrs weckers life come assure shareholders johnson johnson acquisition micrus endovascular llc continue shape lead future health care important new option treatment ischemic stroke deliver meaningful innovation patient case fibrin pad start strategic partner customer build agile business seize new market israelbase omrix pharmaceuticals ltd working solve opportunity remain commit prove operate unmet medical need surgical bleeding collaboration model set value embody credo develop determined acquisition allow proud well manage complex development intricate regulatory thank extraordinary achievement dedication filing necessary achieve success convergent product people johnson johnson well position today anxiously await surgeon time recent history deliver sustainable growth approach use broad base business loyal shareholder expertise tackle disease state multiple front diabete example offer device like blood glucose monitor insulin pump develop new drug canagliflozin help patient consumer achieve healthy william c weldon live consumer wellness prevention business chairman board director chief executive officer nutritional product splenda sweetener march operate agility base trong value important way innovate way operate focus improve operation reflect commitment deliver highquality product adapt rapidly evolve marketplace meaningful innovation agility foundation decade sustained growth remain unwavere exclude special item commitment operating model value f ree cash flow define operate cash flow capital spending tenet credo provide clear focus reconciliation nongaap financial measure chairman letter business segment highlight fter challenging year collaboration company like pharmacyclic inc jointly develop market anticancer johnson johnson return compound building strength oncology deliver operational sale term pipeline progress leader new molecular entity approval zytiga growth continue oncology xarelto rivaroxaban cardiovascular strengthen platform leadership disease edurant rilpivirine hiv progress pharmaceutical business segment result profitable growth new commitment continued investment product launch product launch strong pipeline pipeline compound investment key growth area medical device diagno stic billion sale medical device johnson johnson distinct business segment diagnostic mdd business unit large medical device share common focus human health business world operational sale growth percent pharmaceutical year see challenge mdd market billion sale eighth large issue depuy asr hip system recall european pharmaceutical business world sixth large austerity measure pricing pressure slowdown elective biotech business strong operational growth percent surgery drive continued economic pressure drive recently launch product like stelara contribute temper growth rate despite ustekinumab simponi golimumab zytiga abiraterone challenge mdd business segment compete acetate incivo telaprevir invega sustenna global market undergone dynamic change paliperidone palmitate mdd show strong doubledigit growth build continue success recently bric brazil russia india china market launch product strengthen leadership position introduce innovative product core therapeutic area include immunology infectious asiapacific europe roll disease neuroscience oncology product launch day acuvue moist brand contact lense johnson johnson lead united astigmatism state new pharmaceutical product past year continue advance important product expand immunology leadership sale regulatory process percent mdd amendment global distribution agreement merck co pipeline advance major milestone breakthrough largestselle product remicade infliximab product like sedasys system computerassiste simponi golimumab personalize sedation system fibrin pad area receive approval incivo europe surgical bleeding progress food hepatitis c market incivek strategic drug administration increase investment partner vertex pharmaceuticals inc emerge market new innovation center india complete acquisition crucell nv building china continue support number training key leadership position vaccine enter new institute world johnson johnson annual reportwith action pharmaceutical segment sale mdd business unit able remicade sale major product sustain leadership billion dollar position percent key sale risperd l consta platform grow maintain sale change share majority platform total ve strategic operational procr eprex v el e portfolio decision business segment refocus cardiovascular business prezista exit drugelute stent business shift investment levaquinfloxin highergrowth highernee area like electrophysiology decision concerta help fund growth potential promising area decision aciphexpariet acquire synthes inc strengthen leadership position orthopaedic acquisition sterilmed inc experience reprocess surgical instrument example medical device diagnostic ethicon continuously look segment sale endo u r gery business good longterm sale major franchise growth opportunitie billion dollar sale consumer et h ic n sale change orthoclinical billion sale diagnostic total consumer business segment operational sixth large consumer health care company world operational sale decline percent reflect impact remediation supply v cis ai ro en issue associate overthe diab et e care counter otc business decline partially offset solid growth certain franchise include skin care oral c na er ue w ri oth g et nro g p ne dr f hr em la tce es r f ir nom e e pu card co av ra e scular mouthwash brand consumer group continue expand emerge market acquisition line otc consumer segment sale skin care coughandcold brand russia sale major franchise jb chemicals pharmaceutical billion dollar limit continue innovate sale introduce neutrogena natural sale change aveeno smart essential total nicorette quickmist operational listerine zero women recovery remediation pharmao ct ec u tical h e al h mcneil consumer healthcare nu tr onal business continue major commitment date consent decree food drug wound care administration achieve product return market volume continue ramp oral care product reintroduce baby care operationalexcludestheimpactofcurrency business highlight pharmaceutical accelerate cancer rd f bill hait compelling science johnson johnson acquire cougar biotechnology july base hold great promise develop positive result complete phase iii medicine address high unmet need study marketing application file regulatory authority network allow insight europe country go world science essential entire development program proceed say hait md phd global head janssen research rapidly year time patient treat development llc take understanding marketing approval canada medical need compelling science european union switzerland meaningful innovation patient quickly new approa ch cancer rd example zytiga abiraterone surgical reduction hormone note oncologist join acetate oral oncedaily medication cancer continue rely johnson johnson march hait use combination prednisone approval zytiga treatment catalyst change bring treatment man metastatic option extend life man focus helping centralize rd castrationresistant prostate cancer kind metastatic castration therapeutic area oncology hait crpc receive prior resistant prostate cancer limit create tumor strategy group tsg chemotherapy contain docetaxel chemotherapy long focus area high unmet food drug administration effective patient treatment need hematological malignancy lung grant marketing approval zytiga option cancer prostate cancer tsgs april expedite abiraterone acetate discover specialize tumor micro sixmonth review accelerate imperial cancer research royal environment strategic research focus regulatory review process grant marsden hospital london tumor long view european medicine agency lead license cougar biotechnology inc tumor cell living isolation tumor cell marketing authorization european begin test compound man close environment commission september crpc take androgen environment grow well transformative prostate deprivation therapy say hait cancer treatment come market breakthrough research hinge kind insight enable exemplify fundamental shift scientific understanding tumor paradigmchange scientific progress approach research development microenvironmentspecifically idea lead zytiga validate tsg apply janssen tumor source approach research development remain testosterone say importantly hait help open compound leader abiraterone acetate mind look company transform prostate cancer michael l meyers md phd janssen labs invest science treatment research development llc science globally prostate cancer second identify key science drug development competitive frequently diagnose cancer man patient fact drug difficult say hait way fifth common cancer overall develop way cut edge wall inside accord estimate national accelerate process try brick mortar cancer institute new collaborate acquire drug say hait exciting new case prostate cancer diagnose recognize value abiraterone thing develop nearly man acetate champion acquisition collaboration way die disease cougar biotechnology fact promise fuel advance androgen hormone work shorten timeline oncology research development testosterone know fuel prostate start phase iii trial example ongoing agreement cancer tumor despite chemical registration drug david h koch institute integrative johnson johnson annual reportsights set cience bill hait vision future research development focus find mining compelling science bring product market fast cancer research massachusetts massachusetts general hospital develop drug discovery development institute technology foster oncology commercialize nextgeneration hait say key meaningful research technology development circulate tumor cell ctc technology collaboration right people area cancer diagnostic cancer capturing counting characterize internally likeminde people seek biology premalignancie genetic model tumor cell find patient blood say hait end day disease profile tumor micro enable ctcs oncologist term contract environment diagnostic tool personalizing point company group important collaboration patient care researcher confidence people announce january accelerate improve process work expert johnson johnson annual report cure hepatitis c incivo telaprevir new directacting antiviral protease inhibitor treatment genotype chronic hepatitis c virus hcv combination pegylate interferon ribavirin approve european member state september arrival directacting antiviral offer patient hope cure say charles gore president world hepatitis alliance accord world health organization million people worldwide infect hepatitis c longterm health consequence cirrhosis liver cancer liver transplanta tionhepatitis c carry high economic burden patient society name medical innovation move treatment manufacturing vaccine cleveland clinic telaprevir kyung mi choi work double chance clearing prevention crucell ultramodern vaccine virus half treatment manufacturing facility time compare prior open standard treatment incheon south korea majority hcv genotype vaccine fundamentally s affordable large patient different pharmaceutical majority globe facility world jim witek global medical medicine s crucell affair leader incivo vaccine prepare acquire affiliate vaccine worldwide say product new body virus johnson johnson unicef worlds large highlight janssen attack explain jaap february working distributor childhood pharmaceutical company goudsmit chief scientific new ultramodern vaccine expand infectious disease officer crucell nv manufacturing facility crucell work portfolio rd vaccinate healthy people incheon south korea evaluate possibility infection hivaid drug treat large vaccine prevent hcv tuberculosis sick people aim facility world infectious disease area allow bring innovative vaccination prevent capable make focus prevention disease therapy help disease million dose year elderly certain redefine improve treat take scientific pentavalent vaccine cancer alzheimer ment outcomes say expertise pharmaceu combination vaccine disease incivo telaprevir codevelope tical business grow diphtheria tetanus dream world vertex pharmaceutical tibotec affiliate janssen pharmaceutical treatment model whooping cough hepatitis b companies johnson johnson include prevention haemophilus influenza infectious disease say johan janssen company right commercialize telaprevir europe latin vaccine equally important type b bacteria van hoof manage director america middle east africa india consideration ability cause meningitis pneumonia crucell australia new zealand hundred million otitis facility make infectious disease commercial incivo common genotype europe dose vaccine price half pentavalent control johnson johnson annual reportaddresse burden hiv expand march non multiple medicine licensing agree immunology exclusive license grant tablet simplify hiv ment generic manufacturer therapy agree generic manufacturer leadership south africa india ment sign prior hiv medicine available manufacture market receive regulatory approval low special access price distribute rilpivirine rilpivirine allow generic country high investigational antihiv manufacturer generic hiv burden include india medication subsequently rilpivirine combination nation subsaharan global approval grant approval pill available quickly africa recently agree amend distribution food drug administration collaboration generic ment modify agreement merck co fda european company extend provide access rilpivirine inc help janssen medicine agency licensing share technical lowresource country pharmaceuticals inc expand johnson johnson skill provide help include vietnam leadership geographic expand scope ensure safety quality thailand cover presence immunology global access program fda percent people live serve patient license generic partner grant approval edurant hiv worldwide stelara ustekinumab speed access rilpivirine rilpivirine treatment treatment moderate important new medicine nave adult access medicine severe plaque psoriasis treat hiv say alan take hiv therapy hiv medication help thabo approve country staple manager strategic antihiv medication feel strong enjoy recognize prestigious relationship clinton commercialize janssen time mother south prix galien usa award health access initiative therapeutic division africa johnson johnson good biotechnology product agreement exist janssen product lp expand global access stelara phase iii generic manufacturer prezista darunavir program study treatment ensure widespread access intelence etravirine hiv portfolio available psoriatic arthritis crohns supply rilpivirine company provide people like disease phase ii study singleagent medicine treatment option patient treatment sarcoidosis fixeddose combination stage disease medicine need primary biliary cirrhosis simponi golimumab oncemonthly subcutaneously administer antitnfalpha therapy achieve approval country simponi phase iii stud ie treatment ulcerative colitis juvenile idiopathic arthritis intravenous formulation rheumatoid arthritis phase ii study sarcoidosis september remicade infliximab receive food drug administration approval biologic treatment pediatric ulcer ative colitis mark th approval remicade available country july marketing right remicade simponi transfer merck janssen pharmaceutical company approximately territorie johnson johnson annual report consumer innovate iconic brand mother seven mommy blogger christine bandaid brand adhesive bandage use quiltvent technology young tend good number scrape promote breathabilitya feature cut kid bike skateboard climb tree consumer say wantand enable bandage wick away blood s scrape leave wound clean cut bruise say christine daughter neosporin brand enter eczema skin care area son range age neosporin essential christine treat children campaign bring fun activity new product design people owie sing squeeze commercial brightly color puppet eczema plus trial pack stick song tv commercial large event include baby buggy contain line include cheerful puppet sing bedtime bash charity event attend gentle nonirritating daily care neosporin antibiotic celebrity parent child wash moisturize cream ointment bandaid brand initiative reach influential clinically show restore visibly adhesive bandage minor wound mommy daddy blogger spread healthy skin day catchy get stuck head word social medium itch flareup hydrocortisone cream singing day long christine say christine example unique relipid formula product long contain humectant emollient marketing today consumer ambassador campaign lipid botanical blend help retain nearly year old bandaid brand promote squeeze stick moisture essential healthy johnson johnson brands twitter parent look skin neosporin brand join blogger event host video contest heart sweat johnson johnson trademark portfolio blog reader post video passion innovate formulas pfizer consumer healthcare family lincoln calif dancing say elena fernandezkleinlein senior acquisition long represent gold singing song director rd global topical health care standard antibiotic ointment appeal broad audience johnson johnson family consumer brand naturally mean mom christine say company proud able neosporin old kid pretty good help eczema sufferer bandaid brand say susan tang helping treat young kid heritage brand group brand director topical health mom squeeze stick launch innovative product care johnson johnson family old sibling meet consumer need example consumer company note neutrogena yearold iconic parent trust generation develop trust new produc ts brand learn consumer insight care child product johnson johnson family parent hard time get share store aisle consumer company iconic brand little swimmer sit long provide exceptional wound care innovation drive growth dry reapply sunscreen lead percent consumer use meet consumer need effort range launch neutrogena wet antibiotic cream bandage marketing educational tool skin sunblock spray sunscreen accord study reinforce creative packaging research design apply directly wet skin message product development lead new product spray quickly topselle johnson johnson consumer historic brand new product sun category companies inc develop neosporin bandaid neutrogena corporation squeeze stick initiative run brand example launch launch product line commercial english spanish new product early new neutrogena natural face johnson johnson annual reportbringe brand christine young child experience scrape cut sing squeeze stick song use neosporin antibiotic ointment bandaid brand adhesive bandage help feel well marketing campaign bring iconic brand lip product product packaging build firstofitskind easytouse design marketing average percent naturally derive green server run brand campaign commercial focus harsh chemical sulfate paraben website solely solar wind energy demonstrate spray fast action petrochemical dyes phthalate nicorette team deeply resonate consumer neutrogena science team examine extended brand long history consumer trust thousand natural ingredient find launch nicorette quickmist brand generation invest good bionutrient peruvian fastacte mouth spray relief heritage brand tara seed promote healthylooking cigarette craving development successful relevant consumer skin addition neutrogena launch involve host innovation need say jesse wu worldwide naturals use environmentally sensitive base consumer insight include chairman consumer group postconsumer recycle material desire speed effectiveness johnson johnson johnson johnson annual report aspire customer consumer want well understanding emerge market consumer like heleneide pereira de brito help emerge market consumer business satisfy need population thecounter business jb listerine essencial chemical pharmaceutical appeal consumer ltd include doktor mom heleneide pereira de brito consumer new design brand wellknown line paulo brazil feel emerge market low cost comprehensive product midtier confident fresh breath include brazil marketing campaign consumer russia beautiful smile people aspire speak aspiration acquisition helping feel good purchase traditional western consumer business expand portfolio look help brand look continue gain deep product meet consumer consumer feel affordability combination understanding need need emerge market prepare accomplish benefit create value emerge market leverage exist thing daily life say takis baladi area world lead capability say karina lense senior vice president emerge enhance product consumer marketing brand manager listerine markets europe middle east marketing well connect strength continue johnson johnson industrial africa johnson johnson consumer innovate drive growth ltda brazil share consumer family example meet new consumer need insight helped bring company consumer johnson johnson family emerge market listerine essencial significant portion company acquire baladis say johnson johnson annual reportsupporting sustainable source consumer palm oil increase equal percent nongovernmental france unwrap le petit unsustainable rate cause estimate palm oil use organization ngo marseillais bar damage rainforest purchase greenpalm support project increase soap notice threaten environment program endorse availability certify additional logo endangered species rspo sustainable palm oil supply greenpalm program le petit represent greenpalm program example partnership marseillais recently begin small portion global palm oil allow demonstrate dutch ngo solidaridad greenpalm logo usageless percent commitment healthy train farmer sustainable packaging highlight effort join future goal source palm oil farming technique support sustainable palm roundtable sustainable palm oil palm oil oil production palm oil rspo derivative certify accelerate palm oil ingredient help difference sustainable source say promote growth derive palm oil sustainability important simon perry source sustainable palm oil say commonly personal ingredient say paulette frank manager johnson johnson frank small user care product soap vice president sustainability family consumer company big voice lotion shampoos cream environment health achieve goal oil come safety johnson johnson johnson johnson return fruit oil palm tree family consumer company global palm oil source production food strategy include engage quality biofuel demand sustainable palm oil certificate supplier collaborate mcneil product mcneil consumer healthcare continue progress commitment return highquality product shelve consumer shipment resume number adult children tylenol product anticipate key select product continue reintroduce number johnson johnson manufacturing facility hundred supply chain associateshave involved effort return trust brand store shelf work continue outfit manufacturing facility fort washington pa stateoftheart equipment process provide quality product consumer reopen site worldclass facility reduce impa ct effort encourage sustainable palm oil supply source manufacturing overthe johnson johnson works organization engage sustainable palm oil farming practice counter liquid medicine johnson johnson annual report medical device diagnostic revive recover w hen ehrenfrie wecker wiesenbach germany return home bakery breakfast roll morning august find wife brunhilde bed wave arm unable speak take hand let change paradigm medicine hand fall say prof bendszus say dramatic realize not right know immediately wife significant need severe stroke minute year million people suffer stroke count mr wecker say ambulance worldwide million die rush mrs wecker hospital million permanently evaluation include mri disabled stroke lead cause show experience acute death heart disease cancer ischemic stroke blockage artery leading cause long lead brain term disability hemorrhagic stroke doctor propose new occur artery brain burst option revive se device self ischemic stroke blood flow expand blood clot retrieval removal brain block account device design remove blood clot percent stroke year restore blood flow brain patient revive se device acute ischemic stroke say device codman shurtleff inc not think bad ischemic stroke mark new growth ask thought area johnson johnson company good wife mr wecker recall develop additional stroke minimally invasive procedure take product begin long minute advantage term commitment bring forward micrus endovascular corporation damage innovation advance treatment global developer manufacturer long brain deprived blood stroke improve patient care minimally invasive device patient suffer outcome say karen prange general hemorrhagic ischemic stroke severe permanent impairment manager vice president codman operate codman neurovascular die say surgeon prof martin neurovascular business global neuroscience neurovascular bendszus md chairman department company receive european union company develop market neuroradiology university hospital approval revive se device product diagnosis treatment heidelberg germany february launch device neurological disorder codman body speak day leave september depuy family company hospital week later s approve distribution unite rich history pioneer product absolutely fine nowit amazing state clinical trial plan orthopaedic neurological care hospital routinely use potential future use fastgrowth area neurovascular revive se device acute ischemic revive se device represent market expand stroke rare experience success september acquisition percent annually johnson johnson annual reportlife stroke revive se device helped save brunhilde wecker life suffer stroke enjoy active lifestyle time garden husband ehrenfrie life re tore stroke complete paralysis wecker husband son visit mrs weckers mri locate blood right procedure not believe sit clot vessel leave brain neurologist administer wave smile prof bendszus insert revive se standard treatment ischemic stroke speak perfectly fine mr wecker device groin microcatheter tpa clotdissolve drug say leave hospital day guide artery blockage day mrs wecker serve stroke need rehabilitation area watch image screen potato roast pork lunch home mrs wecker resume devices mesh basket expand cut meat lifestyle work tax adviser push clot vessel wall try cut meat visit grandchild enjoy restore blood flow brain prof hand work say day garden bendszus retrieve removed not hand say operation take blood clot cause mrs weckers cut schweinebraten mrs minute probably save life johnson johnson annual report set example animas vibe device undertake matt june persevere continuous glucose monitoring get water cgmenable insulin pump scared diabete hour relay system dexcom g massive understatement factor ve swim english cgm technology allow hold channel raise money allow realtime glucose huge relief say matt medical condition juvenile diabete research information alert high diabete big ve get deal foundation swimmer low reading glucose trend life say matt cox life diabete wear information background s village high lane waterproof animas vibe animas vibe try northwest england insulin pump brave device help matt manage animas insulin pump water matt set cold water diabete channel proof meter hour positive example especially pump swim easy dexcom g transmitter waterproof meter hour important son possible jack type diabete clearly doable inspirational swim matt cox take relay swim july matt join right tool say matt english channel support family want swimmer animas corporation son jack diabetes not hold type diabete receive ce mark approval accomplish goal johnson johnson annual reportmanaging growth number strategic decision reshape portfolio device diagnostic business redeploy resource accelerate growth long term april johnson johnson announce plan acquire synthes inc premier global developer manufacturer orthopaedic device acquisition large purchase johnson johnson history strengthen company leadership position global orthopaedic market september ethicon endosurgery inc announce agreement acquire sterilmed inc leader reprocess replace knee remanufacture medical improve outlook device broaden successful knee replacement restore life portfolio product offer surgery mrs kamatchi leave increasingly costconscious daughter dhanalakshmi hospital customer focus family cardiovascular care household task franchise exit drug mrs ramasamy kamatchi underserved patient like pain elute stent business well yearold farmer trichy mrs kamatchi company focus area india life commit safe neurological disorder significant medical need transform depuy effective use product teach learn great opportunity reach knee suffer india need need sur growth lead debilitate knee pain time joint geon patient electrophysiology business year replacement surgeon feed insight continue underwent kneereplacement today treat number product innovation progress aspect surgery able care patient suffer market access strategy say synthe acquisition include family enjoy activity debilitate arthritis help michael del prado company integration planning grandchild address gap group chairman asiapacific process continue pay attention stateoftheart depuy strategy work expect transaction close knee family institute advance help build health half synthe say mrs kamatchi education research care capacity india depuy franchise happy satisfied open near chennai region position succeed develop new rd capital city tamil nadu depuy institute time dramatic change commercial model july transfer chennai orthopaedic market meet specific emerge market knowledge development professional education center offer patient surgeon need depuy orthopaedic skill facility johnson johnson hospitals broad range inc make life increase capacity india family company build innovative technology change technology health care professional world serve meet orthopaedic accessible affordable care people suffer unique patient need need hundred million osteoarthritis spinal emerge market johnson johnson annual report commitment remain steadfast tohoku pacific coast earthquake tsunami strike japan friday march wake disaster toshiaki kobayashi responsible operation manufacturing distribution labeling facility sukagawawa johnson johnson colleagues japan immediate concern earthquake tsunami vision care operation tokyo suffer priority ensure water damage sprinkler employee safe facility major damage reestablish safe community safe percent function march anxious work orthoclinical diagnostic ocd customer say kobayashi sukagawa office sendai severely damage plant manager johnson johnson employee relocate medical company jjmc division jjmc office repair johnson johnson kk ocd office reopen later month sukagawa plant primarily janssen facility escape initial damage manufacturing distribution center suffer minor damage day medical device include sterrad later earthquake mount sterilization product carto fuji area operation resume system advanced imaging technology march sendai branch office handle label medical jjmc operational heavily device diagnostic product sell damage sukagawa close undergo japan damage facility repair concurrently supply chain leader significant identify contact hundred supplier assess validate safety assess damage measure raw material finish regulatory agency secure immediately disaster product labeling face subsequent risk radiation manufacturing suspend exposure damage nuclear power recovery begin affect product cidex opa plant leader johnson johnson tour sukagawa building produce gargrave united supply chain initiate extensive day disaster kingdom facility jjmc team ongoing assessment miserable say hiroyuki watanabe fasttracke regulatory approval company operation distribution senior manager jjmc quality assurance uk product available japan supplier network japan kobayashi year employee say recovery external manufacturer priority ensure safety product couple day focus contract ramp production raw material company clean challenge cover demand supply chain supply stop say work turnaround time day cross sukagawa plant difficult regulatory review approval functional team quickly locate water toilet food available unprecedented thank strong employee find safe emergency supply include food support jjmc team include assessment water arrive tokyo help regulatory affair explain watanabe operate company consumer company recovery work plant march labeling room site damage hour label sukagawa restart operate percent capacity disaster product ready percent capacity nearly week repair manufacturing line donate shelter camp town disaster additional space continue repair automate need tokyo promptly audit approve distribution warehouse complete johnson johnson annual reportcare customer employee find safe earthquake tsunami toshiaki kobayashi say focus fast serve customer despite significant damage sukagawa facility think fast child world vision shortage fuel electricity food distribute product japan janssen pharmaceutical kks necessary item employee japan customer say kobayashi support rescue effort include work tirelessly clock employee share focus work donate medical equipment supply reestablish support supply togetherit amazing funding group doctor patient doctor family need work affect area vision care product repair damage facility aid japan division provide free lense patient provide need assistance assist people japan relief worker seven affect tohoku region difficult time johnson johnson prefecture identify clinic serve culturally japanese people family company significant emergency lens distribution point strong team spirit important financial commitment product japan presidents council approve help successful recovery say donation addition employee recommendation use fund pledge kobayashi expect retiree johnson johnson johnson johnson family surprisingly good teamwork company donate generously disaster company japan mid long emphasize care people relief partner include japanese term project japanese culture say red cross society direct relief big lesson d like learn international international rescue business care disaster importance committee project hope save spite indescribable hardship care help johnson johnson annual report care meaningful difference w hen look woman passion order difference local organization look mother look private sector perspective family say babatunde osotimehin bring enthusiasm strategic planning willingness try implement md executive director unfpa innovative approach say sharon united nations population fund important dagostino vice president worldwide corporate contribution community holistic way deal poverty relation bring rigor metric evaluation work help factor woman child vulnerable program demonstrate measurable particularly program country woman outcome provide organization datum attract additional source child live funding unfpa unaid subsaharan africa company diverse partner unicef world bank world south asia woman die align strategic mission health organization seriously injure make lifechange longterm h partnership coordinate suffer disability day difference human health initiative ensure international newborn die recognize close organization work women day life press health care concern well able children health local death prevent address local need say dagostino programs johnson johnson factor include poor health infra example japan private sector partner structure lack qualified health johnson johnson support support h worker mean basic organization call resilience happy natural act give life instead provide assistance woman johnson johnson private cause deatha time hope involve go abusive sector organization come forward future instead time family relationship resilience offer session true partner initiative say crisis despair series workshop lecture aim dr osotimehin believe ethiopia tanzania area educate survivor abuse enable support johnson johnson risk mother newborn high heal well big difference government commitment equip reenter community start ground save life improve maternalchild health working build new relationship strong h johnson johnson connect build legacy caring provide training program area able provide support partnership h health care worker critical care need think change component response united reach mother newborn world bit bit say sachi nakajima nations secretary general action organization founder renew global effort achieve working communitybase survivor millennium development goal organization say joy marini director corporate johnson johnson inspire relationships gro w contributions johnson johnson credo partner hundred partner relationship grow effort keep long organization care people time way contribute people stand commitment health world company live planet business wellbee mother child work partner program longstanding collaboration global maternal mortality country help world wildlife fund wwf reduce onethird past implement new approach year ago johnson johnson years h member report enable program expand reach early adopter wwf day approximately woman die people employee climate saver program company pregnancy complication childbirth world volunteer time skill set goal achieve percent absolute johnson johnson annual reportcare woman child dr babatunde osotimehin executive director unfpa greatest hope h collaboration difference life people serve say bring effort synergy lot individual organization reduction co emission wwfs healthy community healthy way wwf provide critical johnson johnson ecosystem program africa input responsible source policy surpass goal achieve absolute link health environment palm oil johnson johnson working reduction percent health local people johnson johnson wwf identify opportunity johnson johnson set high bar early participant wwfs support project promote sustainable time company global forest trade network focus practice field set greenhouse gas reduction target reliable sustainable source johnson johnson say suzanne apple vice president paper wood product work number area business industry wwf send strong company paper pulp important say apple message company participate business apple say johnson johnson join force big collaboration expand send strong message time impact create sustainable include philanthropic commitment supplier come table future planet johnson johnson annual report row leave right board director william c weldon chairman board directors chief executive officer chairman executive committee mary sue coleman phd president university michigan james g cullen retire president chief operating officer bell atlantic corporation second row leave right ian el davis senior advisor apax partner chairman worldwide manage director mckinsey company michael johns md chancellor emory university susan l lindquist phd member director whitehead institute biomedical research professor biology massachusetts institute technology row leave right anne mulcahy chairman chief executive officer xerox corporation leo f mullin retire chairman chief executive officer delta air lines inc william perez senior advisor greenhill co inc retired president chief executive officer wm wrigley jr company fourth row leave right charles prince retired chairman chief executive officer citigroup inc david satcher md phd director center excellence health disparity director satcher health leadership institute poussaintsatcher cosby chair mental health morehouse school medicine surgeon general ronald williams chairman chief executive officer aetna inc johnson johnson annual reportnominate corporate governance committee nominate corporate governance committee compose entirely independent director responsible board oversee corporate governance matter review possible candidate board membership recommend nominee election committee responsible overseeing process performance evaluation board committee additionally committee review companys executive succession plan executive resource audit william perez chairman audit committee compose entirely independent jame g cullen director help board oversee company financial anne mulcahy accounting reporting practice recommend charles prince independent public auditor appointment board review performance addition committee monitor adequacy internal accounting practice procedure public policy control review companys financial reporting process public policy advisory committee review company disclosure procedure help board oversee policy program practice public health issue company legal compliance program environment health safety employee committee review company james g cullen chairman governmental affairs policy public policy issue mary sue coleman phd facing company committee advise make ian el davis recommendations board issue appropriate leo f mullin public policy advisory committee compose independent director company vice chairman compensation benefit executive committee vice president global compensation benefit committee compose entirely corporate affair government affair policy independent director establish company executive global supply chain compensation philosophy principle approve leo f mullin chairman annual compensation longterm incentive ian el davis company director executive officers committee susan l lindquist phd review philosophy policy nonboard david satcher md phd management compensation committee determine ronald williams management compensation establishe perquisite compensation policy nonexecutive employee alex gorsky additionally committee oversee management clifford e holland retirement pension longterm incentive saving robert salerno health welfare plan cover company employee michael e sneed charles prince chairman science technology michael johns md science technology advisory committee compose anne mulcahy independent director company vice president william perez science technology help board scientific matter ronald williams impact company business include monitor strategy effectiveness company research finance development organization review effectiveness finance committee exercise authority board scientific aspect company product safety process interval board meeting finance oversee major business development activity relate committee compose chairman board acquisition new science technology identify preside director understand significant new science technology policy issue trend william c weldon chairman james g cullen david satcher md phd chairman mary sue coleman phd michael johns md susan l lindquist phd garry neil md johnson johnson annual report board director corporate officer executive committee william c weldon alex gorsky executive committee johnson johnson chairman board directors vice chairman principal management group responsible chief executive officer executive committee strategic operation allocation chairman executive committee sherilyn mccoy resources company committee oversee vice chairman coordinate activitie consumer dominic j caruso vice president finance executive committee pharmaceutical medical device diagnostic chief financial officer business segment john papa executive committee treasurer douglas k chia michael h ullmann corporate secretary vice president assistant general counsel general counsel executive committee stephen j cosgrove corporate controller chief accounting officer peter fasolo vice president global human resource executive committee worldwide chairman company group chairmen jesse j wu charles e austin consumer group roberto de marques joaquin duato michael jf del prado paul stoffels md grace del rosario castano pharmaceuticals group seth hz fischer karen licitra gary p fischetti global medical solution jane griffiths group william n hait md phd gary j pruden jose antonio justino global surgery group guy j lebeau md ashley mcevoy patrick mutchler michel paul jacques peeters pericle p stamatiades jennifer l taubert kim taylor nicholas j valeriani johnson johnson annual reportcorporategovernanceandmanagementsresponsibility johnsonjohnsonisguidedbythevaluessetforthinourcredo pricewaterhousecoopersllpanindependentregisteredpublic createdbygeneralrobertwoodjohnsonintheseprinciple accountingfirmisengagedtoperformanintegratedauditofour haveguidedusovertheyearsandcontinuetosetthetoneof consolidatedfinancialstatementsandinternalcontroloverfinancial integrityfortheentirecompanyatalllevelstheemployeesof reportingthereportofindependentregisteredpublicaccounte johnsonjohnsonarecommittedtotheethicalprinciplesembod firmisonpage iedinourcredoandtheseprincipleshavebeenwovenintothe theauditcommitteeofourboardofdirectorsiscompose fabricofthecompany solelyofindependentdirectorswiththefinancialknowledgeand thevaluesarticulatedinourcredoextendtoouraccounte experiencetoprovideappropriateoversightwereviewinternal andfinancialresponsibilitiestojohnsonjohnsonshareholder controlmattersandkeyaccountingandfinancialreportingissue andinvestorswethemanagementofjohnsonjohnsonare withtheauditcommitteeonaregularbasisinadditiontheinde responsiblefortheintegrityandobjectivityoftheaccompanye pendentauditorsthegeneralcounselthechieffinancialofficer financialstatementsandrelatedinformationwearealsoresponsi thechiefcomplianceofficerandthevicepresidentofinternal bleforensuringthatfinancialdataisreportedaccuratelyandina auditregularlymeetinprivatesessionswithourauditcommittee mannerthatfacilitatestheunderstandingofthisdata todiscusstheresultsoftheirworkincludingobservationsonthe asevidenceofourcommitmenttothisresponsibilitywe adequacyofinternalfinancialcontrolsthequalityoffinancial maintainawelldesignedsystemofinternalaccountingcontrol reportingandconfirmationthattheyareproperlydischargingtheir encouragestrongandeffectivecorporategovernancefromour responsibilitiesandotherrelevantmatter boardofdirectorscontinuouslyreviewourbusinessresultsand ourexecutivecommitteeiscontinuouslyinvolvedinthe strategicchoicesandfocusonfinancialstewardship reviewoffinancialresultsaswellasdevelopingandunderstande ourcorporatestaffofprofessionallytrainedinternalauditor strategiesandkeyinitiativesforlongtermgrowthourintentisto whotravelworldwidemonitoroursystemofinternalaccounting ensurethatwemaintainobjectivityinourbusinessassessment controlsdesignedtoprovidereasonableassurancethatassetsare constructivelychallengetheapproachtobusinessopportunitiesand safeguardedandthattransactionsandeventsarerecordedproperly issuesandmonitorourbusinessresultsandtherelatedcontrol ourinternalcontrolsincludeselfassessmentsandinternalreview ourconsolidatedfinancialstatementsandfinancialdatathat ofouroperatingcompanie followhavebeenpreparedinconformitywithaccountingprinciple duringthecompanycontinuedtoinvestsignificanttime generallyacceptedintheunitedstatesofamericaandinclude andresourcesinordertoensurecompliancewithsectionof amountsthatarebaseduponourbestjudgmentswearecommit thesarbanesoxleyactofbasedontheworkperformedwe tedtopresentanddiscussresultsofoperationsinaclearand haveconcludedthatourinternalcontroloverfinancialreporting transparentmannerinordertoprovidetimelycomprehensiveand waseffectiveasofjanuarywereferyoutomanagement understandableinformationtoourshareholder reportoninternalcontroloverfinancialreportingonpage werequirethemanagementteamsofouroperatingcompa niestocertifytheircompliancewithourpolicyonbusinessconduct whichsetsforththecompanyscommitmenttoconductitsbusi nessaffairswithintegrityandcomplywiththegoverninglawsand regulationswehaveasystematicprogramdesignedtoensure compliancewiththesepoliciesandprovidemeansofreportingany concernsaboutviolationsofthepolicypleasevisitourwebsiteat williamcweldon dominicjcaruso wwwinvestorjnjcomgovernanceconductcfmtoviewourpolicy chairmanboardofdirector vicepresidentfinance onbusinessconduct andchiefexecutiveofficer andchieffinancialofficer tableofcontent managementsdiscussionandanalysis auditedconsolidatedfinancialstatement organizationandbusinesssegment consolidatedbalancesheet resultsofoperation consolidatedstatementsofearning analysisofsalesbybusinesssegment consolidatedstatementsofequity analysisofconsolidatedearningsbeforeprovision consolidatedstatementsofcashflow fortaxesonincome notestoconsolidatedfinancialstatement liquidityandcapitalresource reportofindependentregisteredpublicaccountingfirm otherinformation managementsreportoninternalcontrolover cautionaryfactorsthatmayaffectfutureresult financialreporte supportingschedule summaryofoperationsandstatisticaldata shareholderreturnperformancegraph reconciliationofnongaapfinancialmeasure johnson johnson annual report managementsdiscussionandanalysisofresultsofoperationsandfinancialcondition organizationandbusinesssegment managementsobjective thecompanymanageswithinastrategicframeworkaimedat descriptionofthecompanyandbusinesssegment achievingsustainablegrowthtoaccomplishthisthecompanys johnsonjohnsonanditssubsidiariesthecompanyhave managementoperatesthebusinessconsistentwithcertainstrate approximatelyemployeesworldwideengagedinthe gicprinciplesthathaveprovensuccessfulovertimetothisendthe researchanddevelopmentmanufactureandsaleofabroadrange companyparticipatesingrowthareasinhumanhealthcareandis ofproductsinthehealthcarefieldthecompanyconductsbusiness committedtoattainingleadershippositionsinthesegrowtharea invirtuallyallcountriesoftheworldwiththeprimaryfocuson throughthedevelopmentofhighqualityinnovativeproductsand productsrelatedtohumanhealthandwellbee servicesnewproductsintroducedwithinthepastfiveyear thecompanyisorganizedintothreebusinesssegment accountedforapproximatelyofsalesinbillion consumerpharmaceuticalandmedicaldevicesanddiagnostics orofsaleswasinvestedinresearchanddevelopmentthis theconsumersegmentincludesabroadrangeofproductsusedin investmentreflectsmanagementscommitmenttotheimportance thebabycareskincareoralcarewoundcareandwomenshealth ofongoingdevelopmentofnewanddifferentiatedproductsand fieldsaswellasnutritionalandoverthecounterpharmaceutical servicestosustainlongtermgrowth productsandwellnessandpreventionplatformstheseproduct withmorethanoperatingcompanieslocatedin aremarketedtothegeneralpublicandsoldbothtoretailoutlet countriesthecompanyviewsitsprincipleofdecentralizedman anddistributorsthroughouttheworldthepharmaceuticalsegment agementasanassetandfundamentaltothesuccessofabroadly includesproductsinthefollowingareasantiinfectiveantipsy basedbusinessitalsofostersanentrepreneurialspiritcombine choticcontraceptivedermatologygastrointestinalhematology theextensiveresourcesofalargeorganizationwiththeabilityto immunologyneurologyoncologypainmanagementthrombosis anticipateandreactquicklytolocalmarketchangesandchallenge vaccinesandinfectiousdiseasestheseproductsaredistribute thecompanyiscommittedtodevelopingglobalbusinesslead directlytoretailerswholesalersandhealthcareprofessionalsfor erswhocanachievegrowthobjectivesbusinessesaremanagedfor prescriptionusethemedicaldevicesanddiagnosticssegment thelongterminordertosustainleadershippositionsandachieve includesabroadrangeofproductsdistributedtowholesalershos growththatprovidesanenduringsourceofvaluetoourshareholder pitalsandretailersusedprincipallyintheprofessionalfieldsby ourcredounifiesthemanagementteamandthecompanys physiciansnursestherapistshospitalsdiagnosticlaboratoriesand dedicatedemployeesinachievingtheseobjectivesandprovidesa clinicstheseproductsincludecardiovascularcareselectrophysi commonsetofvaluesthatserveasaconstantreminderofthe ologyandcirculatorydiseasemanagementproductsdepuy companysresponsibilitiestoitscustomersemployeescommuni orthopaedicjointreconstructionspinalcareneurologicaland tiesandshareholdersthecompanybelievesthatthesebasic sportsmedicineproductsethiconssurgicalcareaestheticsand principlesalongwithitsoverallmissionofimprovingthequality womenshealthproductsethiconendosurgerysminimallyinva oflifeforpeopleeverywherewillenablejohnsonjohnsonto sivesurgicalproductsandadvancedsterilizationproductsdiabete continuetobeamongtheleadersinthehealthcareindustry caresbloodglucosemonitoringandinsulindeliveryproduct orthoclinicaldiagnosticsprofessionaldiagnosticproductsand resultsofoperation visioncaresdisposablecontactlense thecompanysstructureisbasedupontheprincipleof analysisofconsolidatedsale decentralizedmanagementtheexecutivecommitteeof inworldwidesalesincreasedtobillioncompare johnsonjohnsonistheprincipalmanagementgroupresponsible todecreasesofinandinthesesale forthestrategicoperationsandallocationoftheresourcesofthe changesconsistedofthefollowing companythiscommitteeoverseesandcoordinatestheactivitie oftheconsumerpharmaceuticalandmedicaldevicesand salesdecreaseincreasedueto volume diagnosticsbusinesssegment inallofitsproductlinesthecompanycompeteswithcompa price niesbothlocallyandgloballythroughouttheworldcompetition currency existsinallproductlineswithoutregardtothenumberandsizeof total thecompetingcompaniesinvolvedcompetitioninresearchinvolv ingthedevelopmentandtheimprovementofnewandexiste salesbyuscompanieswerebillioninbillionin productsandprocessesisparticularlysignificantthedevelopment andbillioninthisrepresentsdecreasesof ofnewandinnovativeproductsisimportanttothecompanyssuc ininandinsalesbyinternational cessinallareasofitsbusinessthisalsoincludesprotectingthe companieswerebillioninbillioninand companysportfolioofintellectualpropertythecompetitiveenvi billioninthisrepresentsanincreaseofin ronmentrequiressubstantialinvestmentsincontinuingresearchand anincreaseofinandadecreaseofin inmaintainingsalesforcesinadditionthedevelopmentandmain tenanceofcustomerdemandforthecompanysconsumerproduct involvessignificantexpendituresforadvertisingandpromotion johnson johnson annual reportintheminimummedicaidrebateratefromtoandalso usand extendedtherebatetodrugsprovidedthroughmedicaidmanage internationalsale careorganizationsadditionallyindiscountswereprovide foryear inbillionsofdollar onthecompanysbrandnamedrugstopatientswhofallwithinthe medicarepartdcoveragegapdonutholetheimpactwasan increaseinsalesrebatesreducingsalesrevenuebyapproximately international millionandmillioninandrespectively incompaniesthatsellbrandedprescriptiondrugstospeci fiedusgovernmentprogramspaidanannualnontaxdeductiblefee basedonanallocationofthecompanysmarketshareoftotalbrande prescriptiondrugsalesfromtheprioryearthefullyearimpactto sellingmarketingandadministrativeexpenseswasmillionunder thecurrentlawbeginninginthecompanywillberequiredtopay thefiveyearcompoundannualgrowthratesforworldwide ataxdeductibleexcisetaximposedonthesaleofcertainmedical usandinternationalsaleswereandrespec devicesthetaxisestimatedtobebetweenmillion tivelythetenyearcompoundannualgrowthratesforworldwide andwillberecordedinsellingmarketingandadministrativeexpense usandinternationalsaleswereandrespectively salesby segment salesby geographic inbillionsofdollars region inbillionsofdollar consumer pharmaceutical medicaldevices e wu ero sp tee rnhemisphere anddiagnostic excludingus asia pacificafrica analysisofsalesbybusinesssegments salesineuropeachievedgrowthofascomparedtothe prioryearincludingoperationalgrowthofandapositiveimpact consumersegment fromcurrencyofsalesinthewesternhemisphereexclude consumersegmentsalesinwerebillionanincreaseof theusachievedgrowthofascomparedtotheprioryear fromaoperationaldeclinewasoffsetbyapositive includingoperationalgrowthofandapositiveimpactfrom currencyimpactofusconsumersegmentsaleswere currencyofsalesintheasiapacificafricaregionachieve billionadecreaseofinternationalsaleswerebillion growthofascomparedtotheprioryearincludingoperational anincreaseofwhichincludedoperationalgrowthanda growthofandapositiveimpactfromcurrencyof positivecurrencyimpactof inandthecompanydidnothaveacustomer theoverthecounterotcpharmaceuticalsandnutritional thatrepresentedormoreoftotalconsolidatedrevenue franchisesaleswerebillionadecreaseoffrom theresultsbenefitedfromtheinclusionofardweek salesintheuswerenegativelyimpactedbythesuspensionofpro seenotetotheconsolidatedfinancialstatementsforannual ductionatmcneilconsumerhealthcaresfortwashingtonpenn closingdatedetailsthecompanyestimatedthatthefiscalyear sylvaniafacilityaswellastheimpactonproductionvolumesrelate growthratewasenhancedbyapproximatelyduetothe toongoingeffortstoenhancequalityandmanufacturingsystemsat rdweek itsothermanufacturingsites duringthefiscalfirstquarterofaconsentdecreewa ushealthcarereform signedwiththeusfoodanddrugadministrationfdawhichgov thepatientprotectionandaffordablecareactandthehealthcare ernscertainmcneilconsumerhealthcaremanufacturingoperation andeducationreconciliationactofweresignedintolawin theconsentdecreeidentifiesproceduresthatwillhelpprovideaddi marchthehealthcarereformlegislationincludedanincrease tionalassuranceofproductqualitytothefdamcneilcontinuesto majorconsumerfranchisesale change dollarsinmillion vs vs otcpharmaceuticalsnutritional skincare babycare womenshealth oralcare woundcareother total management discussion analysis result operation financial condition operatethemanufacturingfacilitiesinlaspiedraspuertoricoand procritepoetinalfaandeprexepoetinalfahadcom lancasterpennsylvaniahoweverproductionvolumesfromthesefacil binedsalesofbillioninadeclineofcomparedtothe itieshavebeenimpactedduetotheadditionalreviewandapproval prioryearlowersalesofprocritandeprexwereprimarilydue processesrequiredregardingtheproductspreviouslyproducedatthe toadecliningmarketforerythropoiesisstimulatingagentsesas fortwashingtonfacilitymcneilcontinuestoworkontheresitingof andincreasedcompetitionforeprex theseproductstootherfacilitiesmcneilismakingprogressonthe risperdalconstarisperidonealongactinginjectable validationsatthesealternativesitesandamodestamountofproduct antipsychoticachievedsalesofbillioninrepresentingan returnedtothemarketinthefourthquarterofproductswill increaseofascomparedtotheprioryearduetointernational continuetobereintroducedthroughoutand growthtotalussalesofthecompanyslongactinginjectable theskincarefranchiseachievedsalesofbillionin includingrisperdalconstaandinvegasustenna aincreaseascomparedttootheprioryearprimarilyduetogrowth paliperidonepalmitateincreasedbystrongdoubledigitsversus intheneutrogenadabaojohnsonsadultandlepetit ayearagoduetoanincreaseinthecompanyscombinedmarket marseillaisproductlinesthebabycarefranchisesalesgrew shareintheantipsychoticmarket bytobillioninprimarilyduetogrowthincleanser velcadebortezomibaproductforthetreatmentof wipesandhaircarethewomenshealthfranchisesaleswere multiplemyelomaforwhichthecompanyhascommercialright billionadecreaseofprimarilyimpactedbythedivestiture inmarketsoutsidetheusachievedsalesofbillionin ofcertainbrandstheoralcarefranchisesalesgrewbyto representinganincreaseofprimarilyduetostronggrowth billioninprimarilyduetoincreasedsalesoflisterine inasiaandlatinamerica productsthewoundcareotherfranchisesaleswerebillion concertamethylphenidatehclsaleswerebilliona inflatascomparedtotheprioryear declineofcomparedtotheprioryeartheussupplyanddis consumersegmentsalesinwerebillionadecrease tributionagreementwithwatsonlaboratoriesinctodistributean offromwithofthischangeduetoanoperational authorizedgenericversionofconcertabecameeffectivemay declinepartiallyoffsetbypositivecurrencyimpactofuscon allregionsoutsidetheusachievedsalesgrowth sumersegmentsaleswerebillionadecreaseofinterna prezistadarunaviraproteaseinhibitorforthetreatment tionalsaleswerebillionanincreaseofwithanoperational ofhivachievedsalesofbillioninrepresentingan declineofoffsetbypositivecurrencyimpactof increaseofascomparedtotheprioryearprimarilydueto marketsharegrowth pharmaceuticalsegment aciphexparietrabeprazolesodiumsaleswere thepharmaceuticalsegmentachievedsalesofbillionin billionadeclineofversustheprioryearduetoincrease representinganincreaseofovertheprioryearwithopera competitionfromgenericsinthecategory tionalgrowthofandapositivecurrencyimpactof levaquinlevofloxacinfloxinofloxacinsaleswere ussaleswerebillionadecreaseofinternational billionadeclineofversustheprioryearduetotheloss saleswerebillionanincreaseofwhichinclude ofmarketexclusivityintheusinjunelevaquinsale operationalgrowthandapositivecurrencyimpactof willcontinuetodeclineinthefirsthalfofversusthefirsthalf remicadeinfliximababiologicapprovedforthetreatment ofanumberofimmunemediatedinflammatorydiseasesachieve inotherpharmaceuticalsaleswerebillionrepre salesofbillioninwithgrowthofovertheprioryearon sentinggrowthofovertheprioryearcontributorstothe acombinedbasisusexportandinternationalsalesofremicade increaseweresalesofnewlyacquiredproductsfromcrucellnv increasednearlyduetotheimpactoftheagreementwithmerck crucellandnewlyapprovedproductsincludingzytiga coincmerckcomplementedbyinternationalmarketgrowth abirateroneacetateandincivotelapreviradditionalcontrib onaprilthecompanyannounceditreachedanagreement utorstothegrowthwerestelaraustekinumabinvega withmerckwhichincludeddistributionrightstoremicadeand sustennapaliperidonepalmitatesimponigolimumab simponigolimumabwherebyeffectivejulycertainterrito nucyntatapentadolandintelenceetravirinethis rieswererelinquishedtothecompanyonjulythecompany growthwaspartiallyoffsetbylowersalesofduragesicfentanyl begantorecordsalesofproductpreviouslyrecordedbymerckfrom transdermalfentanyltransdermalsystemandtopamax certainterritoriesincludingcanadabrazilaustraliaandmexico topiramateduetocontinuedgenericcompetition whichwerepreviouslysuppliedbymerck majorpharmaceuticalproductsale change dollarsinmillion vs vs remicadeinfliximab procriteprexepoetinalfa risperdalconstarisperidone velcadebortezomib concertamethylphenidatehcl prezistadarunavir aciphexparietrabeprazolesodium levaquinfloxinlevofloxacinofloxacin otherpharmaceutical total prioryearamountshavebeenreclassifiedtoconformtocurrentpresentation johnson johnson annual reportduringthecompanyreceivedseveralregulatoryapproval theethiconendosurgeryfranchiseachievedsalesofbillion includingusapprovalfortwoindicationsforxareltorivaroxa inaincreaseovertheprioryeargrowthwasattributable banananticoagulantcodevelopedwithbayerhealthcarethe toincreasedsalesofadvancedsterilizationandharmonicprod firstoneforthepreventionprophylaxisofdeepveinthrombosis uctlinesandoutsidetheustheendomechanicalproductline dvtwhichmayleadtoapulmonaryembolismpeinpeople additionallysalesofnewlyacquiredproductsfromsterilmedcon undergoingkneeorhipreplacementsurgeryandthesecondoneto tributedtothegrowthtotalgrowthwasnegativelyimpactedbythe reducetheriskofstrokeandsystemicembolisminpatientswithnon divestitureofthebreastcarebusinessinthethirdquarterof valvularatrialfibrulationedurantrilpivirineinboththeus theethiconfranchiseachievedsalesofbillionin andtheeuropeanunioneuforhivintreatmentnavepatient anincreaseovertheprioryearemergingmarketgrowth incivotelaprevirintheeuforthetreatmentofhepatitiscvirus insuturesnewlylaunchedproductsethiconphysiomeshand andzytigaabirateroneacetateintheusandeuforthetreat ethiconsecurestrapandgrowthinthebiosurgicalwomen mentofmetasticcastrationresistantprostatecancerinaddition healthandurologyandacclarentproductlinescontributedtothe thefdaapprovedadditionalindicationsforremicadeinflix increaseinsale imabforthetreatmentofmoderatelytoseverelyactiveulcerative thevisioncarefranchiseachievedsalesofbillionin colitisinpediatricpatientsandnucyntaertapentadol anincreaseovertheprioryearcontributorstothegrowth extendedreleasetabletsanoralanalgesicforthemanagementof weredayacuvueandastigmatismlense moderatetoseverechronicpaininadult thediabetescarefranchiseachievedsalesofbillionin thecompanysubmittednewdrugapplicationsndasto aincreaseovertheprioryearthegrowthwasprimarily thefdaseekingapprovalfortheuseofxareltorivaroxaban duetosalesintheonetouchproductline anoralanticoagulanttoreducetheriskofthromboticcardio salesinthecardiovascularcarefranchisewerebilliona vasculareventsinpatientswithacutecoronarysyndromeandfor declineofversustheprioryearsaleswereimpactedbythe nucyntaertapentadolextendedreleasetabletsanoral companysdecisiontoexitthedrugelutingstentmarketandlower analgesicforthemanagementofneuropathicpainassociatedwith salesofendovascularproductsduetoincreasedcompetitionsales diabeticperipheralneuropathyinadults fordrugelutingstentswereapproximatelyandofthetotal pharmaceuticalsegmentsalesinwerebilliona cardiovascularcarefranchisesalesinandrespectively decreaseoffromwithanoperationaldeclineof thedeclineinsaleswaspartiallyoffsetbystronggrowthin andapositivecurrencyimpactofussaleswerebillion biosensewebsterthecompanyselectrophysiologybusiness adecreaseofinternationalsaleswerebillionan theorthoclinicaldiagnosticsfranchiseachievedsalesof increaseofwhichincludedoperationalgrowthanda billioninaincreaseovertheprioryearthegrowth positivecurrencyimpactof wasprimarilyattributabletothestrengthofthevitrosand analyzerspartiallyoffsetbylowersalesindonorscreene medicaldevicesanddiagnosticssegment themedicaldevicesanddiagnosticssegmentachievedsale themedicaldevicesanddiagnosticssegmentachievedsalesof ofbillioninrepresentinganincreaseofoverthe billioninrepresentinganincreaseofovertheprior prioryearwithoperationalgrowthofandapositivecurrency yearwithoperationalgrowthofandapositivecurrencyimpact impactofussaleswerebillionanincreaseof ofussaleswerebillionadecreaseofascom overtheprioryearinternationalsaleswerebillionanincrease paredtotheprioryearinternationalsaleswerebillionan ofovertheprioryearwithgrowthoffromoperation increaseofovertheprioryearwithoperationalgrowthof andapositivecurrencyimpactof andapositivecurrencyimpactof thedepuyfranchiseachievedsalesofbillionina analysisofconsolidatedearning increaseovertheprioryearthisgrowthwasprimarilydueto beforeprovisionfortaxesonincome salesofmiteksportsmedicineandtraumaproductlinesandnewly acquiredproductsfrommicrusthegrowthwaspartiallyoffsetby consolidatedearningsbeforeprovisionfortaxesonincome lowersalesofkneesandhipsintheusduetoincreasedcompeti decreasedbybilliontobillioninascomparedto tioncontinuedpricingpressureasoftermarketandtheimpactof billioninadecreaseofthedecreasewasprimarily thedepuyasrhiprecall duetocostsassociatedwithproductliabilityandlitigationexpense theimpactoftheotcanddepuyasrhiprecallsandtherestruc turingexpenserelatedtothecardiovascularcarebusinessaddi tionallyinvestmentspendingthefeeonbrandedpharmaceutical majormedicaldevicesanddiagnosticsfranchisesale change dollarsinmillion vs vs depuy ethiconendosurgery ethicon visioncare diabetescare cardiovascularcare orthoclinicaldiagnostic total previouslyreferredtoascordis management discussion analysis result operation financial condition productsincurredduetotheushealthcarereformlegislationand incostofproductssoldasapercenttosalesincreasedcom theintegrationcostsincludinganinventorystepupchargeassoci paredtotheprioryearthiswasprimarilyattributabletoongoe atedwiththeacquisitionofcrucellcontributedtothedecreasein remediationcostsintheconsumerotcbusinessandinventory earningsthiswaspartiallyoffsetbygainsfromdivestiture writeoffsduetotherestructuringofthecardiovascularcarebusi theincreaseofascomparedtowasprimarily nessinadditionlowermarginsandintegrationcostsincludingan relatedtolowersellingmarketingandadministrativeexpensesdue inventorystepupchargeassociatedwiththeacquisitionofcrucell tocostcontainmentactionsresultingfromtherestructuringplanini negativelyimpactedcostofproductssoldpercenttosalesofsell tiatedandimplementedinincomefromlitigationsettlement ingmarketingandadministrativeexpensesincreasedincom andthegainonthedivestitureofthebreastcarebusinessofethicon paredtotheprioryearprimarilyduetoinvestmentspendingaswell endosurgeryincthiswaspartiallyoffsetbycostsassociatedwith asthefeeonbrandedpharmaceuticalproductsincurredduetothe productliabilityexpenseandtheimpactoftheotcanddepuy ushealthcarereformlegislation asrhiprecallsadditionaloffsetswerelowernetsellingpricesin incostofproductssoldasapercenttosalesincreased thepharmaceuticalbusinessduetoushealthcarereformlegisla comparedtotheprioryearprimarilyduetocostsassociatedwith tionandpricereductionsincertainmedicaldevicesanddiagnostic theimpactoftheotcrecallandremediationeffortsinthecon businessesthedecreaseofascomparedto sumerbusinesslowernetsellingpricesinthepharmaceuticalbusi wasprimarilyrelatedtolowersalesthenegativeimpactofproduct nessduetoushealthcarereformlegislationandpricereduction mixlowerinterestincomeduetolowerratesofinterestearne incertainmedicaldevicesanddiagnosticsbusinessesaddition andrestructuringchargesofbillionthiswaspartiallyoffsetby allyunfavorableproductmixattributabletothelossofmarket lowersellingmarketingandadministrativeexpensesduetocost exclusivityfortopamaxcontributedtotheincreasetherewasa containmenteffortsacrossallthebusinessesasapercenttosale decreaseinthepercenttosalesofsellingmarketingandadminis consolidatedearningsbeforeprovisionfortaxesonincomein trativeexpensesincomparedtotheprioryearprimarilydueto wasversusin costcontainmentinitiativesprincipallyresultingfromtherestruc thesectionsthatfollowhighlightthesignificantcomponents turingplanimplementedinthedecreasewaspartiallyoffset ofthechangesinconsolidatedearningsbeforeprovisionfortaxes bylowernetsellingpricesinthepharmaceuticalbusinessdueto onincome ushealthcarereformlegislationandpricereductionsincertain medicaldevicesanddiagnosticsbusinesse costofproductssoldandsellingmarketingandadministrative incostofproductssoldasapercenttosalesincreased expensescostofproductssoldandsellingmarketingand comparedtotheprioryearprimarilyduetothecontinuednegative administrativeexpensesasapercenttosaleswereasfollow impactofproductmixandinventorywriteoffsassociatedwith ofsales therestructuringactivityadditionallyincludedcertainnon costofproductssold recurringpositiveitemstherewasadecreaseinthepercentto percentpointincreaseovertheprioryear salesofsellingmarketingandadministrativeexpensesin comparedtotheprioryearprimarilyduetocostcontainmenteffort sellingmarketingandadministrativeexpense acrossallthebusinessesandtheannualizedsavingsrecognize percentpointincreasedecreaseoverthe fromtherestructuringprograminadditioninthe prioryear companyutilizedtheproceedsassociatedwiththedivestitureof theprofessionalwoundcarebusinessofethiconinctofund increasedinvestmentspending researchanddevelopmentexpensebysegmentofbusinesswasasfollow dollarsinmillion ofsale ofsale ofsale consumer pharmaceutical medicaldevicesanddiagnostic totalresearchanddevelopmentexpense percentincreasedecreaseovertheprioryear asapercenttosegmentsale researchanddevelopmentexpenseresearchanddevelopment restructuringincordiscorporationasubsidiaryof activitiesrepresentasignificantpartofthecompanysbusiness johnsonjohnsonannouncedthediscontinuationofitsclinical theseexpendituresrelatetotheprocessesofdiscoveringteste developmentprogramforthenevosirolimuselutingcoronary anddevelopingnewproductsimprovingexistingproductsaswell stentandcessationofthemanufactureandmarketingofcypher asensuringproductefficacyandregulatorycompliancepriorto andcypherselectplussirolimuselutingcoronarystentsby launchthecompanyremainscommittedtoinvestinginresearch theendofthecompanywillfocusonothercardiovascular anddevelopmentwiththeaimofdeliveringhighqualityandinnova therapieswheresignificantpatientneedsexistinthefiscalsecond tiveproductsinworldwidecostsofresearchanddevelopment quarterofthecompanyrecordedapretaxchargeof activitiesincreasedbycomparedtotheincreasein millionofwhichmillionisincludedincostofproductssold thepharmaceuticalsegmentwasprimarilyduetohigherlevelsof inthecompanyannouncedglobalrestructuringinitiative spendingtoadvancethecompanyspharmaceuticalpipelinethe expectedtogeneratepretaxannualcostsavingsofapproximately decreaseinthemedicaldevicesanddiagnosticssegmentwasdue billionwhenfullyimplementedtheassociatedsavingshaspro tothediscontinuationofitsclinicaldevelopmentprogramforthe videdadditionalresourcestoinvestinnewgrowthplatformsensure nevosirolimuselutingcoronarystent thesuccessfullaunchofthecompanysmanynewproductsand johnson johnson annual reportcontinuedgrowthofthecorebusinessesandprovideflexibilityto costsassociatedwiththerecallofcertainotcproductspartially adjusttothechangedandevolvingglobalenvironmentinthefiscal offsetbythegainonthedivestitureofmonistatin fourthquarterofthecompanyrecordedapretaxchargeof consumersegmentoperatingprofitdecreasedfrom billionofwhichmillionwasincludedincostofproductssold theprimaryreasonsforthedecreaseintheoperatingprofitwere seenotetotheconsolidatedfinancialstatementsfor lowersalesandhighercostsassociatedwiththerecallofcertain additionaldetailsrelatedtotherestructuring otcproductsandthesuspensionofproductionatmcneil consumerhealthcaresfortwashingtonpennsylvaniafacility otherincomeexpensenetotherincomeexpensenet includesroyaltyincomegainsandlossesrelatedtothesaleand pharmaceuticalsegmentinpharmaceuticalsegment writedownofcertaininvestmentsinequitysecuritiesheldby operatingprofitdecreasedfromtheprimarydriversof johnsonjohnsondevelopmentcorporationgainsandlosseson thedecreaseintheoperatingprofitmarginwerehigherlitigation thedisposalofpropertyplantandequipmentcurrencygainsand expensesrecordedintheimpactoftheushealthcare lossesnoncontrollinginterestsandlitigationsettlementsin reformfeeandlowermarginsandintegrationcostsincludingan theunfavorablechangeofbillioninotherincomeexpense inventorystepupchargeassociatedwiththecrucellacquisition netwasprimarilyduetolitigationexpensesofbillionina thiswaspartiallyoffsetbygainsonthedivestituresoftheanimal comparedtoabillionnetgainfromlitigationsettlementsin healthbusinessandorthodermatologicsthegainrelatedtothe additionallyascomparedtoincludedhigher companysearlierinvestmentincrucellandlowermanufacture expensesofbillionrelatedtoproductliabilitybillionfor costsinpharmaceuticalsegmentoperatingprofitincrease costsrelatedtothedepuyasrhiprecallprogramandanadjust fromtheprimaryreasonsfortheincreaseinoperate mentofbilliontothevalueofthecurrencyoptionanddeal profitwerelowermanufacturingcoststhegainonadivestitureand costsrelatedtotheplannedacquisitionofsynthesincinclude benefitsfromcostimprovementinitiativesrelatedtotherestruc inwerehighergainsonthedivestituresofbusinessesof turingplanimplementedinpartiallyoffsetbymillion billionascomparedto ofexpenserelatedtolitigationmattersincreasedproductliability inthefavorablechangeofbillioninotherincome expenseandtheimpactofthenewlyenactedushealthcare expensenetascomparedtowasprimarilyduetoanetgain reformlegislation fromlitigationsettlementsandgainsonthedivestitureofbusinesse medicaldevicesanddiagnosticssegmentinmedical partiallyoffsetbyproductliabilityexpenseinotherincome devicesanddiagnosticssegmentoperatingprofitdecrease expensenetincludednetlitigationsettlementsofbillion fromtheprimarydriversofthedeclineintheoperatingprofit margininthemedicaldevicesanddiagnosticssegmentwereprod operatingprofitbysegment uctliabilityandlitigationexpensescostsassociatedwiththedepuy operatingprofitsbysegmentofbusinesswereasfollow asrhiprecallprogramrestructuringexpensecostsincurred percentof relatedtotheplannedacquisitionofsynthesincandincrease segmentsales investmentspendinginmedicaldevicesanddiagnostic dollarsinmillion segmentoperatingprofitincreasedfromtheimprove consumer operatingprofitwasduetoagainofbillionfromnetlitigation pharmaceutical mattersandthegainonthedivestitureofthebreastcarebusiness medicaldevicesand recordedinthiswaspartiallyoffsetbyincreasedproduct diagnostic liabilityexpensemillionofcostsassociatedwiththedepuy total asrhiprecallprogramandpricereductionsincertainmedical lessexpensesnotallocate devicesanddiagnosticsbusinesse tosegment interestincomeexpenseinterestincomeindecreasedby earningsbeforeprovision millionascomparedtotheprioryearduetolowerratesofinter fortaxesonincome estearneddespitehigheraveragecashbalancescashcashequiva seenotetotheconsolidatedfinancialstatementsformoredetail lentsandmarketablesecuritiestotaledbillionattheendof amountsnotallocatedtosegmentsincludeinterestincomeexpensenoncontrolle andaveragedbillionascomparedtothebillion interestsandgeneralcorporateincomeexpenseincludedinwasabillion averagecashbalanceintheincreaseintheaveragecashbal expensefortheadjustmenttothevalueofthecurrencyoptionrelatedtotheplanned acquisitionofsynthesinc ancewasprimarilyduetocashgeneratedfromoperatingactivitie andnetcashproceedsfromdivestiture operatingprofit interestexpenseinincreasedbymillionascompared bysegment toduetoahigheraveragedebtbalancethetotaldebtbalance inbillionsofdollar attheendofwasbillionascomparedtobillionat theendofthehigheraveragedebtbalanceofbillionin consumer versusbillioninwasduetoincreasedborrowing pharmaceutical thecompanyincreasedborrowingscapitalizingonfavorableterm medicaldevice inthecapitalmarketstheproceedsoftheborrowingswereuse anddiagnostic forgeneralcorporatepurpose interestincomeinincreasedbymillionovertheprior yearduetohigheraveragecashbalancescashcashequivalent andmarketablesecuritiestotaledbillionattheendof andaveragedbillionascomparedtothebillionaverage cashbalanceintheincreaseintheaveragecashbalancewas consumersegmentinconsumersegmentoperatingprofit primarilyduetocashgeneratedfromoperatingactivitiesandnet decreasedfromtheprimarydriversofthedeclinein cashproceedsfromlitigationmattersanddivestiture operatingprofitwereunfavorableproductmixandremediation management discussion analysis result operation financial condition interestexpenseinwasrelativelyflatascomparedto operate duetoaloweraverageratedespiteahigherdebtbalancethe cashflowand totaldebtbalanceattheendofwasbillionascompare capitalexpenditure tobillionattheendofthehigheraveragedebtbalance inbillionsofdollar ofbillioninversusbillioninwasdueto capitalexpenditure increasedborrowingsthecompanyincreasedborrowingscapital operatingcashflow izingonfavorabletermsinthecapitalmarketstheproceedsofthe borrowingswereusedforgeneralcorporatepurpose interestincomeindecreasedbymillionascom paredtoduetolowerratesofinterestearneddespitehigher averagecashbalancesthecashbalanceincludingmarketable securitieswasbillionattheendofandaverage billionascomparedtothebillionaveragecashbalance intheincreaseintheaveragecashbalancewasprimarily concentrationofcreditrisk duetocashgeneratedfromoperatingactivitie globalconcentrationofcreditriskwithrespecttotradeaccount interestexpenseinincreasedbymillionascompare receivablescontinuestobelimitedduetothelargenumberofcus toduetoahigherdebtbalancethenetdebtbalanceatthe tomersgloballyandadherencetointernalcreditpoliciesandcredit endofwasbillionascomparedtobillionattheend limitsrecenteconomicchallengesinitalyspaingreeceandportu ofthehigheraveragedebtbalanceofbillionin galthesoutherneuropeanregionhaveimpactedcertainpayment versusbillioninwasprimarilyrelatedtofundingacquisi patternswhichhavehistoricallybeenlongerthanthoseexperi tionsandinvestmentsandthepurchaseofthecompanyscommon encedintheusandotherinternationalmarketsthetotalnet stockunderthecommonstockrepurchaseprogramannounce tradeaccountsreceivablebalanceinthesoutherneuropeanregion onjuly wasapproximatelybillionasofjanuaryandapproxi matelybillionasofjanuaryapproximatelybillion provisionfortaxesonincometheworldwideeffectiveincometax asofjanuaryandapproximatelybillionasofjanuary ratewasininandinthe ofthesoutherneuropeanregionnettradeaccountsreceivable taxrateincreasedascomparedtoduetocertainusexpense balancerelatedtothecompanysconsumervisioncareand whicharenotfullytaxdeductibleandhigherusstatetaxespar diabetescarebusinessesaswellascertainpharmaceuticaland tiallyoffsetbyincreasesintaxableincomeinlowertaxjurisdiction medicaldevicesanddiagnosticscustomerswhichareinlinewith relativetohighertaxjurisdictionsthetaxratedecreasedas historicalcollectionpatterns comparedtoduetodecreasesintaxableincomeinhighertax theremainingbalanceofnettradeaccountsreceivableinthe jurisdictionsrelativetotaxableincomeinlowertaxjurisdictionsand southerneuropeanregionhasbeennegativelyimpactedbythe certainustaxadjustment timingofpaymentsfromcertaingovernmentownedorsupporte healthcarecustomersaswellascertaindistributorsofthepharma liquidityandcapitalresource ceuticalandmedicaldevicesanddiagnosticslocalaffiliatesthe totalnettradeaccountsreceivablebalanceforthesecustomer liquiditycashflow cashandcashequivalentswerebillionattheendofas wereapproximatelybillionatjanuaryandjanuary comparedwithbillionattheendoftheprimarysource thecompanycontinuestoreceivepaymentsfromthesecus ofcashthatcontributedtothebillionincreaseversustheprior tomersandinsomecaseslatepaymentpremiumsforcustomer yearwerebillionofcashgeneratedfromoperatingactivitie wherepaymentisexpectedoverperiodsoftimelongerthanone billionnetproceedsfromlongandshorttermdebtbillion yearrevenueandtradereceivableshavebeendiscountedoverthe proceedsfromthedisposalofassetsandproceedsfromnetinvest estimatedperiodoftimeforcollectionallowancesfordoubtful mentsalesofbillionthemajorusesofcashweredividend accountshavebeenincreasedforthesecustomersbuthavebeen toshareholdersofbillioncapitalspendingofbillion immaterialtodatethecompanywillcontinuetoworkclosely acquisitionsofbilliontherepurchaseofcommonstocknet withthesecustomersmonitortheeconomicsituationandtake ofproceedsfromtheexerciseofoptionsofbillionandotherof appropriateactionsasnecessary billionprimarilyrelatedtointangibleasset cashflowsfromoperationswerebillioninthemajor financingandmarketrisk sourcesofcashflowwerenetincomeofbillionadjustedfor thecompanyusesfinancialinstrumentstomanagetheimpactof noncashchargesfordepreciationandamortizationstockbase foreignexchangeratechangesoncashflowsaccordinglythe compensationanddeferredtaxprovisionofbilliontheremain companyentersintoforwardforeignexchangecontractstoprotect ingchangetooperatingcashflowofbillionwasprimarilydueto thevalueofcertainforeigncurrencyassetsandliabilitiesandto anincreaseinothercurrentandnoncurrentliabilitiesrelatedto hedgefutureforeigncurrencytransactionsprimarilyrelatedtoprod accrualsrecordedforlitigationmattersproductliabilityand uctcostsgainsorlossesonthesecontractsareoffsetbythegain employeebenefitplans orlossesontheunderlyingtransactionsaappreciationofthe inthecompanycontinuedtohaveaccesstoliquidity usdollarfromthejanuarymarketrateswouldincreasethe throughthecommercialpapermarketforadditionaldetailson unrealizedvalueofthecompanysforwardcontractsbymil borrowingsseenotetotheconsolidatedfinancialstatement lionconverselyadepreciationoftheusdollarfromthe thecompanyanticipatesthatoperatingcashflowsexisting januarymarketrateswoulddecreasetheunrealizedvalueof creditfacilitiesandaccesstothecommercialpapermarketswill thecompanysforwardcontractsbymillionineitherscenario providesufficientresourcestofundoperatingneedsin thegainorlossontheforwardcontractwouldbeoffsetbythegain orlossontheunderlyingtransactionandthereforewouldhaveno impactonfutureanticipatedearningsandcashflows thecompanyhedgestheexposuretofluctuationsincurrency exchangeratesandtheeffectoncertainassetsandliabilitiesin johnson johnson annual reportforeigncurrencybyenteringintocurrencyswapcontractsa combinationofavailablecashanddebtinadditionthecompany changeinthespreadbetweenusandforeigninterestratesonthe hasanannualprogramtorepurchasesharesforuseinemployee companysinterestratesensitivefinancialinstrumentswouldeither stockandincentiveplans increaseordecreasetheunrealizedvalueofthecompanysswap thecompanyincreaseditsdividendinforthethcon contractsbyapproximatelymillionineitherscenarioat secutiveyearcashdividendspaidwerepersharein maturitythegainorlossontheswapcontractwouldbeoffsetby comparedwithdividendsofpershareinandper thegainorlossontheunderlyingtransactionandthereforewould shareinthedividendsweredistributedasfollow havenoimpactonfutureanticipatedcashflow thecompanydoesnotenterintofinancialinstrumentsfor firstquarter tradingorspeculativepurposesfurtherthecompanyhasapolicy secondquarter ofonlyenteringintocontractswithpartiesthathaveatleastana orequivalentcreditratingthecounterpartiestothesecontract thirdquarter aremajorfinancialinstitutionsandthereisnosignificantconcentra fourthquarter tionofexposurewithanyonecounterpartymanagementbelieve total theriskoflossisremote thecompanyhasaccesstosubstantialsourcesoffundsat onjanuarytheboardofdirectorsdeclaredaregularquar numerousbanksworldwideinseptemberthecompany terlycashdividendofpersharepayableonmarch securedanewdaycreditfacilitytotalcreditavailabletothe toshareholdersofrecordasoffebruarythecompany companyapproximatesbillionwhichexpiresseptember expectstocontinuethepracticeofpayingregularcashdividend interestchargedonborrowingsunderthecreditlineagree mentisbasedoneitherbidsprovidedbybankstheprimerateor otherinformation londoninterbankofferedratesliborplusapplicablemargin commitmentfeesundertheagreementarenotmaterial criticalaccountingpoliciesandestimates totalborrowingsattheendofandwerebillion managementsdiscussionandanalysisofresultsofoperation andbillionrespectivelytheincreaseinborrowingsbetween andfinancialconditionarebasedonthecompanysconsolidate andwasaresultoffinancingforgeneralcorporatepur financialstatementsthathavebeenpreparedinaccordancewith posesinnetcashcashandcurrentmarketablesecuritiesnet accountingprinciplesgenerallyacceptedintheusgaapthe ofdebtwasbillioncomparedtonetcashofbillionin preparationofthesefinancialstatementsrequiresthatmanagement totaldebtrepresentedoftotalcapitalshareholder makeestimatesandassumptionsthataffecttheamountsreporte equityandtotaldebtinandoftotalcapitalin forrevenuesexpensesassetsliabilitiesandotherrelateddisclo shareholdersequitypershareattheendofwa suresactualresultsmayormaynotdifferfromtheseestimatesthe comparedwithatyearendanincreaseof companybelievesthattheunderstandingofcertainkeyaccounte asummaryofborrowingscanbefoundinnotetothe policiesandestimatesareessentialinachievingmoreinsightinto consolidatedfinancialstatement thecompanysoperatingresultsandfinancialconditionthesekey accountingpoliciesincluderevenuerecognitionincometaxeslegal andselfinsurancecontingenciesvaluationoflonglivedasset contractualobligationsandcommitment thecompanyscontractualobligationsareprimarilyforleasesdebt assumptionsusedtodeterminetheamountsrecordedforpension andunfundedretirementplanswithnoothersignificantobliga andotheremployeebenefitplansandaccountingforstockoptions tionstosatisfytheseobligationsthecompanywillusecashfrom revenuerecognitionthecompanyrecognizesrevenuefrom operationsthefollowingtablesummarizesthecompanyscontrac productsaleswhengoodsareshippedordeliveredandtitleand tualobligationsandtheiraggregatematuritiesasofjanuary riskoflosspasstothecustomerprovisionsforcertainrebatessale seenotesandtotheconsolidatedfinancialstatementsfor incentivestradepromotionscouponsproductreturnsanddis furtherdetail countstocustomersareaccountedforasreductionsinsalesinthe sameperiodtherelatedsalesarerecorde longterm intereston unfunded debt debt retirement operating productdiscountsgrantedarebasedonthetermsofarrange dollarsinmillion obligation obligation plan lease total mentswithdirectindirectandothermarketparticipantsaswell asmarketconditionsincludingpriceschargedbycompetitor rebatesthelargestbeingthemedicaidrebateprovisionareesti matedbasedoncontractualtermshistoricalexperiencetrend analysisandprojectedmarketconditionsinthevariousmarket servedthecompanyevaluatesmarketconditionsforproductsor groupsofproductsprimarilythroughtheanalysisofwholesalerand otherthirdpartysellthroughandmarketresearchdataaswella total internallygeneratedinformation salesreturnsaregenerallyestimatedandrecordedbasedon fortaxmattersseenotetotheconsolidatedfinancialstatement historicalsalesandreturnsinformationproductsthatexhibit unusualsalesorreturnpatternsduetodatingcompetitionorother sharerepurchaseanddividend marketingmattersarespecificallyinvestigatedandanalyzedaspart onjulythecompanyannouncedthatitsboardofdirector oftheaccountingforsalesreturnaccrual approvedastockrepurchaseprogramauthorizingthecompanyto salesreturnsallowancesrepresentareserveforproductsthat buybackuptobillionofthecompanyscommonstockas maybereturnedduetoexpirationdestructioninthefieldorin ofjanuarythecompanyrepurchasedanaggregateof specificareasproductrecallthereturnsreserveisbasedonhis millionsharesofjohnsonjohnsoncommonstockatacost toricalreturntrendsbyproductandbymarketasapercenttogross ofbillionandthestockrepurchaseprogramwascomplete salesinaccordancewiththecompanysaccountingpoliciesthe thecompanyfundedthesharerepurchaseprogramthrougha management discussion analysis result operation financial condition companygenerallyissuescredittocustomersforreturnedgood consumersegment thecompanyssalesreturnsreservesareaccountedforinaccor balanceat balanceat dancewiththeusgaapguidanceforrevenuerecognitionwhen beginning payment end rightofreturnexistssalesreturnsreservesarerecordedatfullsale dollarsinmillion ofperiod accrual credit ofperiod valuesalesreturnsintheconsumerandpharmaceuticalsegment arealmostexclusivelynotresalablesalesreturnsforcertainfran accruedrebate chisesinthemedicaldevicesanddiagnosticssegmentaretypically accruedreturn resalablebutarenotmaterialthecompanyrarelyexchangesprod accruedpromotion uctsfrominventoryforreturnedproductsthesalesreturnsreserve subtotal forthetotalcompanyhasrangedbetweenandofannual reservefordoubtfulaccount nettradesalesduringthepriorthreefiscalreportingyear reserveforcashdiscount promotionalprogramssuchasproductlistingallowancesand total cooperativeadvertisingarrangementsarerecordedintheyear incurredcontinuingpromotionalprogramsincludecouponsand accruedrebate volumebasedsalesincentiveprogramstheredemptioncostof accruedreturn consumercouponsisbasedonhistoricalredemptionexperienceby accruedpromotion productandvaluevolumebasedincentiveprogramsarebasedon estimatedsalesvolumesfortheincentiveperiodandarerecorded subtotal asproductsaresoldthecompanyalsoearnsservicerevenuefor reservefordoubtfulaccount copromotionofcertainproductsforallyearspresentedservice reserveforcashdiscount revenueswerelessthanoftotalrevenuesandareincludedin total salestocustomersthesearrangementsareevaluatedtodetermine includesreserveforcustomerrebatesofmillionatjanuaryandmillionat theappropriateamountstobedeferre januaryrecordedasacontraasset inadditionthecompanyentersintocollaborationarrange mentsthatcontainmultiplerevenuegeneratingactivitiesthe pharmaceuticalsegment revenueforthesearrangementsisrecognizedaseachactivityis performedordeliveredbasedontherelativefairvalueupfront balanceat balanceat beginning payment end feesreceivedaspartofthesearrangementsaredeferredandrecog dollarsinmillion ofperiod accrual credit ofperiod nizedasrevenueearnedovertheobligationperiodseenoteto theconsolidatedfinancialstatementsforadditionaldisclosure accruedrebate oncollaboration accruedreturn reasonablylikelychangestoassumptionsusedtocalculatethe accruedpromotion accrualsforrebatesreturnsandpromotionsarenotanticipatedto subtotal haveamaterialeffectonthefinancialstatementsthecompany currentlydisclosestheimpactofchangestoassumptionsinthe reservefordoubtfulaccount quarterlyorannualfilinginwhichthereisamaterialfinancial reserveforcashdiscount statementimpact total belowaretablesthatshowtheprogressionofaccruedrebate returnspromotionsreservefordoubtfulaccountsandreservefor accruedrebate cashdiscountsbysegmentofbusinessforthefiscalyearsende accruedreturn januaryandjanuary accruedpromotion subtotal reservefordoubtfulaccount reserveforcashdiscount total includesreserveforcustomerrebatesofmillionatjanuaryandmillion atjanuaryrecordedasacontraasset includesadditionalsalesrebatestomedicaidmanagedcareorganizationsasaresultof theushealthcarereformlegislation johnson johnson annual reportmedicaldevicesanddiagnosticssegment futurecashflowsinevaluatingthevalueofthecompanysproperty plantandequipmentgoodwillandintangibleassetsasthese balanceat balanceat assumptionsandestimatesmaychangeovertimeitmayormaynot begin payment end dollarsinmillion ofperiod accrual credit ofperiod benecessaryforthecompanytorecordimpairmentcharge employeebenefitplansthecompanysponsorsvariousretirement accruedrebate andpensionplansincludingdefinedbenefitdefinedcontribution accruedreturn andterminationindemnityplanswhichcovermostemployee accruedpromotions worldwidetheseplansarebasedonassumptionsforthediscount subtotal rateexpectedreturnonplanassetsexpectedsalaryincreasesand reservefordoubtfulaccount healthcarecosttrendratesseenotetotheconsolidatedfinan reserveforcashdiscount cialstatementsforfurtherdetailsontheseratesandtheeffecta ratechangewouldhaveonthecompanysresultsofoperation total stockbasedcompensationthecompanyrecognizescompensa tionexpenseassociatedwiththeissuanceofequityinstrumentsto accruedrebate employeesfortheirservicesthefairvalueofeachawardisesti accruedreturn matedonthedateofgrantusingtheblackscholesoptionvaluation accruedpromotion modelandisexpensedinthefinancialstatementsovertheveste subtotal periodtheinputassumptionsusedindeterminingfairvalueare reservefordoubtfulaccount theexpectedlifeexpectedvolatilityriskfreerateandthedividend reserveforcashdiscount yieldseenotetotheconsolidatedfinancialstatementsfor total additionalinformation includesreserveforcustomerrebatesofmillionatjanuaryandmillion atjanuaryrecordedasacontraasset newaccountingpronouncement accrualsandpaymentscreditsforhavebeenrevisedbymilliontoappropriately refertonotetotheconsolidatedfinancialstatementsforrecently reflectnoncashcreditsadjustmentsconsistentwithcurrentyearpresentationrelatedto adoptedaccountingpronouncementsandrecentlyissuedaccount theethiconfranchisepreviouslyreportednetintheaccrualscolumn ingpronouncementsnotyetadoptedasofjanuary incometaxesincometaxesarerecordedbasedonamount refundableorpayableforthecurrentyearandincludetheresultsof economicandmarketfactor anydifferencebetweenusgaapaccountingandtaxreporte thecompanyisawarethatitsproductsareusedinanenvironment recordedasdeferredtaxassetsorliabilitiesthecompanyestimate whereformorethanadecadepolicymakersconsumersandbusi deferredtaxassetsandliabilitiesbasedoncurrenttaxregulation nesseshaveexpressedconcernsabouttherisingcostofhealthcare andrateschangesintaxlawsandratesmayaffectrecorde inresponsetotheseconcernsthecompanyhasalongstande deferredtaxassetsandliabilitiesinthefuturemanagementbelieve policyofpricingproductsresponsiblyfortheperiodin thatchangesintheseestimateswouldnothaveamaterialeffecton theunitedstatestheweightedaveragecompoundannualgrowth thecompanysresultsofoperationscashflowsorfinancialposition rateofthecompanysnetpriceincreasesforhealthcareproduct atjanuaryandjanuarythecumulative prescriptionandoverthecounterdrugshospitalandprofessional amountsofundistributedinternationalearningswereapproximately productswasbelowtheusconsumerpriceindexcpi billionandbillionrespectivelyatjanuaryand inflationratescontinuetohaveaneffectonworldwide januarythecompanysforeignsubsidiariesheldbalance economiesandconsequentlyonthewaycompaniesoperatethe ofcashandcashequivalentsintheamountsofbillionand companyaccountedforoperationsinvenezuelaashighlyinflation billionrespectivelythecompanyintendstocontinueto aryinandasthepriorthreeyearcumulativeinflation reinvestitsundistributedinternationalearningstoexpandit ratesurpassedinthefaceofincreasingcoststhecompany internationaloperationsthereforenoustaxexpensehasbeen strivestomaintainitsprofitmarginsthroughcostreductionpro recordedwithrespecttotheundistributedportionnotintende gramsproductivityimprovementsandperiodicpriceincrease forrepatriation thecompanyisexposedtofluctuationsincurrencyexchange seenotetotheconsolidatedfinancialstatementsfor ratesachangeinthevalueoftheusdollarascomparedto furtherinformationregardingincometaxes allforeigncurrenciesinwhichthecompanyhadsalesincomeor expenseinwouldhaveincreasedordecreasedthetranslation legalandselfinsurancecontingenciesthecompanyrecord offoreignsalesbyapproximatelymillionandincomeby accrualsforvariouscontingenciesincludinglegalproceedingsand million productliabilityclaimsastheseariseinthenormalcourseofbusi thecompanyfacesvariousworldwidehealthcarechange nesstheaccrualsarebasedonmanagementsjudgmentastothe thatmaycontinuetoresultinpricingpressuresthatincludehealth probabilityoflossesandwhereapplicableactuariallydetermine carecostcontainmentandgovernmentlegislationrelatingtosale estimatesadditionallythecompanyrecordsinsurancereceivable promotionsandreimbursementofhealthcareproduct amountsfromthirdpartyinsurerswhenrecoveryisprobablea changesinthebehaviorandspendingpatternsofpurchaser appropriatereservesagainstthesereceivablesarerecordedforesti ofhealthcareproductsandservicesincludingdelayingmedical matedamountsthatmaynotbecollectedfromthirdpartyinsurer proceduresrationingprescriptionmedicationsreducingthe thecompanyfollowstheprovisionsofusgaapwhenrecord frequencyofphysicianvisitsandforegoinghealthcareinsurance inglitigationrelatedcontingenciesaliabilityisrecordedwhenaloss coverageasaresultofthecurrentglobaleconomicdownturn isprobableandcanbereasonablyestimatedthebestestimateofa maycontinuetoimpactthecompanysbusinesse losswithinarangeisaccruedhoweverifnoestimateintherangeis thecompanyalsooperatesinanenvironmentwhichhas betterthananyothertheminimumamountisaccrue becomeincreasinglyhostiletointellectualpropertyrightsgeneric longlivedandintangibleassetsthecompanyassesseschange drugfirmshavefiledabbreviatednewdrugapplicationsanda ineconomicconditionsandmakesassumptionsregardingestimated management discussion analysis result operation financial condition seekingtomarketgenericformsofmostofthecompanyskeyphar cautionaryfactorsthatmayaffect maceuticalproductspriortoexpirationoftheapplicablepatent futureresult coveringthoseproductsintheeventthecompanyisnotsuccessful indefendingthepatentclaimschallengedinandafilingsthe thisannualreportcontainsforwardlookingstatementsforward genericfirmswillthenintroducegenericversionsoftheproductat lookingstatementsdonotrelatestrictlytohistoricalorcurrentfact issueresultinginthepotentialforsubstantialmarketshareand andanticipateresultsbasedonmanagementsplansthataresubject revenuelossesforthatproductforfurtherinformationseethe touncertaintyforwardlookingstatementsmaybeidentifiedby discussiononlitigationagainstfilersofabbreviatednewdrug theuseofwordssuchasplansexpectswillanticipate applicationsinnotetotheconsolidatedfinancialstatement estimatesandotherwordsofsimilarmeaninginconjunctionwith amongotherthingsdiscussionsoffutureoperationsfinancialper formancethecompanysstrategyforgrowthproductdevelopment legalproceeding johnsonjohnsonandcertainofitssubsidiariesareinvolvedin regulatoryapprovalmarketpositionandexpenditure variouslawsuitsandclaimsregardingproductliabilityintellectual forwardlookingstatementsarebasedoncurrentexpectation propertycommercialandothermattersgovernmentalinvestiga offutureeventsthecompanycannotguaranteethatanyforward tionsandotherlegalproceedingsthatarisefromtimetotimein lookingstatementwillbeaccuratealthoughthecompanybelieve theordinarycourseofbusiness thatithasbeenreasonableinitsexpectationsandassumption thecompanyrecordsaccrualsforsuchcontingencieswhenit investorsshouldrealizethatifunderlyingassumptionsproveinac isprobablethataliabilitywillbeincurredandtheamountoftheloss curateorthatunknownrisksoruncertaintiesmaterializeactual canbereasonablyestimatedthecompanyhasaccruedforcertain resultscouldvarymateriallyfromthecompanysexpectationsand litigationmattersandcontinuestomonitoreachrelatedlegalissue projectionsinvestorsarethereforecautionednottoplaceundue andadjustaccrualsfornewinformationandfurtherdevelopment relianceonanyforwardlookingstatementsthecompanydoesnot inaccordancewithascfortheseandotherlitigation undertaketoupdateanyforwardlookingstatementsasaresultof andregulatorymatterscurrentlydisclosedforwhichalossisproba newinformationorfutureeventsordevelopment bleorreasonablypossiblethecompanyisunabletodeterminean risksanduncertaintiesincludebutarenotlimitedtogeneral estimateofthepossiblelossorrangeoflossbeyondtheamount industryconditionsandcompetitioneconomicfactorssucha alreadyaccruedthesematterscanbeaffectedbyvariousfactors interestrateandcurrencyexchangeratefluctuationstechnological includingwhetherdamagessoughtintheproceedingsareunsub advancesnewproductsandpatentsattainedbycompetitorschal stantiatedorindeterminatescientificandlegaldiscoveryhasnot lengesinherentinnewproductdevelopmentincludingobtaine commencedorisnotcompleteproceedingsareinearlystages regulatoryapprovalschallengestopatentssignificantlitigation matterspresentlegaluncertaintiestherearesignificantfactsin adversetothecompanyimpactofbusinesscombinationsfinancial disputeortherearenumerouspartiesinvolve distressandbankruptciesexperiencedbysignificantcustomer inthecompanysopinionbasedonitsexaminationofthese andsupplierschangestogovernmentallawsandregulationsand mattersitsexperiencetodateanddiscussionswithcounselthe usandforeignhealthcarereformstrendstowardhealthcarecost ultimateoutcomeoflegalproceedingsnetofliabilitiesaccruedin containmentincreasedscrutinyofthehealthcareindustrybygov thecompanysbalancesheetisnotexpectedtohaveamaterial ernmentagencieschangesinbehaviorandspendingpatternsof adverseeffectonthecompanysfinancialpositionhoweverthe purchasersofhealthcareproductsandservicesfinancialinstability resolutioninanyreportingperiodofoneormoreofthesematter ofinternationaleconomiesandsovereignriskdisruptionsdue eitheraloneorintheaggregatemayhaveamaterialadverse tonaturaldisastersmanufacturingdifficultiesordelaysproduct effectonthecompanysresultsofoperationsandcashflowsfor efficacyorsafetyconcernsresultinginproductrecallsor thatperiod regulatoryaction seenotetotheconsolidatedfinancialstatementsfor thecompanysreportonformkfortheyearendedjanuary furtherinformationregardinglegalproceeding includesinexhibitadiscussionofadditionalfactorsthat couldcauseactualresultstodifferfromexpectationsthecompany notesthesefactorsaspermittedbytheprivatesecuritieslitigation commonstockmarketprice thecompanyscommonstockislistedonthenewyorkstock reformactof exchangeunderthesymboljnjthecompositemarketpricerange forjohnsonjohnsoncommonstockduringandwere high low high low firstquarter secondquarter thirdquarter fourthquarter yearendclose johnson johnson annual reportconsolidatedbalancesheet johnsonjohnsonandsubsidiarie atjanuaryandjanuarydollarsinmillionsexceptshareandpersharedatanote asset currentasset cashandcashequivalentsnotesand marketablesecuritiesnotesand accountsreceivabletradelessallowancesfordoubtfulaccount inventoriesnotesand deferredtaxesonincomenote prepaidexpensesandotherreceivable totalcurrentassets propertyplantandequipmentnetnotesand intangibleassetsnetnotesand goodwillnotesand deferredtaxesonincomenote otherasset totalasset liabilitiesandshareholdersequity currentliabilitie loansandnotespayablenote accountspayable accruedliabilitie accruedrebatesreturnsandpromotion accruedcompensationandemployeerelatedobligations accruedtaxesonincome totalcurrentliabilities longtermdebtnote deferredtaxesonincomenote employeerelatedobligationsnotesand otherliabilitie totalliabilitie shareholdersequity preferredstockwithoutparvalue authorizedandunissuedshare commonstockparvaluepersharenote authorizedsharesissuedshare accumulatedothercomprehensiveincomenote retainedearning lesscommonstockheldintreasuryatcostnote sharesandshare totalshareholdersequity totalliabilitiesandshareholdersequity seenotestoconsolidatedfinancialstatement consolidate financial statement consolidatedstatementsofearning johnsonjohnsonandsubsidiarie dollarsinmillionsexceptpersharefiguresnote salestocustomer costofproductssold grossprofit sellingmarketingandadministrativeexpense researchanddevelopmentexpense interestincome interestexpensenetofportioncapitalizednote otherincomeexpensenet restructuringnote earningsbeforeprovisionfortaxesonincome provisionfortaxesonincomenote netearning basicnetearningspersharenotesand dilutednetearningspersharenotesand cashdividendspershare basicaveragesharesoutstandingnotesand dilutedaveragesharesoutstandingnotesand seenotestoconsolidatedfinancialstatements johnson johnson annual reportconsolidatedstatementsofequity johnsonjohnsonandsubsidiarie accumulate treasury comprehensive retain comprehensive commonstock stock dollarsinmillionsnote total income earning income issuedamount balancedecember netearning cashdividendspaid employeecompensationandstockoptionplans repurchaseofcommonstock othercomprehensiveincomenetoftax currencytranslationadjustment unrealizedlossesonsecuritie employeebenefitplans gainsonderivativeshedge totalcomprehensiveincome balancejanuary netearning cashdividendspaid employeecompensationandstockoptionplans repurchaseofcommonstock othercomprehensiveincomenetoftax currencytranslationadjustment unrealizedgainsonsecuritie employeebenefitplans lossesonderivativeshedge totalcomprehensiveincome balancejanuary netearning cashdividendspaid employeecompensationandstockoptionplans repurchaseofcommonstock othercomprehensiveincomenetoftax currencytranslationadjustment unrealizedgainsonsecuritie employeebenefitplans lossesonderivativeshedge totalcomprehensiveincome balancejanuary seenotestoconsolidatedfinancialstatement consolidate financial statement consolidatedstatementsofcashflow johnsonjohnsonandsubsidiarie dollarsinmillionsnote cashflowsfromoperatingactivitie netearning adjustmentstoreconcilenetearningstocashflowsfrom operatingactivitie depreciationandamortizationofpropertyandintangible stockbasedcompensation deferredtaxprovision accountsreceivableallowance changesinassetsandliabilitiesnetofeffectsfromacquisition increasedecreaseinaccountsreceivable increasedecreaseininventorie increasedecreaseinaccountspayableandaccruedliabilitie increasedecreaseinothercurrentandnoncurrentasset increaseinothercurrentandnoncurrentliabilitie netcashflowsfromoperatingactivitie cashflowsfrominvestingactivitie additionstopropertyplantandequipment proceedsfromthedisposalofasset acquisitionsnetofcashacquirednote purchasesofinvestment salesofinvestment otherprimarilyintangible netcashusedbyinvestingactivitie cashflowsfromfinancingactivitie dividendstoshareholder repurchaseofcommonstock proceedsfromshorttermdebt retirementofshorttermdebt proceedsfromlongtermdebt retirementoflongtermdebt proceedsfromtheexerciseofstockoptionsexcesstaxbenefit netcashusedbyfinancingactivitie effectofexchangeratechangesoncashandcashequivalent increaseincashandcashequivalent cashandcashequivalentsbeginningofyearnote cashandcashequivalentsendofyearnote supplementalcashflowdata cashpaidduringtheyearfor interest incometaxe supplementalscheduleofnoncashinvestingandfinancingactivitie treasurystockissuedforemployeecompensationand stockoptionplansnetofcashproceed conversionofdebt acquisition fairvalueofassetsacquire fairvalueofliabilitiesassumedandnoncontrollinginterest netcashpaidforacquisition seenotestoconsolidatedfinancialstatement johnson johnson annual reportnotestoconsolidatedfinancialstatement summaryofsignificantaccountingpolicie expenseinthecompanysfinancialstatementandwillbeamortize principlesofconsolidation onastraightlinebasisfortheyearasperthefasbguidancethe theconsolidatedfinancialstatementsincludetheaccountsof adoptionofthisstandarddidnothaveamaterialimpactonthe johnsonjohnsonanditssubsidiariesthecompany companysresultsofoperationscashflowsorfinancialposition intercompanyaccountsandtransactionsareeliminate recentlyissuedaccountingstandard descriptionofthecompanyandbusinesssegment notadoptedasofjanuary thecompanyhasapproximatelyemployeesworldwide duringthefiscalthirdquarterofthefasbissuedamendment engagedintheresearchanddevelopmentmanufactureandsaleof togoodwillimpairmenttestingundertheamendmentsinthisupdate abroadrangeofproductsinthehealthcarefieldthecompany anentityhastheoptiontofirstassessqualitativefactorstodetermine conductsbusinessinvirtuallyallcountriesoftheworldanditspri whethertheexistenceofeventsorcircumstancesleadstoadetermi maryfocusisonproductsrelatedtohumanhealthandwellbeing nationthatitismorelikelythannotthatthefairvalueofareporting thecompanyisorganizedintothreebusinesssegment unitislessthanitscarryingamountifafterassessingthetotalityof consumerpharmaceuticalandmedicaldevicesanddiagnostic eventsorcircumstancesanentitydeterminesitisnotmorelikelythan theconsumersegmentincludesabroadrangeofproductsusedin notthatthefairvalueofareportingunitislessthanitscarrye thebabycareskincareoralcarewoundcareandwomenshealth amountthenperformingthetwostepimpairmenttestisunnece fieldsaswellasnutritionalandoverthecounterpharmaceutical saryhoweverifanentityconcludesotherwisethenitisrequiredto productsandwellnessandpreventionplatformstheseproduct performthefirststepofthetwostepimpairmenttestthisguidance aremarketedtothegeneralpublicandsoldbothtoretailoutlet iseffectiveforannualandinterimgoodwillimpairmenttestsper anddistributorsthroughouttheworldthepharmaceuticalsegment formedforfiscalyearsbeginningafterdecembertheadop includesproductsinthefollowingareasantiinfectiveantipsychotic tionofthisstandardisnotexpectedtohaveamaterialimpactonthe contraceptivedermatologygastrointestinalhematologyimmunol companysresultsofoperationscashflowsorfinancialposition ogyneurologyoncologypainmanagementthrombosisvaccine duringthefiscalsecondquarterofthefasbissuedan andinfectiousdiseasestheseproductsaredistributeddirectlyto amendmenttothedisclosurerequirementsforpresentationofcom retailerswholesalersandhealthcareprofessionalsforprescription prehensiveincometheamendmentrequiresthatallnonowner usethemedicaldevicesanddiagnosticssegmentincludesabroad changesinstockholdersequitybepresentedeitherinasinglecon rangeofproductsdistributedtowholesalershospitalsandretailer tinuousstatementofcomprehensiveincomeorintwoseparatebut usedprincipallyintheprofessionalfieldsbyphysiciansnursesthera consecutivestatementsthisguidanceiseffectiveretrospectively pistshospitalsdiagnosticlaboratoriesandclinicstheseproduct fortheinterimperiodsandannualperiodsbeginningafterdecem includecardiovascularcareselectrophysiologyandcirculatory berhoweverthefasbagreedtoanindefinitedeferralof diseasemanagementproductsdepuysorthopaedicjointrecon thereclassificationrequirementtheadoptionofthisstandardisnot structionspinalcareneurologicalandsportsmedicineproduct expectedtohaveamaterialimpactonthecompanysresultsof ethiconssurgicalcareaestheticsandwomenshealthproduct operationscashflowsorfinancialposition ethiconendosurgerysminimallyinvasivesurgicalproductsand duringthefiscalsecondquarterofthefasbissue advancedsterilizationproductsdiabetescaresbloodglucosemoni amendmentstodisclosurerequirementsforcommonfairvalue toringandinsulindeliveryproductsorthoclinicaldiagnostic measurementtheseamendmentsresultinconvergenceoffair professionaldiagnosticproductsandvisioncaresdisposable valuemeasurementanddisclosurerequirementsbetweenusgen contactlense erallyacceptedaccountingprinciplesgaapandinternational financialreportingstandardsifrsthisguidanceiseffective newaccountingpronouncement prospectivelyfortheinterimperiodsandannualperiodsbeginne recentlyadoptedaccountingpronouncement afterdecemberearlyadoptionisprohibitedtheadoption duringthefiscalfirstquarterofthecompanyadoptedthe ofthisstandardisnotexpectedtohaveamaterialimpactonthe financialaccountingstandardsboardfasbguidanceandamend companysresultsofoperationscashflowsorfinancialposition mentsissuedrelatedtorevenuerecognitionunderthemilestone methodtheobjectiveoftheaccountingstandardupdateistopro cashequivalent videguidanceondefiningamilestoneanddeterminingwhenitmay thecompanyconsiderssecuritieswithmaturitiesofthreemonth beappropriatetoapplythemilestonemethodofrevenuerecognition orlesswhenpurchasedtobecashequivalent forresearchordevelopmenttransactionsthisupdatebecameeffec tiveonaprospectivebasisformilestonesachievedinfiscalyearsand investment interimperiodswithinthoseyearsbeginningonorafterjune shorttermmarketablesecuritiesarecarriedatcostwhichapproxi theadoptionofthisstandarddidnothaveamaterialimpacton matesfairvalueinvestmentsclassifiedasavailableforsaleare thecompanysresultsofoperationscashflowsorfinancialposition carriedatestimatedfairvaluewithunrealizedgainsandlosse duringthefiscalfirstquarterofthecompanyadopte recordedasacomponentofaccumulatedothercomprehensive thefasbguidanceonhowpharmaceuticalcompaniesshouldrecog incomelongtermdebtsecuritiesthatthecompanyhastheability nizeandclassifyinthecompanysfinancialstatementsthenon andintenttoholduntilmaturityarecarriedatamortizedcost deductibleannualfeepaidtothegovernmentinaccordancewiththe managementdeterminestheappropriateclassificationofitsinvest patientprotectionandaffordablecareactasamendedbythe mentindebtandequitysecuritiesatthetimeofpurchaseand healthcareandeducationreconciliationactthisfeeisbasedonan reevaluatessuchdeterminationateachbalancesheetdatethe allocationofacompanysmarketshareoftotalbrandedprescription companyperiodicallyreviewsitsinvestmentsinequitysecuritie drugsalestousgovernmentprogramsfromtheprioryeartheesti forimpairmentandadjuststheseinvestmentstotheirfairvalue matedfeewasrecordedasasellingmarketingandadministrative whenadeclineinmarketvalueisdeemedtobeotherthan note consolidated financial statement temporaryiflossesonthesesecuritiesareconsideredtobeother promotionalprogramssuchasproductlistingallowancesand thantemporarythelossisrecognizedinearning cooperativeadvertisingarrangementsarerecordedintheyear incurredcontinuingpromotionalprogramsincludecouponsand propertyplantandequipmentanddepreciation volumebasedsalesincentiveprogramstheredemptioncostof propertyplantandequipmentarestatedatcostthecompany consumercouponsisbasedonhistoricalredemptionexperience utilizesthestraightlinemethodofdepreciationovertheestimated byproductandvaluevolumebasedincentiveprogramsarebased usefullivesoftheasset ontheestimatedsalesvolumesfortheincentiveperiodandare recordedasproductsaresoldthecompanyalsoearnsservicerev buildingandbuildingequipment year enueforcopromotionofcertainproductsandincludesitinsalesto landandleaseholdimprovement year customersthesearrangementsareevaluatedtodeterminethe machineryandequipment year appropriateamountstobedeferred thecompanycapitalizescertaincomputersoftwareanddevelopment costsincludedinmachineryandequipmentwhenincurredinconnec shippingandhandle tionwithdevelopingorobtainingcomputersoftwareforinternaluse shippingandhandlingcostsincurredweremillionmil capitalizedsoftwarecostsareamortizedovertheestimateduseful lionandmillioninandrespectivelyandare livesofthesoftwarewhichgenerallyrangefromtoyear includedinsellingmarketingandadministrativeexpensethe thecompanyreviewslonglivedassetstoassessrecoverability amountofrevenuereceivedforshippingandhandlingislessthan usingundiscountedcashflowswhencertaineventsorchangesin ofsalestocustomersforallperiodspresente operatingoreconomicconditionsoccuranimpairmentassessment maybeperformedontherecoverabilityofthecarryingvalueof inventory theseassetsiftheassetisdeterminedtobeimpairedthelossis inventoriesarestatedatthelowerofcostormarketdeterminedby measuredbasedonthedifferencebetweentheassetsfairvalueand thefirstinfirstoutmethod itscarryingvalueifquotedmarketpricesarenotavailablethe companywillestimatefairvalueusingadiscountedvalueof intangibleassetsandgoodwill estimatedfuturecashflow theauthoritativeliteratureonusgaaprequiresthatgoodwilland intangibleassetswithindefinitelivesbeassessedannuallyfor revenuerecognition impairmentthecompanycompletedtheannualimpairmenttest thecompanyrecognizesrevenuefromproductsaleswhenthe forinthefiscalfourthquarterandnoimpairmentwasdeter goodsareshippedordeliveredandtitleandriskoflosspasstothe minedfutureimpairmenttestswillbeperformedannuallyin customerprovisionsforcertainrebatessalesincentivestradepro thefiscalfourthquarterorsoonerifatriggeringeventoccur motionscouponsproductreturnsanddiscountstocustomersare purchasedinprocessresearchanddevelopmentisaccountedfora accountedforasreductionsinsalesinthesameperiodtherelate anindefinitelivedintangibleassetuntiltheunderlyingprojectis salesarerecorde completedatwhichpointtheintangibleassetwillbeaccountedfor productdiscountsgrantedarebasedonthetermsofarrange asadefinitelivedintangibleassetorabandonedatwhichpointthe mentswithdirectindirectandothermarketparticipantsaswell intangibleassetwillbewrittenoff asmarketconditionsincludingpriceschargedbycompetitors intangibleassetsthathavefiniteusefullivescontinuetobe rebatesthelargestbeingthemedicaidrebateprovisionareesti amortizedovertheirusefullivesandarereviewedforimpairment matedbasedoncontractualtermshistoricalexperiencetrend whenwarrantedbyeconomicconditionsseenoteforfurther analysisandprojectedmarketconditionsinthevariousmarket detailsonintangibleassetsandgoodwill servedthecompanyevaluatesmarketconditionsforproductsor groupsofproductsprimarilythroughtheanalysisofwholesalerand financialinstrument otherthirdpartysellthroughandmarketresearchdataaswella asrequiredbyusgaapallderivativeinstrumentsarerecordedon internallygeneratedinformation thebalancesheetatfairvaluechangesinthefairvalueofderivative salesreturnsaregenerallyestimatedandrecordedbasedon arerecordedeachperiodincurrentearningsorothercomprehensive historicalsalesandreturnsinformationproductsthatexhibit incomedependingonwhetherthederivativeisdesignatedaspartof unusualsalesorreturnpatternsduetodatingcompetitionor ahedgetransactionandifsothetypeofhedgetransaction othermarketingmattersarespecificallyinvestigatedandanalyze thecompanydocumentsallrelationshipsbetweenhedge aspartoftheaccountingforsalesreturnsaccrual itemsandderivativestheoverallriskmanagementstrategy salesreturnsallowancesrepresentareserveforproductsthat includesreasonsforundertakinghedgetransactionsandentere maybereturnedduetoexpirationdestructioninthefieldorinspe intoderivativestheobjectivesofthisstrategyareminimize cificareasproductrecallthereturnsreserveisbasedonhistorical foreigncurrencyexposuresimpactonthecompanysfinancial returntrendsbyproductandbymarketasapercenttogrosssale performanceprotectthecompanyscashflowfromadverse inaccordancewiththecompanysaccountingpoliciesthe movementsinforeignexchangeratesensuretheappropriate companygenerallyissuescredittocustomersforreturnedgood nessoffinancialinstrumentsandmanagetheenterpriserisk thecompanyssalesreturnsreservesareaccountedforinaccor associatedwithfinancialinstitutionsseenoteforadditional dancewithusgaapguidanceforrevenuerecognitionwhenright informationonfinancialinstrument ofreturnexistssalesreturnsreservesarerecordedatfullsale valuesalesreturnsintheconsumerandpharmaceuticalsegment productliability arealmostexclusivelynotresalablesalesreturnsforcertainfran accrualsforproductliabilityclaimsarerecordedonanundis chisesinthemedicaldevicesanddiagnosticssegmentaretypically countedbasiswhenitisprobablethataliabilityhasbeenincurre resalablebutarenotmaterialthecompanyrarelyexchangesprod andtheamountoftheliabilitycanbereasonablyestimatedbase uctsfrominventoryforreturnedproductsthesalesreturnsreserve onexistinginformationtheaccrualsareadjustedperiodicallyas forthetotalcompanyhasrangedbetweenandofannual additionalinformationbecomesavailableasaresultofcostand salestocustomersduringthepriorthreefiscalreportingyears availabilityfactorseffectivenovemberthecompany johnson johnson annual reportceasedpurchasingthirdpartyproductliabilityinsurancebasedon operationsingeneraltheincomestatementpresentationforthese theavailabilityofpriorcoveragereceivablesforinsurancerecover collaborationsisasfollow iesrelatedtoproductliabilityclaimsarerecordedonanundis naturetypeofcollaboration statementofearningspresentation countedbasiswhenitisprobablethatarecoverywillberealize thirdpartysaleofproduct salestocustomer royaltiesmilestonespaidto concentrationofcreditrisk collaborativepartner globalconcentrationofcreditriskwithrespecttotradeaccount postregulatoryapproval costofgoodssold receivablescontinuestobelimitedduetothelargenumberof royaltiesreceivedfromcollaborativepartner otherincomeexpensenet customersgloballyandadherencetointernalcreditpoliciesand upfrontpaymentsmilestone creditlimitsrecenteconomicchallengesinitalyspaingreeceand paidtocollaborativepartner portugalthesoutherneuropeanregionhaveimpactedcertain preregulatoryapproval researchanddevelopmentexpense paymentpatternswhichhavehistoricallybeenlongerthanthose researchanddevelopmentpayment experiencedintheusandotherinternationalmarketsthetotal tocollaborativepartner researchanddevelopmentexpense nettradeaccountsreceivablebalanceinthesoutherneuropean researchanddevelopment regionwasapproximatelybillionasofjanuaryand paymentsreceivedfrom approximatelybillionasofjanuaryapproximately collaborativepartner reductionofresearchanddevelopmentexpense billionasofjanuaryandapproximatelybillionasof milestonesarecapitalizedasintangibleassetsandamortizedtocostofgoodssoldover januaryofthesoutherneuropeanregionnettradeaccounts theusefullife receivablebalancerelatedtothecompanysconsumervisioncare anddiabetescarebusinessesaswellascertainpharmaceutical advertising andmedicaldevicesanddiagnosticscustomerswhichareinline costsassociatedwithadvertisingareexpensedintheyearincurre withhistoricalcollectionpattern andareincludedinsellingmarketingandadministrativeexpense theremainingbalanceofnettradeaccountsreceivableinthe advertisingexpensesworldwidewhichcomprisedtelevisionradio southerneuropeanregionhasbeennegativelyimpactedbythe printmediaandinternetadvertisingwerebillionbillion timingofpaymentsfromcertaingovernmentownedorsupporte andbillioninandrespectively healthcarecustomersaswellascertaindistributorsofthepharma ceuticalandmedicaldevicesanddiagnosticslocalaffiliatesthe incometaxe totalnettradeaccountsreceivablebalanceforthesecustomer incometaxesarerecordedbasedonamountsrefundableorpayable wereapproximatelybillionatjanuaryandjanuary forthecurrentyearandincludetheresultsofanydifference thecompanycontinuestoreceivepaymentsfromthesecus betweenusgaapaccountingandtaxreportingrecordeda tomersandinsomecaseslatepaymentpremiumsforcustomer deferredtaxassetsorliabilitiesthecompanyestimatesdeferre wherepaymentisexpectedoverperiodsoftimelongerthanone taxassetsandliabilitiesbasedoncurrenttaxregulationsandrate yearrevenueandtradereceivableshavebeendiscountedoverthe changesintaxlawsandratesmayaffectrecordeddeferredtax estimatedperiodoftimeforcollectionallowancesfordoubtful assetsandliabilitiesinthefuturemanagementbelievesthat accountshavebeenincreasedforthesecustomersbuthavebeen changesintheseestimateswouldnothaveamaterialeffectonthe immaterialtodatethecompanywillcontinuetoworkclosely companysresultsofoperationscashflowsorfinancialposition withthesecustomersmonitortheeconomicsituationandtake atjanuaryandjanuarythecumulative appropriateactionsasnecessary amountsofundistributedinternationalearningswereapproximately billionandbillionrespectivelyatjanuaryand researchanddevelopment januarythecompanysforeignsubsidiariesheldbalance researchanddevelopmentexpensesareexpensedasincurre ofcashandcashequivalentsintheamountsofbillionand upfrontandmilestonepaymentsmadetothirdpartiesinconnec billionrespectivelythecompanyintendstocontinueto tionwithresearchanddevelopmentcollaborationsareexpensedas reinvestitsundistributedinternationalearningstoexpandit incurreduptothepointofregulatoryapprovalpaymentsmadeto internationaloperationsthereforenoustaxexpensehasbeen thirdpartiessubsequenttoregulatoryapprovalarecapitalizedand recordedwithrespecttotheundistributedportionnotintende amortizedovertheremainingusefullifeoftherelatedproduct forrepatriation amountscapitalizedforsuchpaymentsareincludedinother seenotetotheconsolidatedfinancialstatementsfor intangiblesnetofaccumulatedamortization furtherinformationregardingincometaxe thecompanyentersintocollaborativearrangementstypically withotherpharmaceuticalorbiotechnologycompaniestodevelop netearningspershare andcommercializedrugcandidatesorintellectualpropertythese basicearningspershareiscomputedbydividingnetearningsavail arrangementstypicallyinvolvetwoormorepartieswhoareactive abletocommonshareholdersbytheweightedaveragenumberof participantsinthecollaborationandareexposedtosignificantrisk commonsharesoutstandingfortheperioddilutedearningsper andrewardsdependentonthecommercialsuccessoftheactivitie sharereflectsthepotentialdilutionthatcouldoccurifsecuritie thesecollaborationsusuallyinvolvevariousactivitiesbyoneor wereexercisedorconvertedintocommonstockusingthetreasury morepartiesincludingresearchanddevelopmentmarketingand stockmethod sellinganddistributionoftenthesecollaborationsrequireupfront milestoneandroyaltyorprofitsharepaymentscontingentuponthe useofestimate occurrenceofcertainfutureeventslinkedtothesuccessoftheasset thepreparationofconsolidatedfinancialstatementsinconformity indevelopmentamountsduefromcollaborativepartnersrelate withaccountingprinciplesgenerallyacceptedintheusrequire todevelopmentactivitiesaregenerallyreflectedasareductionof managementtomakeestimatesandassumptionsthataffectthe researchanddevelopmentexpensebecausetheperformanceof amountsreportedestimatesareusedwhenaccountingforsale contractdevelopmentservicesisnotcentraltothecompany discountsrebatesallowancesandincentivesproductliabilitie incometaxesdepreciationamortizationemployeebenefit note consolidated financial statement contingenciesandintangibleassetandliabilityvaluationsfor inventory instanceindeterminingannualpensionandpostemploymentben attheendofandinventorieswerecomprisedof efitcoststhecompanyestimatestherateofreturnonplanasset dollarsinmillion andthecostoffuturehealthcarebenefitsactualresultsmayor rawmaterialsandsupplie maynotdifferfromthoseestimate thecompanyfollowstheprovisionsofusgaapwhenrecord goodsinprocess inglitigationrelatedcontingenciesaliabilityisrecordedwhenaloss finishedgood isprobableandcanbereasonablyestimatedthebestestimateofa totalinventorie losswithinarangeisaccruedhoweverifnoestimateintherangeis betterthananyothertheminimumamountisaccrue propertyplantandequipment annualclosingdate attheendofandpropertyplantandequipmentatcost thecompanyfollowstheconceptofafiscalyearwhichendsonthe andaccumulateddepreciationwere sundaynearesttotheendofthemonthofdecembernormally dollarsinmillion eachfiscalyearconsistsofweeksbuteveryfiveorsixyearsthe landandlandimprovement fiscalyearconsistsofweeksaswasthecaseinandwillbe buildingsandbuildingequipment thecaseagainin machineryandequipment reclassification constructioninprogress certainpriorperiodamountshavebeenreclassifiedtoconformto totalpropertyplantandequipmentgross currentyearpresentation lessaccumulateddepreciation totalpropertyplantandequipmentnet cashcashequivalentsandcurrent thecompanycapitalizesinterestexpenseaspartofthecostofcon marketablesecuritie structionoffacilitiesandequipmentinterestexpensecapitalizedin attheendofandcashcashequivalentsandcurrent andwasmillionmillionandmillion marketablesecuritieswerecomprisedof respectively dollarsinmillion depreciationexpenseincludingtheamortizationofcapitalize cash interestinandwasbillionbillionand governmentsecuritiesandobligation billionrespectively corporatedebtsecuritie uponretirementorotherdisposalofpropertyplantandequip mentthecostsandrelatedamountsofaccumulateddepreciation moneymarketfund oramortizationareeliminatedfromtheassetandaccumulate timedeposit depreciationaccountsrespectivelythedifferenceifanybetween totalcashcashequivalentsand thenetassetvalueandtheproceedsarerecordedinearning currentmarketablesecuritie theestimatedfairvaluewasmillionasofjanuary intangibleassetsandgoodwill reflectingamillionunrealizedgainingovernmentsecuritiesand attheendofandthegrossandnetamountsof obligationstheestimatedfairvaluewasthesameasthecarrye intangibleassetswere valueasofjanuary asofjanuarycurrentmarketablesecuritiesconsiste dollarsinmillion ofmillionandmillionofgovernmentsecuritiesand intangibleassetswithdefinitelive obligationsandcorporatedebtsecuritiesrespectively patentsandtrademarksgross asofjanuarycurrentmarketablesecuritiesconsiste lessaccumulatedamortization ofmillionandmillionofgovernmentsecuritiesand patentsandtrademarksnet obligationsandcorporatedebtsecuritiesrespectively otherintangiblesgross fairvalueofgovernmentsecuritiesandobligationsandcorpo lessaccumulatedamortization ratedebtsecuritieswereestimatedusingquotedbrokerpricesin otherintangiblesnet activemarket thecompanyinvestsitsexcesscashinbothdepositswith intangibleassetswithindefinitelive majorbanksthroughouttheworldandotherhighqualitymoney trademark marketinstrumentsthecompanyhasapolicyofmakinginvest purchasedinprocessresearchanddevelopment mentsonlywithcommercialinstitutionsthathaveatleastana totalintangibleassetswithindefinitelive orequivalentcreditrate totalintangibleassetsnet theacquisitionofcrucellnvduringthefiscalfirstquarterof increasedpurchasedinprocessresearchanddevelopmentby approximatelybillionandpatentsandtrademarksbyapproxi matelybillionduringthefiscalsecondquarterofthe companyreclassifiedapproximatelybillionfrompurchase inprocessresearchanddevelopmenttoamortizableother intangiblestoreflectthecommercializationofzytiga johnson johnson annual reportgoodwillasofjanuaryandjanuaryasallocate currentearningseffectoftherelatedforeigncurrencyassetsand bysegmentofbusinesswasasfollow liabilitiesthecompanydoesnotenterintoderivativefinancial instrumentsfortradingorspeculativepurposesorcontaincreditrisk meddevice relatedcontingentfeaturesorrequirementstopostcollateralonan dollarsinmillion consumer pharmaceutical anddiagnostic total ongoingbasisthecompanymonitorscounterpartycreditrating goodwillatjanuary thecompanyconsiderscreditnonperformancerisktobelow acquisition becausethecompanyentersintoagreementswithcommercialinsti currencytranslationother tutionsthathaveatleastanaorequivalentcreditratingasof goodwillatjanuary januarythecompanyhadnotionalamountsoutstandingfor acquisition forwardforeignexchangecontractsandcrosscurrencyinterestrate currencytranslationother swapsofbillionandbillionrespectively goodwillatjanuary allderivativeinstrumentsarerecordedonthebalancesheetat fairvaluechangesinthefairvalueofderivativesarerecordedeach includesreclassificationbetweensegment periodincurrentearningsorothercomprehensiveincomedepende theweightedaverageamortizationperiodsforpatentsandtrade onwhetherthederivativeisdesignatedaspartofahedgetransaction marksandotherintangibleassetsareyearsandyear andifsothetypeofhedgetransaction respectivelytheamortizationexpenseofamortizableassetswas thedesignationasacashflowhedgeismadeattheentrancedate millionmillionandmillionbeforetaxforthefiscal intothederivativecontractatinceptionallderivativesareexpecte yearsendedjanuaryjanuaryandjanuary tobehighlyeffectivechangesinthefairvalueofaderivativethatis respectivelywhichincludesthewritedownsofcertainpatent designatedasacashflowhedgeandishighlyeffectivearerecorde andintangibleassetsthesewritedownsdidnothaveamaterial inaccumulatedothercomprehensiveincomeuntiltheunderlye impactonthecompanysresultsofoperationscashflowsor transactionaffectsearningsandarethenreclassifiedtoearningsin financialposition thesameaccountasthehedgedtransactiongainslossesonnet theestimatedamortizationexpenseforthefivesucceede investmenthedgesareaccountedforthroughthecurrencytranslation yearsapproximatesmillionbeforetaxperyearsubstantially accountandareinsignificantonanongoingbasisthecompany alloftheamortizationexpenseisincludedincostofproductssold assesseswhethereachderivativecontinuestobehighlyeffectiveinoff settingchangesinthecashflowsofhedgeditemsifandwhenaderiva tiveisnolongerexpectedtobehighlyeffectivehedgeaccountingis fairvaluemeasurements discontinuedhedgeineffectivenessifanyisincludedincurrentperiod thecompanyusesforwardexchangecontractstomanageitsexpo earningsinotherincomeexpensenetrefertonotefordisclo suretothevariabilityofcashflowsprimarilyrelatedtotheforeign suresofmovementsinaccumulatedothercomprehensiveincome exchangeratechangesoffutureintercompanyproductandthird asofjanuarythebalanceofdeferrednetlosseson partypurchasesofrawmaterialsdenominatedinforeigncurrency derivativesincludedinaccumulatedothercomprehensiveincome thecompanyalsousescrosscurrencyinterestrateswapstomanage wasmillionaftertaxforadditionalinformationseenote currencyriskprimarilyrelatedtoborrowingsbothtypesofderivative thecompanyexpectsthatsubstantiallyalloftheamountrelatedto aredesignatedascashflowhedgesthecompanyalsousesforward foreignexchangecontractswillbereclassifiedintoearningsoverthe exchangecontractstomanageitsexposuretothevariabilityofcash nextmonthsasaresultoftransactionsthatareexpectedtooccur flowsforrepatriationofforeigndividendsthesecontractsaredesig overthatperiodthemaximumlengthoftimeoverwhichthe natedasnetinvestmenthedgesadditionallythecompanyuse companyishedgingtransactionexposureismonthsexclude forwardexchangecontractstooffsetitsexposuretocertainforeign interestrateswapstheamountultimatelyrealizedinearningswill currencyassetsandliabilitiestheseforwardexchangecontractsare differasforeignexchangerateschangerealizedgainsandlosse notdesignatedashedgesandthereforechangesinthefairvaluesof areultimatelydeterminedbyactualexchangeratesatmaturityof thesederivativesarerecognizedinearningstherebyoffsettingthe thederivative thefollowingtableisasummaryoftheactivityrelatedtodesignatedderivativesforthefiscalyearsendedjanuaryand january gainloss gainloss reclassifiedfrom gainloss recognizedin accumulatedoci recognizedin cashflowhedge accumulatedoci intoincome otherincomeexpense dollarsinmillion foreignexchangecontract foreignexchangecontract b b foreignexchangecontract c c crosscurrencyinterestrateswap foreignexchangecontract e e total allamountsshowninthetableabovearenetoftax effectiveportion ineffectiveportion aincludedinsalestocustomer bincludedincostofproductssold cincludedinresearchanddevelopmentexpense dincludedininterestincomeinterestexpensenet eincludedinotherincomeexpensenet note consolidated financial statement forthefiscalyearsendedjanuaryandjanuaryaloss thehierarchyaredescribedbelowwithlevelhavingthehigh ofmillionandmillionrespectivelywasrecognizedinother priorityandlevelhavingthelow incomeexpensenetrelatingtoforeignexchangecontractsnot thefairvalueofaderivativefinancialinstrumentieforward designatedashedginginstrument exchangecontractcurrencyswapistheaggregationbycurrencyof inadditionduringthefiscalsecondquarterofthe allfuturecashflowsdiscountedtoitspresentvalueattheprevaile companyenteredintoanoptiontohedgethecurrencyriskassoci marketinterestratesandsubsequentlyconvertedtotheusdollar atedwiththecashportionofthepaymentfortheplannedacquisi atthecurrentspotforeignexchangeratethecompanydoesnot tionofsynthesinctheoptionwasnotdesignatedasahedgeand believethatfairvaluesofthesederivativeinstrumentsmaterially thereforechangesinthefairvalueoftheoptionarerecognizedin differfromtheamountsthatcouldberealizeduponsettlementor otherincomeexpensenetduringthefiscalyearendedjanuary maturityorthatthechangesinfairvaluewillhaveamaterialeffect themarktomarketadjustmenttoreducethevalueofthecur onthecompanysresultsofoperationscashflowsorfinancialposi rencyoptionwasmillionwhichexpiredinjanuarythe tionthecompanyalsoholdsequityinvestmentsthatareclassifie costbasisoftheoptionwasmillion aslevelastheyaretradedinanactiveexchangemarket duringthefiscalfourthquarterofthecompanyreclassi thefollowingthreelevelsofinputsareusedtomeasure fiedforeigncurrencybondmarktomarketadjustmentsfromforeign fairvalue currencytranslationtogainlossonderivativesandhedgesthere levelquotedpricesinactivemarketsforidenticalasset wasnonetimpactwithinothercomprehensiveincomeasaresult andliabilitie ofthisreclassification fairvalueistheexitpricethatwouldbereceivedtosellan levelsignificantotherobservableinput assetorpaidtotransferaliabilityfairvalueisamarketbase levelsignificantunobservableinput measurementthatshouldbedeterminedusingassumptionsthat marketparticipantswoulduseinpricinganassetorliability theauthoritativeliteratureestablishesathreelevelhierarchyto prioritizetheinputsusedinmeasuringfairvaluethelevelswithin thecompanyssignificantfinancialassetsandliabilitiesmeasuredatfairvalueasofjanuaryandjanuarywereasfollow dollarsinmillion level level level total total derivativesdesignatedashedginginstrument asset foreignexchangecontract crosscurrencyinterestrateswap total liability foreignexchangecontract crosscurrencyinterestrateswap total derivativesnotdesignatedashedginginstrument asset foreignexchangecontract swissfrancoption total liability foreignexchangecontract otherinvestment currencyoptionrelatedtotheplannedacquisitionofsynthesinc assetsandliabilitiesareallclassifiedaslevelwiththeexceptionofotherinvestmentsofmillionwhichareclassifiedaslevel includesmillionandmillionofnoncurrentassetsforthefiscalyearsendingjanuaryandjanuaryrespectively includesmillionandmillionofnoncurrentliabilitiesforthefiscalyearsendingjanuaryandjanuaryrespectively classifiedasnoncurrentotherasset seenotesandforfinancialassetsandliabilitiesheldatcarryingamountontheconsolidatedbalancesheet johnson johnson annual reportborrowing thecompanyhasashelfregistrationwiththeussecuritie thecomponentsoflongtermdebtareasfollow andexchangecommissionthatenablesthecompanytoissuedebt securitiesandwarrantstopurchasedebtsecuritiesonatimely effective effective basisthecompanyissuedbondsinmayforatotalofbil dollarsinmillion rate rate lionforgeneralcorporatepurpose debenturesdue aggregatematuritiesoflongtermobligationscommencingin notesdue debenturesdue monthliborfrndue dollarsinmillion monthliborfrndue notesdue notesdue debenturesdue incometaxe debenturesdue theprovisionfortaxesonincomeconsistsof notesdue dollarsinmillion beuro currentlypayable beuro ustaxe zerocouponconvertible subordinateddebenturesdue internationaltaxe debenturesdue totalcurrentlypayable notesdue defer debenturesdue ustaxe notesdue internationaltaxe mmgbp totaldeferre mmgbp provisionfortaxesonincome notesdue debenturesdue acomparisonofincometaxexpenseattheusstatutoryrateof notesdue inandtothecompanyseffectivetaxrateis debenturesdue asfollow debenturesdue dollarsinmillion notesdue international earningsbeforetaxesonincome lesscurrentportion taxrate usstatutoryrate weightedaverageeffectiverate internationaloperationsexcludingireland translationrateatjanuary irelandandpuertoricooperation translationrateatjanuary researchandorphandrugtaxcredit theexcessofthefairvalueoverthecarryingvalueofdebtwasbillioninand billionin usstateandlocal usmanufacturingdeduction fairvalueofthenoncurrentdebtwasestimatedusingmarket ustaxoninternationalincome priceswhichwerecorroboratedbyquotedbrokerpricesin allother activemarket thecompanyhasaccesstosubstantialsourcesoffundsat effectivetaxrate numerousbanksworldwideinseptemberthecompany includesusexpensesnotfullytaxdeductibleprimarilyrelatedtolitigationexpense securedanewdaycreditfacilitytotalcreditavailabletothe companyapproximatesbillionwhichexpiresseptember thecompanyhassubsidiariesoperatinginpuertoricoundervarious interestchargedonborrowingsunderthecreditlineagree taxincentivegrantstheincreaseinthetaxratewasprimarily mentsisbasedoneitherbidsprovidedbybankstheprimerateor duetocertainusexpenseswhicharenotfullytaxdeductible londoninterbankofferedratesliborplusapplicablemargin andhigherusstatetaxespartiallyoffsetbyincreasesintaxable commitmentfeesundertheagreementsarenotmaterial incomeinlowertaxjurisdictionsrelativetohighertaxjurisdiction throughoutthecompanycontinuedtohaveaccessto thedecreaseinthetaxrateascomparedtowasprima liquiditythroughthecommercialpapermarketshorttermborrow rilyduetodecreasesintaxableincomeinhighertaxjurisdiction ingsandthecurrentportionoflongtermdebtamountedtoapproxi relativetotaxableincomeinlowertaxjurisdictionsandcertain matelybillionattheendofofwhichbillionwas ustaxadjustment borrowedunderthecommercialpaperprogramtheremainder representsprincipallylocalborrowingbyinternationalsubsidiarie note consolidated financial statement temporarydifferencesandcarryforwardsforand unrecognizedtaxbenefitswillsignificantlychangeoverthenext wereasfollow twelvemonthsthecompanyisnotabletoprovideareasonably reliableestimateofthetimingofanyotherfuturetaxpayment relatingtouncertaintaxposition deferredtax deferredtax thecompanyclassifiesliabilitiesforunrecognizedtaxbenefit dollarsinmillion asset liability asset liability andrelatedinterestandpenaltiesaslongtermliabilitiesinter employeerelatedobligation expenseandpenaltiesrelatedtounrecognizedtaxbenefitsarecla stockbasedcompensation sifiedasincometaxexpensethecompanyrecognizedaftertax depreciation interestofmillionexpensemillionincomeandmillion nondeductibleintangible expenseinandrespectivelythetotalamountof internationalrdcapitalize accruedinterestwasmillionandmillioninand fortax respectively reservesliabilitie incomereportedfortaxpurpose employeerelatedobligation netoperatingloss attheendofandemployeerelatedobligationsrecorde carryforwardinternational ontheconsolidatedbalancesheetwere miscellaneousinternational miscellaneousus dollarsinmillion pensionbenefit totaldeferredincometaxe postretirementbenefit thedifferencebetweenthenetdeferredtaxonincomeperthe postemploymentbenefit balancesheetandthenetdeferredtaxaboveisincludedintaxe deferredcompensation onincomeonthebalancesheetthecompanyhaswhollyowne totalemployeeobligation internationalsubsidiariesthathavecumulativenetlossesthe lesscurrentbenefitspayable companybelievesthatitismorelikelythannotthatthesesub employeerelatedobligationsnoncurrent sidiarieswillrealizefuturetaxableincomesufficienttoutilizethese deferredtaxasset prepaidemployeerelatedobligationsofmillionandmil thefollowingtablesummarizestheactivityrelatedto lionforandrespectivelyareincludedinotherassetson unrecognizedtaxbenefit theconsolidatedbalancesheet dollarsinmillion beginningofyear pensionsandotherbenefitplan increasesrelatedtocurrentyeartaxposition thecompanysponsorsvariousretirementandpensionplan increasesrelatedtopriorperiodtaxposition includingdefinedbenefitdefinedcontributionandtermination decreasesrelatedtopriorperiodtaxposition indemnityplanswhichcovermostemployeesworldwidethe settlement companyalsoprovidespostretirementbenefitsprimarilyhealth caretoallusretiredemployeesandtheirdependent lapseofstatuteoflimitation manyinternationalemployeesarecoveredbygovernment endofyear sponsoredprogramsandthecosttothecompanyisnotsignificant retirementplanbenefitsareprimarilybasedontheemployee theunrecognizedtaxbenefitsofbillionatjanuaryif compensationduringthelastthreetofiveyearsbeforeretirement recognizedwouldaffectthecompanysannualeffectivetaxrate andthenumberofyearsofserviceinternationalsubsidiarieshave thecompanyconductsbusinessandfilestaxreturnsinnumerous plansunderwhichfundsaredepositedwithtrusteesannuitiesare countriesandcurrentlyhastaxauditsinprogresswithanumberof purchasedundergroupcontractsorreservesareprovide taxauthoritiestheusinternalrevenueserviceirshascom thecompanydoesnotfundretireehealthcarebenefitsin pleteditsauditforthetaxyearsthroughhowevertherearea advanceandhastherighttomodifytheseplansinthefuture limitednumberofissuesremainingopenforpriortaxyearsgoe thecompanyusesthedateofitsconsolidatedfinancial backtoinothermajorjurisdictionswherethecompanycon statementsjanuaryandjanuaryrespectivelyas ductsbusinesstheyearsremainopengenerallybacktotheyear themeasurementdateforallusandinternationalretirementand thecompanydoesnotexpectthatthetotalamountof otherbenefitplans johnson johnson annual reportnetperiodicbenefitcostsforthecompanysdefinedbenefitretirementplansandotherbenefitplansforandinclude thefollowingcomponent retirementplan otherbenefitplan dollarsinmillion servicecost interestcost expectedreturnonplanasset amortizationofpriorservicecost amortizationofnettransitionasset recognizedactuariallosse curtailmentsandsettlement netperiodicbenefitcost thenetperiodicbenefitcostattributabletousretirementplan unrecognizedgainsandlossesfortheuspensionplansareamor wasmillionmillionandmillioninand tizedovertheaverageremainingfutureserviceforeachplanfor respectively planswithnoactiveemployeestheyareamortizedovertheaverage amountsexpectedtoberecognizedinnetperiodicbenefitcost lifeexpectancytheamortizationofgainsandlossesfortheother inthecomingyearforthecompanysdefinedbenefitretirement usbenefitplansisdeterminedbyusingacorridorofthe plansandotherpostretirementplan greaterofthemarketvalueofassetsortheprojectedbenefitobliga tiontotalunamortizedgainsandlossesinexcessofthecorridorare dollarsinmillion amortizedovertheaverageremainingfutureservice amortizationofnettransitionobligation priorservicecostsbenefitsfortheuspensionplansare amortizationofnetactuariallosse amortizedovertheremainingfutureserviceofplanparticipantsat amortizationofpriorservicecost thetimeoftheplanamendmentpriorservicecostbenefitforthe otherusbenefitplansisamortizedovertheaverageremaine servicetofulleligibilityageofplanparticipantsatthetimeofthe planamendment theweightedaverageassumptionsinthefollowingtablerepresenttheratesusedtodeveloptheactuarialpresentvalueofprojecte benefitobligationfortheyearlistedandalsothenetperiodicbenefitcostforthefollowingyear retirementplan otherbenefitplan dollarsinmillion usbenefitplan discountrate expectedlongtermrateofreturnonplanasset rateofincreaseincompensationlevel internationalbenefitplans discountrate expectedlongtermrateofreturnonplanasset rateofincreaseincompensationlevel thecompanysdiscountratesaredeterminedbyconsideringcur thefollowingtabledisplaystheassumedhealthcarecosttrend rentyieldcurvesrepresentinghighqualitylongtermfixedincome ratesforallindividual instrumentstheresultingdiscountratesareconsistentwiththe healthcareplan durationofplanliabilitie healthcarecosttrendrateassumedfornextyear theexpectedlongtermrateofreturnonplanassetsassump ratetowhichthecosttrendrateisassume tionisdeterminedusingabuildingblockapproachconsidering todeclineultimatetrend historicalaveragesandrealreturnsofeachassetclassincertain yeartheratereachestheultimatetrendrate countrieswherehistoricalreturnsarenotmeaningfulconsidera tionisgiventolocalmarketexpectationsoflongtermreturns aonepercentagepointchangeinassumedhealthcarecosttrend rateswouldhavethefollowingeffect onepercentage onepercentage dollarsinmillion pointincrease pointdecrease healthcareplan totalinterestandservicecost postretirementbenefitobligation note consolidated financial statement thefollowingtablesetsforthinformationrelatedtothebenefitobligationandthefairvalueofplanassetsatyearendandforthe companysdefinedbenefitretirementplansandotherpostretirementplan retirementplan otherbenefitplan dollarsinmillion changeinbenefitobligation projectedbenefitobligationbeginningofyear servicecost interestcost planparticipantcontribution amendment actuariallosse divestituresacquisition curtailmentssettlementsrestructure benefitspaidfromplan effectofexchangerate projectedbenefitobligationendofyear changeinplanasset planassetsatfairvaluebeginningofyear actualreturnonplanasset companycontribution planparticipantcontribution settlement divestituresacquisition benefitspaidfromplanasset effectofexchangerate planassetsatfairvalueendofyear fundedstatusendofyear amountsrecognizedinthecompanysbalancesheetconsistofthefollowe noncurrentasset currentliabilitie noncurrentliabilitie totalrecognizedintheconsolidatedbalancesheetendofyear amountsrecognizedinaccumulatedothercomprehensiveincomeconsistofthefollowe netactuarialloss priorservicecostcredit unrecognizednettransitionobligation totalbeforetaxeffect accumulatedbenefitobligationsendofyear changesinplanassetsandbenefitobligationsrecognizedinothercomprehensiveincome netperiodicbenefitcost netactuarialloss amortizationofnetactuariallossgain priorservicecost amortizationofpriorservicecostcredit effectofexchangerate totalrecognizedinothercomprehensiveincomebeforetax totalrecognizedinnetperiodicbenefitcostandothercomprehensiveincome thecompanyplanstocontinuetofunditsusqualifiedplanstocomplywiththepensionprotectionactofinternationalplansare fundedinaccordancewithlocalregulationsadditionaldiscretionarycontributionsaremadewhendeemedappropriatetomeetthelong termobligationsoftheplansforcertainplansfundingisnotacommonpracticeasfundingprovidesnoeconomicbenefitconsequently thecompanyhasseveralpensionplansthatarenotfunde inthecompanycontributedmillionandmilliontoitsusandinternationalpensionplansrespectively johnson johnson annual reportthefollowingtabledisplaysthefundedstatusofthecompanysusqualifiednonqualifiedpensionplansandinternationalfunde andunfundedpensionplansatjanuaryandjanuaryrespectively usplans internationalplan qualifiedplan nonqualifiedplans fundedplan unfundedplan dollarsinmillion planasset projectedbenefitobligation accumulatedbenefitobligation overunderfundedstatus projectedbenefitobligation accumulatedbenefitobligation planswithaccumulatedbenefitobligationsinexcessofplanassetshaveanaccumulatedbenefitobligationprojectedbenefitobligation andplanassetsofbillionbillionandbillionrespectivelyattheendofandbillionbillionandbillion respectivelyattheendof thefollowingtabledisplaystheprojectedfuturebenefitpaymentsfromthecompanysretirementandotherbenefitplan dollarsinmillion projectedfuturebenefitpayment retirementplan otherbenefitplansgross medicarerebate otherbenefitplansnet thefollowingtabledisplaystheprojectedfutureminimumcontributionstothecompanysusandinternationalunfundedretirement planstheseamountsdonotincludeanydiscretionarycontributionsthatthecompanymayelecttomakeinthefuture dollarsinmillion projectedfuturecontribution unfundedusretirementplan unfundedinternationalretirementplan eachpensionplanisoverseenbyalocalcommitteeorboardthatisresponsiblefortheoveralladministrationandinvestmentofthepension plansindetermininginvestmentpoliciesstrategiesandgoalseachcommitteeorboardconsidersfactorsincludinglocalpensionrule andregulationslocaltaxregulationsavailabilityofinvestmentvehiclesseparateaccountscommingledaccountsinsurancefundsetc fundedstatusoftheplansratioofactivestoretireesdurationofliabilitiesandotherrelevantfactorsincludingdiversificationliquidityof localmarketsandliquidityofbasecurrencyamajorityofthecompanyspensionfundsareopentonewentrantsandareexpectedtobe ongoingplanspermittedinvestmentsareprimarilyliquidandorlistedwithlittlerelianceonilliquidandnontraditionalinvestmentssuch ashedgefundsanassetallocationofequitiesandfixedincomeisgenerallypursuedunlesslocalregulationsandilliquidity requireotherwise thecompanysretirementplanassetallocationattheendofandandtargetallocationsforareasfollow percentof target planasset allocation usretirementplan equitysecuritie debtsecuritie totalplanasset internationalretirementplan equitysecuritie debtsecuritie totalplanasset thecompanysotherbenefitplansareunfundedexceptforuslife thefairvalueofjohnsonjohnsoncommonstockdirectly insurancecontractassetsofmillionandmillionatjanuary heldinplanassetswasmillionoftotalplanassetsat andjanuaryrespectively januaryandmillionoftotalplanassetsat january note consolidated financial statement determinationoffairvalueofplanasset similarcharacteristicsordiscountedcashflowswhenquote theplanhasanestablishedandwelldocumentedprocessfor marketpricesforasecurityarenotavailableinanactivemarket determiningfairvaluesfairvalueisbaseduponquotedmarket theyareclassifiedaslevel priceswhereavailableiflistedpricesorquotesarenotavailable debtinstrumentsalimitednumberoftheseinvestmentsare fairvalueisbaseduponmodelsthatprimarilyuseasinput valuedattheclosingpricereportedonthemajormarketonwhich marketbasedorindependentlysourcedmarketparametersinclud theindividualsecuritiesaretradedwherequotedpricesareavail ingyieldcurvesinterestratesvolatilitiesequityordebtprice ableinanactivemarkettheinvestmentsareclassifiedaslevelif foreignexchangeratesandcreditcurve quotedmarketpricesarenotavailableforthespecificsecuritythen whiletheplanbelievesitsvaluationmethodsareappropriate fairvaluesareestimatedbyusingpricingmodelsquotedpricesof andconsistentwithothermarketparticipantstheuseofdifferent securitieswithsimilarcharacteristicsordiscountedcashflowsand methodologiesorassumptionstodeterminethefairvalueofcertain areclassifiedaslevelleveldebtinstrumentsarepricedbase financialinstrumentscouldresultinadifferentestimateoffairvalue onunobservableinput atthereportingdate equitysecuritiescommonstocksarevaluedattheclose pricereportedonthemajormarketonwhichtheindividualsecuri valuationhierarchy tiesaretradedsubstantiallyallcommonstockisclassifiedwithin theauthoritativeliteratureestablishesathreelevelhierarchyto levelofthevaluationhierarchy prioritizetheinputsusedinmeasuringfairvaluethelevelswithin thehierarchyaredescribedinthetablebelowwithlevelhave commingledfundstheinvestmentsarepublicinvestment thehighestpriorityandlevelhavingthelow vehiclesvaluedusingthenavprovidedbythefundadministrator afinancialinstrumentscategorizationwithinthevaluation thenavisbasedonthevalueoftheunderlyingassetsownedby hierarchyisbaseduponthelowestlevelofinputthatissignificant thefundminusitsliabilitiesandthendividedbythenumberof tothefairvaluemeasurement sharesoutstandingassetsinthelevelcategoryhaveaquote followingisadescriptionofthevaluationmethodologiesuse marketpriceinamarketthatisnotactive fortheinvestmentsmeasuredatfairvalue insurancecontractstheinstrumentsareissuedbyinsurance shortterminvestmentscashandquotedshortterminstru companiesthefairvalueisbasedonnegotiatedvalueandthe mentsarevaluedattheclosingpriceortheamountheldondeposit underlyinginvestmentsheldinseparateaccountportfoliosaswell bythecustodianbankotherinvestmentsarethroughinvestment asconsideringthecreditworthinessoftheissuertheunderlye vehiclesvaluedusingthenetassetvaluenavprovidedbythe investmentsaregovernmentassetbackedandfixedincomesecuri administratorofthefundthenavisbasedonthevalueofthe tiesingeneralinsurancecontractsareclassifiedaslevelasthere underlyingassetsownedbythefundminusitsliabilitiesandthen arenoquotedpricesnorotherobservableinputsforprice dividedbythenumberofsharesoutstandingthenavisaquote otherassetsotherassetsarerepresentedprimarilybylimited priceinamarketthatisnotactiveandclassifiedaslevel partnershipsandrealestateinvestmentsaswellascommercial governmentandagencysecuritiesalimitednumberofthese loansandcommercialmortgagesthatarenotclassifiedascorporate investmentsarevaluedattheclosingpricereportedonthemajor debtotherassetsthatareexchangelistedandactivelytradedare marketonwhichtheindividualsecuritiesaretradedwherequote classifiedaslevelwhileinactivelytradedassetsareclassifiedas pricesareavailableinanactivemarkettheinvestmentsareclassi levelmostlimitedpartnershipsrepresentinvestmentsinprivate fiedwithinlevelofthevaluationhierarchyifquotedmarketprice equityandsimilarfundsthatarevaluedbythegeneralpartner arenotavailableforthespecificsecuritythenfairvaluesareesti theseaswellasanyotherassetsvaluedusingunobservableinput matedbyusingpricingmodelsquotedpricesofsecuritieswith areclassifiedaslevel thefollowingtablesetsforththetrustinvestmentsmeasuredatfairvalueasofjanuaryandjanuary quotedprice significant inactive significant marketsfor observable unobservable identicalasset input input level level level totalasset dollarsinmillion shortterminvestmentfund governmentandagencysecuritie debtinstrument equitysecuritie commingledfund insurancecontract otherasset trustinvestmentsatfairvalue johnson johnson annual reportlevelgainsandlosses thetablebelowsetsforthasummaryofchangesinthefairvalueoftheplanslevelassetsfortheyearsendedjanuaryand january debt equity commingle insurance total dollarsinmillion instrument security fund contract asset level balancejanuary realizedgainslosse unrealizedgainslosse purchasessalesissuancesandsettlementsnet balancejanuary realizedgainslosse unrealizedgainslosse purchasessalesissuancesandsettlementsnet balancejanuary savingsplan accumulatedothercomprehensiveincome thecompanyhasvoluntaryksavingsplansdesignedto componentsofothercomprehensiveincomelossconsistof enhancetheexistingretirementprogramscoveringeligibleemploy thefollowing eesthecompanymatchesapercentageofeachemployee total contributionsconsistentwiththeprovisionsoftheplanforwhich gain accumulate hesheiseligibletotalcompanymatchingcontributionstothe foreign gain losseson plansweremillionmillionandmillionin currency losseson employee derivative comprehensive dollarsinmillion translation security benefitplan hedge incomeloss andrespectively december change capitalandtreasurystock unrealizedgainloss changesintreasurystockwere netamountreclassed tonetearning amountsinmillionsexcepttreasury treasurystock netchange stocksharesinthousand share balanceatdecember january employeecompensationandstockoptionplans change repurchaseofcommonstock unrealizedgainloss netamountreclassed balanceatjanuary tonetearning employeecompensationandstockoptionplan netchange repurchaseofcommonstock january balanceatjanuary change employeecompensationandstockoptionplans unrealizedgainloss repurchaseofcommonstock netamountreclasse balanceatjanuary tonetearning netchange aggregatesharesofcommonstockissuedwereapproximately sharesattheendofand january cashdividendspaidwerepershareincompare withdividendsofpershareinandpershare thetaxeffectontheunrealizedgainslossesonequitysecuritie wasexpenseofmillioninexpenseofmillionin andincomeofmillioninthetaxeffectrelatedto employeebenefitplanswasmillionmillionandmil lioninandrespectivelythetaxeffectonthe gainslossesonderivativesandhedgeswasincomeofmillion inandexpenseofmillionandmillioninand respectivelyseenoteforadditionalinformationrelate toderivativesandhedging thecurrencytranslationadjustmentsarenotadjustedfor incometaxesastheyrelatetopermanentinvestmentsin internationalsubsidiarie note consolidated financial statement internationalcurrencytranslation commonstockstockoptionplansandstock fortranslationofitssubsidiariesoperatinginnonusdollarcur compensationagreement renciesthecompanyhasdeterminedthatthelocalcurrenciesofit atjanuarythecompanyhadstockbasedcompensa internationalsubsidiariesarethefunctionalcurrenciesexceptthose tionplansthesharesoutstandingareforcontractsunderthe inhighlyinflationaryeconomieswhicharedefinedasthosewhich companysstockoptionplanthelongtermincentive havehadcompoundcumulativeratesofinflationoformore planthenonemployeedirectorsplanandsciosincstock duringthepastthreeyearsorwhereasubstantialportionofit optionplansduringnooptionsorrestrictedshareswere cashflowsarenotinthelocalcurrency grantedunderanyoftheseplansexceptunderthelongterm inconsolidatinginternationalsubsidiariesbalancesheetcur incentiveplan rencyeffectsarerecordedasacomponentofaccumulatedother thecompensationcostthathasbeenchargedagainstincome comprehensiveincomethisequityaccountincludestheresult fortheseplanswasmillionmillionandmillionfor oftranslatingallbalancesheetassetsandliabilitiesatcurrent andrespectivelythetotalincometaxbenefit exchangeratesexceptforthoselocatedinhighlyinflationary recognizedintheincomestatementforsharebasedcompensation economiesthetranslationofbalancesheetaccountsforhighly costswasmillionmillionandmillionfor inflationaryeconomiesarereflectedintheoperatingresult andrespectivelythetotalunrecognizedcompensation ananalysisofthechangesduringandfor costwasmillionmillionandmillionfor foreigncurrencytranslationadjustmentsisincludedinnote andrespectivelytheweightedaverageperiodforthiscost netcurrencytransactiongainsandlossesincludedinother toberecognizedwasyearsyearsandyearsfor incomeexpensewerelossesofmillionmillionand andrespectivelysharebasedcompensationcost millioninandrespectively capitalizedaspartofinventorywereinsignificantinallperiod stockoption earningspershare stockoptionsexpireyearsfromthedateofgrantandv thefollowingisareconciliationofbasicnetearningspershareto overserviceperiodsthatrangefromsixmonthstofouryears dilutednetearningspershareforthefiscalyearsendedjanuary alloptionsaregrantedattheaverageofthehighandlowpricesof januaryandjanuary thecompanyscommonstockonthenewyorkstockexchange onthedateofgrantunderthelongtermincentiveplan inmillionsexceptpersharedata thecompanymayissueuptomillionsharesofcommonstock basicnetearningspershare sharesavailableforfuturegrantsunderthelongterm averageshare incentiveplanweremillionattheendof outstandingbasic thecompanysettlesemployeestockoptionexerciseswith potentialsharesexercisable treasurysharestreasurysharesarereplenishedthroughoutthe understockoptionplan yearforthenumberofsharesusedtosettleemployeestock lesssharesrepurchase optionexercise undertreasurystockmethod thefairvalueofeachoptionawardwasestimatedonthedate convertibledebtshare ofgrantusingtheblackscholesoptionvaluationmodelthatuse adjustedaverageshare theassumptionsnotedinthefollowingtableexpectedvolatility outstandingdilute representsablendedrateofyeardailyhistoricalaveragevolatility dilutednetearningspershare rateandaweekaverageimpliedvolatilityratebasedonatthe moneytradedjohnsonjohnsonoptionswithalifeofyears thedilutednetearningspersharecalculationincludesthedilutive historicaldataisusedtodeterminetheexpectedlifeoftheoption effectofconvertibledebtthatisoffsetbytherelatedreduction theriskfreeratewasbasedontheustreasuryyieldcurvein ininterestexpenseofmillionaftertaxforyear effectatthetimeofgrant theaveragefairvalueofoptionsgrantedwasand dilutednetearningspershareexcludesmillionmillion inandrespectivelythefairvaluewa andmillionsharesunderlyingstockoptionsforand estimatedbasedontheweightedaverageassumptionsof respectivelyastheexercisepriceoftheseoptionswa greaterthantheiraveragemarketvaluewhichwouldresultinan antidilutiveeffectondilutedearningspershare riskfreerate expectedvolatility expectedlife yrs yrs yrs rentalexpenseandleasecommitment dividendyield rentalsofspacevehiclesmanufacturingequipmentandofficeand dataprocessingequipmentunderoperatingleaseswereapproxi matelymillionmillionandmillioninand respectively theapproximateminimumrentalpaymentsrequiredunder operatingleasesthathaveinitialorremainingnoncancelablelease termsinexcessofoneyearatjanuaryare dollarsinmillion total commitmentsundercapitalleasesarenotsignificant johnson johnson annual reportasummaryofoptionactivityundertheplanasofjanuary stockoptionsexercisableatjanuaryandjanuary januaryandjanuaryandchangesduringtheyear wereatanaveragepriceofandanaveragelifeof endingonthosedatesispresentedbelow yearsandatanaveragepriceofandanaverage lifeofyearsrespectively weight aggregate outstanding average intrinsicvalue sharesinthousand share exerciseprice dollarsinmillion restrictedshareunit sharesatdecember thecompanygrantsrestrictedshareunitswithavestingperiodof threeyearsthecompanysettlesemployeestockissuanceswith optionsgrante treasurysharestreasurysharesarereplenishedthroughoutthe optionsexercised yearforthenumberofsharesusedforemployeestockissuance optionscanceledforfeite asummaryofshareactivityundertheplanasofjanuary sharesatjanuary outstanding optionsgrante sharesinthousand share optionsexercise sharesatdecember optionscanceledforfeite grant sharesatjanuary issue optionsgrante canceledforfeite optionsexercised sharesatjanuary optionscanceledforfeite grant sharesatjanuary issue canceledforfeited thetotalintrinsicvalueofoptionsexercisedwasmillion sharesatjanuary millionandmillioninandrespectively grant thefollowingtablesummarizesstockoptionsoutstandingand issue exercisableatjanuary canceledforfeite sharesinthousand outstanding exercisable sharesatjanuary average average exercise average exercise exercise theaveragefairvalueoftherestrictedshareunitsgrantedwa pricerange option life price option price andinandrespectively usingthefairmarketvalueatthedateofgrantthefairvalueof restrictedshareunitswasdiscountedfordividendswhichare notpaidontherestrictedshareunitsduringthevestingperiod thefairvalueofrestrictedshareunitssettledwasmillion millionandmillioninand respectively averagecontractualliferemaininginyear note consolidated financial statement segmentsofbusinessandgeographicarea salestocustomer dollarsinmillion consumer unitedstate international total pharmaceutical unitedstate international total medicaldevicesanddiagnostic unitedstate international total worldwidetotal operatingprofit identifiableasset dollarsinmillion consumer pharmaceutical medicaldevicesanddiagnostic total lessexpensenotallocatedtosegment generalcorporate worldwidetotal additionstoproperty depreciationand plantequipment amortization dollarsinmillion consumer pharmaceutical medicaldevicesanddiagnostic segmentstotal generalcorporate worldwidetotal salestocustomer longlivedasset dollarsinmillion unitedstate europe westernhemisphereexcludingus asiapacificafrica segmentstotal generalcorporate othernonlonglivedasset worldwidetotal seenoteforadescriptionofthesegmentsinwhichthecompanyoperate exportsalesarenotsignificantinandthecompanydidnothaveacustomerthatrepresentedoftotalrevenue amountsnotallocatedtosegmentsincludeinterestincomeexpensenoncontrollinginterestsandgeneralcorporateincomeexpenseincludedinwasabillionexpensefor theadjustmenttothevalueofthecurrencyoptionrelatedtotheplannedacquisitionofsynthesinc generalcorporateincludescashandmarketablesecuritie includesmillionofnetlitigationexpensecomprisedofmillionandmillioninthepharmaceuticalandmedicaldevicesanddiagnosticssegmentsrespectivelyinclude millionofproductliabilityexpensecomprisedofmillioninthepharmaceuticalsegmentandmillioninthemedicaldevicesanddiagnosticssegmentinclude millionofnetrestructuringexpensecomprisedofmillionexpenseinthemedicaldevicesanddiagnosticssegmentandagainofmillioninthepharmaceuticalsegment themedicaldevicesanddiagnosticssegmentalsoincludesmillionexpenseforthecostassociatedwiththedepuyasrhiprecallprogram includesmillionofnetlitigationgaincomprisedofmillionexpenseinthepharmaceuticalsegmentandagainofmillioninthemedicaldevicesanddiagnosticssegment includesmillionofproductliabilityexpensecomprisedofmillioninthepharmaceuticalsegmentandmillioninthemedicaldevicesanddiagnosticssegmentthemedical devicesanddiagnosticssegmentalsoincludesmillionexpenseforthecostassociatedwiththedepuyasrhiprecallprogram includesmillionofrestructuringexpensecomprisedofmillionmillionandmillionfortheconsumerpharmaceuticalandmedicaldevicesanddiagnostic segmentsrespectivelyincludesmillionoffourthquarternetlitigationgaincomprisedofamillionexpenseinthepharmaceuticalsegmentandagainofmillioninthe medicaldevicesanddiagnosticssegment longlivedassetsincludepropertyplantandequipmentnetforandofandrespectivelyandintangibleassetsandgoodwillnetfor andofandrespectively johnson johnson annual reportselectedquarterlyfinancialdataunaudite selectedunauditedquarterlyfinancialdatafortheyearsandaresummarizedbelow second fourth second fourth dollarsinmillionsexceptpersharedata quarter quarter quarter quarter quarter quarter quarter quarter segmentsalestocustomer consumer pharmaceutical medicaldevicesanddiagnostic totalsale grossprofit earningsbeforeprovisionfortaxesonincome netearning basicnetearningspershare dilutednetearningspershare thefirstquarterofincludesanaftertaxchargeofmillionfromlitigationandproductliabilityexpensesanddepuyasrhiprecallcost thesecondquarterofincludesaftertaxchargesofmillionforrestructuringmillionfromlitigationproductliabilityexpensesanddepuyasrhiprecallcostspartially offsetbyamillionaftertaxgainassociatedwithanadjustmenttothevalueofthecurrencyoptionrelatedtotheplannedacquisitionofsynthesinc thethirdquarterofincludesamillionaftertaxchargeassociatedwithanadjustmenttothevalueofthecurrencyoptionanddealcostsrelatedtotheplannedacquisitionof synthesinc thefourthquarterofincludesaftertaxchargesofmillionfromnetlitigationsettlementsmillionforproductliabilityexpensesmillionforthecostassociatedwith thedepuyasrhiprecallprogramandmillionassociatedwithanadjustmenttothevalueofthecurrencyoptionanddealcostsrelatedtotheplannedacquisitionofsynthesinc thefirstquarterofincludesmillionaftertaxofincomefromnetlitigation thesecondquarterofincludesmillionaftertaxofincomefromnetlitigation thefourthquarterofincludesanaftertaxchargeofmillionfromnetlitigationsettlementsanaftertaxchargeofmillionforproductliabilityexpenseandanaftertax chargeofmillionforthecostassociatedwiththedepuyasrhiprecallprogram businesscombinationsanddivestitures commonstocksubjecttocertainconditionswouldbeexchange certainbusinesseswereacquiredformillionincashand forapproximatelyincashandinjohnsonjohnson millionofliabilitiesassumedduringtheseacquisition commonstocksynthesincisapremierglobaldeveloperand wereaccountedforbythepurchasemethodandaccordingly manufactureroforthopaedicsdevicesondecembera resultsofoperationshavebeenincludedinthefinancialstatement specialmeetingofstockholderswasheldatthesynthesofficesand fromtheirrespectivedatesofacquisition thesynthesshareholdersapprovedtheproposaltoadopttheagree theacquisitionsincludedcrucellnvaglobalbiophar mentandplanofmergertheacquisitionisexpectedtocloseinthe maceuticalcompanyfocusedontheresearchanddevelopment firsthalfof productionandmarketingofvaccinesandantibodiesagainstinfec certainbusinesseswereacquiredformillionincashand tiousdiseaseworldwidetheoverthecounterotcbrandsof millionofliabilitiesassumedduringtheseacquisition jbchemicalspharmaceuticalslimitedincludingrinzarussias wereaccountedforbythepurchasemethodandaccordingly leadingmultisymptomcoughandcoldbrandanddoktormom resultsofoperationshavebeenincludedinthefinancialstatement russiasnumbertwosellingcoughbrandaswellasseveralother fromtheirrespectivedatesofacquisition brandsfullownershipofthejohnsonjohnsonmerckconsumer theacquisitionsincludedacclarentincaprivatelyheld pharmaceuticalscojointventureintheusfrommercksharp medicaltechnologycompanydedicatedtodesigningdevelope dohmecorpandsterilmedincaleaderinthereprocessingand andcommercializingdevicesthataddressconditionsaffectingthe remanufacturingofmedicaldevicesintheus earnoseandthroatentrespivertltdaprivatelyhelddrug theexcessofpurchasepriceovertheestimatedfairvalueof discoverycompanyfocusedondevelopingsmallmoleculeinhale tangibleassetsacquiredamountedtomillionandhasbeen therapiesforthetreatmentofpulmonarydiseasesandmicrus assignedtoidentifiableintangibleassetswithanyresidualrecorde endovascularcorporationaglobaldeveloperandmanufacturerof togoodwillofthisamountapproximatelymillionhasbeen minimallyinvasivedevicesforhemorrhagicandischemicstroke identifiedasthevalueofiprdassociatedwiththeacquisitionof theexcessofpurchasepriceovertheestimatedfairvalueof crucellnv tangibleassetsacquiredamountedtomillionandhasbeen theiprdrelatedtotheacquisitionofcrucellnvofmil assignedtoidentifiableintangibleassetswithanyresidualrecorded lionisassociatedwithvaccinesandantibodiesthatpreventandor togoodwillofthisamountapproximatelymillionhasbeen treatinfectiousdiseasesthevalueoftheiprdwascalculate identifiedasthevalueofiprdassociatedwiththeacquisitionsof usingcashflowprojectionsdiscountedfortheriskinherentinsuch acclarentincrespivertltdandmicrusendovascularcorporation projectsprobabilityofsuccessfactorsrangingfromwere theiprdrelatedtotheacquisitionofacclarentincwa usedtoreflectinherentclinicalandregulatoryriskthediscountrate millionandisassociatedwithnovelendoscopiccatheter appliedwa baseddevicestomeettheneedsofentpatientsthevalueofthe duringthefiscalsecondquarterofthecompanyentere iprdwascalculatedusingcashflowprojectionsdiscountedfor intoadefinitiveagreementtoacquiresynthesincforapproximately theriskinherentinsuchprojectsprobabilityofsuccessfactor billionapproximatelybillionnetofcashacquiredsubject rangingfromwereusedtoreflectinherentclinicaland tothetermsofthemergeragreementandcurrencyvaluesatthetime regulatoryriskthediscountrateappliedwa ofclosingunderthetermsoftheagreementeachshareofsynthe note consolidated financial statement theiprdrelatedtotheacquisitionofrespivertltdwa millionrepresentsthefairvalueoftheinvestmentin millionandisassociatedwithnarrowspectrumkinase elanbasedonelanssharepriceinanactivelytradedmarketasof inhibitorswithauniqueprofileofantiinflammatoryactivitiesas thedateofthistransactiontheiprdrelatedtothistransaction treatmentsformoderatetosevereasthmachronicobstructive wasmillionandisassociatedwithbapineuzumabapotential pulmonarydiseasecopdandcysticfibrosiscfthevalueof firstinclasstreatmentthatisbeingevaluatedforslowingthepro theiprdwascalculatedusingcashflowprojectionsdiscounte gressionofalzheimersdiseasethevalueoftheiprdwascalcu fortheriskinherentinsuchprojectsprobabilityofsuccessfactor latedusingcashflowprojectionsdiscountedfortheriskinherentin rangingfromwereusedtoreflectinherentclinicaland suchprojectsprobabilityofsuccessfactorsrangingfrom regulatoryriskthediscountrateappliedwa wereusedtoreflectinherentclinicalandregulatoryriskthedis theiprdrelatedtotheacquisitionofmicrusendovascular countrateappliedwasthenoncontrollinginterestrelatedto corporationwasmillionandisassociatedwithischemicand thistransactionwasmillionwhichthecompanyhasrecorde flowdivertertechnologiesthevalueoftheiprdwascalculate inothernoncurrentliabilitie usingcashflowprojectionsdiscountedfortheriskinherentinsuch supplementalproformainformationforandin projectsprobabilityofsuccessfactorsrangingfromwere accordancewithusgaapstandardsrelatedtobusinesscombina usedtoreflectinherentclinicalandregulatoryriskthediscount tionsandgoodwillandotherintangibleassetsisnotprovidedas rateappliedwa theimpactoftheaforementionedacquisitionsdidnothaveamate certainbusinesseswereacquiredformillionincash rialeffectonthecompanysresultsofoperationscashflowsor andmillionofliabilitiesassumedandnoncontrollinginterest financialposition duringtheseacquisitionswereaccountedforbythepur duringthecompanydivestituresincludedtheanimal chasemethodandaccordinglyresultsofoperationshavebeen healthbusinesstoelancoadivisionofelilillymonistatin includedinthefinancialstatementsfromtheirrespectivedate canadatheusanditsterritoriesincludingpuertoricoasset ofacquisition oftheorthodermatologicsdivisionintheustosubsidiariesof theacquisitionsincludedmentorcorporationaleade valeantpharmaceuticalsinternationalincandthesurgicalinstru supplierofmedicalproductsfortheglobalaestheticsmarket mentsbusinessofcodmanshurtleffincinthegainson cougarbiotechnologyincadevelopmentstagebiopharmaceutical thedivestituresofbusinesseswerebillionduringthe companywithaspecificfocusononcologyfinsburyorthopaedics companydivestituresincludedthebreastcarebusinessofethicon limitedaprivatelyheldukbasedmanufacturerandglobaldis endosurgeryincthegainsonthedivestitureswererecognizedin tributoroforthopaedicimplantsglostereuropeaprivatelyheld otherincomeexpensenet developerofinnovativedisinfectionprocessesandtechnologiesto preventhealthcareacquiredinfectionsandsubstantiallyallofthe legalproceeding assetsandrightsofelansalzheimersimmunotherapyprogram throughanewlyformedcompanyofwhichthecompanyown johnsonjohnsonandcertainofitssubsidiariesareinvolvedin andelanown variouslawsuitsandclaimsregardingproductliabilityintellectual theexcessofpurchasepriceovertheestimatedfairvalueof propertycommercialandothermattersgovernmentalinvestiga tangibleassetsacquiredamountedtomillionandhasbeen tionsandotherlegalproceedingsthatarisefromtimetotimein assignedtoidentifiableintangibleassetswithanyresidualrecorde theordinarycourseoftheirbusiness togoodwillofthisamountapproximatelymillionhasbeen thecompanyrecordsaccrualsforsuchcontingencieswhenit identifiedasthevalueofiprdprimarilyassociatedwiththeacqui isprobablethataliabilitywillbeincurredandtheamountoftheloss sitionsofcougarbiotechnologyincandsubstantiallyallofthe canbereasonablyestimatedasofjanuarythecompany assetsandrightsofelansalzheimersimmunotherapyprogram hasdeterminedthattheliabilitiesassociatedwithcertainlitigation additionallyapproximatelymillionhasbeenidentifieda mattersareprobableandcanbereasonablyestimatedthe thevalueofotherintangibleassetsincludingpatentsandtechnol companyhasaccruedforthesemattersandwillcontinuetomoni ogyandcustomerrelationshipsprimarilyassociatedwiththe toreachrelatedlegalissueandadjustaccrualsfornewinformation acquisitionofmentorcorporation andfurtherdevelopmentsinaccordancewithascfor theiprdrelatedtotheacquisitionofcougarbiotechnology theseandotherlitigationandregulatorymatterscurrentlydisclose incwasmillionandisassociatedwithabirateroneacetatea forwhichalossisprobableorreasonablypossiblethecompanyis latestagefirstinclasscompoundforthetreatmentofprostate unabletodetermineanestimateofthepossiblelossorrangeof cancerthevalueoftheiprdwascalculatedusingcashflowpro lossbeyondtheamountsalreadyaccruedthesematterscanbe jectionsdiscountedfortheriskinherentinsuchprojectsprobability affectedbyvariousfactorsincludingwhetherdamagessoughtin ofsuccessfactorsrangingfromwereusedtoreflect theproceedingsareunsubstantiatedorindeterminatescientificand inherentclinicalandregulatoryriskthediscountrateapplie legaldiscoveryhasnotcommencedorisnotcompleteproceeding areinearlystagesmatterspresentlegaluncertaintiesthereare duringthecompanyacquiredsubstantiallyallofthe significantfactsindisputeortherearenumerouspartiesinvolve assetsandrightsofelansalzheimersimmunotherapyprogram inthecompanysopinionbasedonitsexaminationofthese throughanewlyformedcompanyjanssenalzheimerimmunother mattersitsexperiencetodateanddiscussionswithcounselthe apyjaiofwhichthecompanyownsandelanown ultimateoutcomeoflegalproceedingsnetofliabilitiesaccruedinthe inadditionthecompanypurchasedapproximatelymillion companysbalancesheetisnotexpectedtohaveamaterialadverse newlyissuedamericandepositaryreceiptsadrsofelanrepre effectonthecompanysfinancialpositionhowevertheresolution sentingofelansoutstandingordinarysharesaspartofthis inanyreportingperiodofoneormoreofthesematterseitheralone transactionthecompanypaidmilliontoelanandcommitte orintheaggregatemayhaveamaterialadverseeffectonthe tofunduptomillionofelansshareofresearchanddevelop companysresultsofoperationsandcashflowsforthatperiod mentspendingbyjaiofthistotalconsiderationofmillion johnson johnson annual reportproductliability eesintheunitedstatesdistrictcourtforthedistrictofconnecti certainofjohnsonjohnsonssubsidiariesareinvolvedinnumerous cutallegingthatseveralfeaturesofeessharmonicscalpel productliabilitycasesthedamagesclaimedaresubstantialand infringedfourtycopatentsinoctoberonmotionsforsum whilethesesubsidiariesareconfidentoftheadequacyofthewarn maryjudgmentpriortotheinitialtrialanumberofclaimswere ingsandinstructionsforusethataccompanytheproductsatissueit foundinvalidandanumberwerefoundinfringedhowevernoclaim isnotfeasibletopredicttheultimateoutcomeoflitigationthe wasfoundbothvalidandinfringedtrialcommencedindecember companyhasestablishedproductliabilityaccrualsincompliance andthecourtdismissedthecasewithoutprejudiceon withascbasedoncurrentlyavailableinformationwhichin groundsthattycodidnotownthepatentsinsuitthedismissal somecasesmaybelimitedchangestotheaccrualsmayberequire withoutprejudicewasaffirmedonappealinjanuarytyco inthefutureasadditionalinformationbecomesavailable filedanothercomplaintintheunitedstatesdistrictcourtforthe multipleproductsofjohnsonjohnsonssubsidiariesaresub districtofconnecticutassertinginfringementofthreeofthefour jecttoproductliabilityclaimsandlawsuitsinwhichclaimantsseek patentsfromthepreviouslawsuitandaddingnewproductstyco substantialcompensatoryandwhereavailablepunitivedamage isseekingmonetarydamagesandinjunctivereliefthiscaseis includinglevaquintheasrxlacetabularsystemanddepuy scheduledtobetriedinmay asrhipresurfacingsystemthepinnacleacetabularcup startinginmarchcordiscorporationcordisfile systemrisperdalpelvicmeshesthecypherstentand patentinfringementlawsuitsintheunitedstatesdistrictcourt duragesicfentanylpatchesasofjanuarytherewere forthedistrictsofnewjerseyanddelawareagainstguidant approximatelyclaimantswithpendinglawsuitsregarde corporationguidantabbottlaboratoriesincabbottboston injuriesallegedlyduetolevaquinwithrespecttothe scientificcorporationbostonscientificandmedtronicaveinc asrxlacetabularsystemanddepuyasrhipresurface medtronicallegingthatthexiencevabbottpromus systemwithrespecttothepinnacleacetabularcup bostonscientificandendeavormedtronicdrugelutingstent systemwithrespecttorisperdalwithrespectto infringeseveralofcordisswrightfaloticopatentscordissought pelvicmesheswithrespecttothecypherstentandwith monetaryreliefinjanuaryinoneofthecasesagainstboston respecttoduragesicfentanylpatche scientifictheunitedstatesdistrictcourtforthedistrictof inaugustdepuyorthopaedicsincdepuyannounce delawarefoundthewrightfaloticopatentsinvalidforlackofwrit aworldwidevoluntaryrecallofitsasrxlacetabularsystemand tendescriptionandorlackofenablementinjunethecourtof depuyasrhipresurfacingsystemusedinhipreplacementsur appealsforthefederalcircuitaffirmedtherulingandinseptember geryclaimsforpersonalinjuryhavebeenmadeagainstdepuyand itdeniedcordissmotionforareheare johnsonjohnsonandthenumberofpendinglawsuitscontinue inoctoberbrucesaffransaffranfiledapatentinfringe toincreasethecompanycontinuestoreceiveinformationwith mentlawsuitagainstjohnsonjohnsonandcordisintheunite respecttopotentialcostsassociatedwiththisrecallinthefourth statesdistrictcourtfortheeasterndistrictoftexasalleging quarterofthecompanyincreaseditsaccrualsforthedepuy infringementonuspatentnoinjanuaryajury asrhiprecallprogramandrelatedproductliabilityafterthe returnedaverdictfindingthatcordisssalesofitscypherstent companycompletedananalysisofnewinformationincludingthe willfullyinfringedapatentissuedtosaffranthejuryawarde numberofexpectedclaimsrecentlyupdatedrevisionratesofthe saffranmillioninmarchthecourtenteredjudgment recalledproductsandproductliabilityexpensepercasechange againstcordisintheamountofmillionrepresentingthejury totheseaccrualsmayberequiredinthefutureasadditional verdictplusmillioninprejudgmentinterestthedistrict informationbecomesavailable courthasdeniedcordissmotiontooverturnthejuryverdictandto thecompanybelievesthattheultimateresolutionofthese vacatethejudgmentcordishasappealedthejudgmentbecause mattersbasedonhistoricalandreasonablylikelyfuturetrendsisnot thecompanybelievesthatthepotentialforanunfavorableoutcome expectedtohaveamaterialadverseeffectonthecompanysfinan isnotprobableithasnotestablishedanaccrualwithrespectto cialpositionannualresultsofoperationsandcashflowstheresolu thecase tioninanyinterimreportingperiodcouldhaveamaterialimpacton innovemberrochediagnosticsoperationsincetal thecompanysresultsofoperationsandcashflowsforthatperiod rochefiledapatentinfringementlawsuitagainstlifescaninc lifescanintheunitedstatesdistrictcourtforthedistrictof intellectualproperty delawareaccusinglifescansentireonetouchlineofblood certainofjohnsonjohnsonssubsidiariesaresubjectfromtime glucosemonitoringsystemsofinfringementoftwopatentsrelate totimetolegalproceedingsandclaimsrelatedtopatenttrademark totheuseofmicroelectrodesensorsinseptemberlifescan andotherintellectualpropertymattersarisingoutoftheirbusiness obtainedafavorablerulingonclaimconstructionthatprecludeda themostsignificantofthesemattersaredescribedbelow findingofinfringementthecourtenteredjudgmentagainstroche injulyandrocheappealedthecourtofappealsreversedthe patentinfringement districtcourtsrulingonclaimconstructionandremandedthecase certainofjohnsonjohnsonssubsidiariesareinvolvedinlawsuits tothedistrictcourtfornewfindingsontheissuerocheisseeke challengingthecoverageandorvalidityofthepatentsontheir monetarydamagesandinjunctiverelief productsalthoughthesesubsidiariesbelievethattheyhavesub startinginfebruarycordisfiledpatentinfringement stantialdefensestothesechallengeswithrespecttoallmaterial lawsuitsintheunitedstatesdistrictcourtforthedistrictofnew patentstherecanbenoassuranceastotheoutcomeofthese jerseyagainstguidantabbottbostonscientificandmedtronic mattersandalossinanyofthesecasescouldpotentiallyadversely allegingthatthexiencevabbottpromusbostonscientific affecttheabilityofthesesubsidiariestoselltheirproductsor andendeavormedtronicdrugelutingstentsinfringeseveralof requirethepaymentofpastdamagesandfutureroyaltie wyethsnowpfizerincmorrispatentswhichhavebeenlicense tocordiscordissoughtmonetaryreliefinjanuarythedis medicaldevicesanddiagnostic trictcourtgrantedthedefendantsmotiontoinvalidatethemorris inoctobertycohealthcaregrouplptycoandussurgi patentsforlackofenablementandfailuretoadequatelydescribe calcorporationfiledalawsuitagainstethiconendosurgeryinc note consolidated financial statement thefullscopeoftheinventioncordiswillappealthisdecisiontothe ingermanyandthenetherlandsthecourtinthenetherlandsheld courtofappealsforthefederalcircuit thedutchpatentinvalidandenteredjudgmentinfavorofjbiseuro injunerembrandtvisiontechnologieslprembrandt peanaffiliatejanssenbiologicsbvbayerappealedthatjudgment filedapatentinfringementlawsuitagainstjohnsonjohnsonvision inthenetherlandsinadditioninmarchjanssencilagnv careincjjvcintheunitedstatesdistrictcourtfortheeastern filedarevocationactioninthehighcourtinlondonseekingto districtoftexasallegingthatjjvcsmanufactureandsaleofit invalidatebayersukpatentrelatingtohumanantitnfantibodie acuvueadvanceandacuvueoasyshydrogelcontact inmayjbisettledallofthesecasesandreceivedapaidup lensesinfringetheiruspatentnothechangpatent royaltyfreelicensetothefamilyofpatentsinsuit rembrandtisseekingmonetaryreliefthecaseisscheduledfortrial inapril litigationagainstfilersofabbreviatednewdrug innovemberhowmedicaosteonicscorphowmedica applicationsandas andstrykerirelandltdstrykerfiledapatentinfringementlawsuit thefollowingsummarizeslawsuitspendingagainstgenericcompa againstdepuyorthopaedicsincdepuyintheunitedstatesdistrict niesthatfiledabbreviatednewdrugapplicationsandasseek courtforthedistrictofnewjerseyalleginginfringementbydepuy ingtomarketgenericformsofproductssoldbyvarioussubsidiarie pinnacleacetabularcupsystemandduralocacetabularcup ofjohnsonjohnsonpriortoexpirationoftheapplicablepatent systemofapatentrelatingtoaduallockingmechanismfeatureinan coveringthoseproductstheseandastypicallyincludeallegation acetabularcupsystemhowmedicaandstrykerareseekingmonetary ofnoninfringementinvalidityandunenforceabilityofthese damagesandinjunctivereliefnotrialdatehasbeenset patentsintheeventthesesubsidiariesarenotsuccessfulinthese actionsorthestatutorymonthstaysexpirebeforetheunite pharmaceutical statesdistrictcourtrulingsareobtainedthethirdpartycompanie inaprilcentocorinccentocornowjanssenbiotechinc involvedwillhavetheabilityuponapprovaloftheunitedstate jbifiledapatentinfringementlawsuitagainstabbottlaborato foodanddrugadministrationfdatointroducegenericversions riesincabbottintheunitedstatesdistrictcourtfortheeastern oftheproductsatissueresultinginverysubstantialmarketshare districtoftexasallegingthatabbottshumiraantitnfalpha andrevenuelossesforthoseproduct productinfringescentocorsuspatentinjunea juryreturnedaverdictfindingthepatentvalidandinfringedand concerta awardedjbidamagesofapproximatelybillioninfebruary injanuaryalzacorporationalzaandorthomcneil thecourtofappealsreversedthejunedecisionandthe janssenpharmaceuticalsincomjpinowjanssenpharmaceuti judgmentofthedistrictcourtandinfebruarytheunite calsincjpifiledapatentinfringementlawsuitintheunite statessupremecourtdeclinedtoreviewthedecision statesdistrictcourtforthedistrictofdelawareagainstkremer inmayabbottbiotechnologyltdabbottfileda urbanllcandkudcoirelandltdcollectivelykudcoin patentinfringementlawsuitagainstcentocornowjbiinthe responsetokudcosandaseekingapprovaltomarketageneric unitedstatesdistrictcourtforthedistrictofmassachusetts versionofconcertabeforetheexpirationoftwoofalzaand allegingthatsimponiinfringesabbottsuspatentnos jpispatentsrelatingtoconcertakudcofiledcounterclaim andthesalfeldpatentsabbottisseeking allegingnoninfringementandinvalidityalzaandjpisubsequently monetarydamagesandinjunctivereliefnotrialdatehasbeenset removedoneofthepatentsfromthelawsuitinseptemberthe thepartieswillparticipateinanarbitrationinaprilonthe partiesenteredintoasettlementagreementpursuanttowhich issueofjbisdefensethatabbottisequitablystoppedfrom kudcowasgrantedalicensetomarketitsgenericversionof assertingthepatent concertastartingonjulyassumingkudcoobtain inaugustabbottgmbhcoabbottgmbhand fdaapproval abbottbioresearchcenterfiledapatentinfringementlawsuit innovemberalzaandomjpinowjpifiledapatent againstcentocornowjbiintheunitedstatesdistrictcourtfor infringementlawsuitintheunitedstatesdistrictcourtforthe thedistrictofmassachusettsallegingthatstelarainfringestwo districtofdelawareagainstimpaxlaboratoriesincimpaxteva unitedstatespatentsassignedtoabbottgmbhjbifiledacom pharmaceuticalsusaincandtevapharmaceuticalindustriesltd plaintintheunitedstatesdistrictcourtforthedistrictofcolumbia collectivelytevainresponsetoimpaxandtevasfilingofamajor foradeclaratoryjudgmentofnoninfringementandinvalidityof amendmenttoitsandaseekingapprovaltomarketageneric theabbottgmbhpatentsaswellasacomplaintforreviewofa versionofconcertabeforetheexpirationofalzaandjpis patentinterferencedecisionthatgrantedpriorityofinventionon patentrelatingtoconcertaimpaxandtevafiledcounterclaim oneofthetwoassertedpatentstoabbottgmbhthecaseshave allegingnoninfringementandinvalidityinmayalzaand beentransferredfromthedistrictofcolumbiatothedistrictof jpifiledasecondlawsuitagainsttevainresponsetotevasfiling massachusettsnotrialdatehasbeensetalsoinaugust ofasecondmajoramendmenttoitsandaseekingapprovalto abbottgmbhandabbottlaboratorieslimitedbroughtapatent marketadditionaldosagestrengthsofitsgenericconcerta infringementlawsuitinthefederalcourtofcanadaallegingthat productbeforetheexpirationofalzaandjpispatentrelatingto stelarainfringesabbottgmbhscanadianpatentnotrialdate concertaineachoftheabovecasesalzaandjpiareseeke hasbeensetinthecanadiancaseineachofthesecasesabbott anorderenjoiningthedefendantsfrommarketingitsgeneric isseekingmonetarydamagesandinjunctiverelief versionofconcertapriortotheexpirationofalzaandjpis inaugustbayerhealthcarellcbayerfiledapatent concertapatent infringementlawsuitagainstcentocororthobiotechincnowjbi inunitedstatesdistrictcourtforthedistrictofmassachusett orthotricyclenlo allegingthatthemanufactureandsalebyjbiofsimponiinfringe inoctoberomjpinowjpiandjohnsonjohnsonpharma abayerpatentrelatingtohumanantitnfantibodiesinjanuary ceuticalresearchdevelopmentllcnowjanssenresearch thecourtissuedjudgmentdismissingbayersinfringement developmentllcjrdfiledapatentinfringementlawsuitagainst claimsbayerappealedthisrulinginadditioninnovember watsonlaboratoriesincandwatsonpharmaceuticalsinc bayerfiledalawsuitunderitseuropeancounterparttothesepatents collectivelywatsonintheunitedstatesdistrictcourtforthe johnson johnson annual reportdistrictofnewjerseyinresponsetowatsonsandaseeke inmarchtibotecandgdsearlefiledapatentinfringe approvaltomarketagenericversionofjpisproductpriortothe mentlawsuitagainsttevapharmaceuticalsusaincandteva expirationofjpispatentrelatingtoorthotricyclenlothe pharmaceuticalsltdcollectivelytevaintheunitedstates otclopatentwatsonfiledacounterclaimalleginginvalidityof districtcourtforthedistrictofnewjerseyinresponsetotevas thepatentinadditioninjanuaryjpifiledapatentinfringe andaseekingapprovaltomarketagenericversionofprezista mentlawsuitagainstlupinltdandlupinpharmaceuticalsinc beforetheexpirationofcertainpatentsrelatingtoprezistathat collectivelylupinintheunitedstatesdistrictcourtforthe tiboteceitherownsorexclusivelylicensesfromgdsearle districtofnewjerseyinresponsetolupinsandaseeke inmarchtibotecfiledapatentinfringementlawsuit approvaltomarketagenericversionoforthotricyclenlo againstheterodrugsltdunitiiiandheterousainccollectively priortotheexpirationoftheotclopatentlupinfiledacounter heterointheunitedstatesdistrictcourtforthedistrictofnew claimalleginginvalidityofthepatentthelupinandwatsoncase jerseyinresponsetoheterosandaseekingapprovaltomarketa havebeenconsolidatedinfebruaryjpiandwatsonentered genericversionofprezistabeforetheexpirationofcertain intoasettlementagreementpursuanttothesettlementagreement patentsrelatingtoprezistathattibotecexclusivelylicensesfrom thepartiesenteredintoasupplyagreementwherebyjpiwillsupply gdsearleinjulyuponagreementbythepartiesthecourt towatsonacombinationaloralcontraceptivecontainingcertain enteredastayofthelawsuitpendingafinaldecisioninthelawsuit specifiedcompoundsfromdecemberorearlierunder againsttevawithrespecttothevalidityandorenforceabilityofthe certaincircumstancesthroughtheexpirationofthepatenton patentsthattiboteclicensesfromgdsearlewithheteroagreee decemberinadditionintheeventwatsondoesnotwishto tobeboundbysuchfinaldecision exerciseitsrightsunderthesupplyagreementjpihasgrantedwat inseptemberthecourtconsolidatedtheabovelawsuit sonalicensetomarketwatsonsandaproductfromdecember aswellaslawsuitsbroughtbytheunitedstatesgovernment orearlierundercertaincircumstancesthroughdecember againsteachofthedefendantsforinfringementofaunitedstate atrialdateforthelupincasehasbeensetformarch governmentownedpatentrelatingtoprezistaforpurposesof innovemberomjpinowjpifiledapatentinfringe pretrialdiscoveryandtrialwiththeprovisothatafterdiscoveryis mentlawsuitagainstmylanincandmylanpharmaceuticalsinc completedanypartycanmovetohavethecasesdeconsolidate collectivelymylanandfamycareltdfamycareintheunite fortrial statesdistrictcourtforthedistrictofnewjerseyinresponseto ineachoftheabovelawsuitstibotecisseekinganorder famycaresandaseekingapprovaltomarketagenericversionof enjoiningthedefendantsfrommarketingtheirgenericversionsof orthotricyclenlopriortotheexpirationoftheotclo prezistabeforetheexpirationoftherelevantpatent patentmylanandfamycarefiledcounterclaimsalleginginvalidity ofthepatent otherintellectualpropertymatter inoctoberjpifiledapatentinfringementlawsuitagainst inseptembercentocororthobiotechproductslpnow sunpharmaglobalfzeandsunpharmaceuticalindustriescollec janssenproductslpjplpintervenedinaninventorshiplawsuit tivelysunintheunitedstatesdistrictcourtforthedistrictof filedbytheuniversityofkansascenterforresearchinckucr newjerseyinresponsetosunsandaseekingapprovaltomarketa againsttheunitedstatesofamericausaintheunitedstates genericversionoforthotricyclenlopriortotheexpiration districtcourtforthedistrictofkansaskucrallegesthattwo oftheotclopatent kucrscientistsshouldbeaddedasinventorsontwousaowne ineachoftheabovecasesjrdandorjpiareseekingan patentsrelatingtovelcadetheusalicensedthepatentsand orderenjoiningthedefendantsfrommarketingtheirgeneric theirforeigncounterpartstomillenniumpharmaceuticalsinc versionsoforthotricyclenlobeforetheexpirationofthe mpiwhointurnsublicensedthepatentsandtheirforeign otclopatent counterpartstojplpforcommercialmarketingoutsidetheunite statesinjulythepartiesreachedasettlementagreementto prezista resolvethedisputesinthiscaseandwillsubmittheinventorship innovembertibotecincnowtibotecllcandtibotec issuetoarbitrationthecasehasbeenstayedpendingthearbitra pharmaceuticalsinccollectivelytibotecfiledapatentinfringe tionasaresultofthesettlementagreementtheoutcomeof mentlawsuitagainstlupinltdlupinpharmaceuticalsinc thearbitrationregardinginventorshipwilldeterminewhetherpre collectivelylupinmylanincandmylanpharmaceuticalsinc specifiedpaymentswillbemadetokucrbutwillnotaffectjplps collectivelymylanintheunitedstatesdistrictcourtforthedis righttomarketvelcadethearbitrationtookplaceindecember trictofnewjerseyinresponsetolupinsandmylansrespective andadecisionisexpectedinapril andasseekingapprovaltomarketgenericversionsoftibotecs indecemberthestateofisraelfiledalawsuitinthedis prezistaproductbeforetheexpirationoftibotecspatentrelat trictcourtintelavivjaffaagainstomrixbiopharmaceuticalsinc ingtoprezistalupinandmylaneachfiledcounterclaimsallege andvariousaffiliatesomrixinthelawsuitthestateclaimsthat noninfringementandinvalidityinjulytibotecfiledanother anemployeeofagovernmentownedhospitalwastheinventoron patentinfringementlawsuitagainstlupinintheunitedstatesdis severalpatentsrelatedtofibringluetechnologythattheemployee trictcourtforthedistrictofnewjerseyinresponsetolupinssup developedwhilehewasagovernmentemployeethestateclaims plementtoitsandatoaddnewdosagestrengthsforitspropose thathehadnorighttotransferanyintellectualpropertytoomrix productinaugusttibotecandgdsearlecompanygd becauseitbelongstothestatethestateisseekingdamagesplus searlefiledapatentinfringementlawsuitagainstlupinandmylan royaltiesonquixilandevicelproductsoralternatively inresponsetotheirnoticelettersadvisingthattheirandasare transferofthepatentstothestate seekingapprovaltomarketgenericversionsoftibotecsprezista productbeforetheexpirationoftwopatentsrelatingtoprezista thattibotecexclusivelylicensesfromgdsearle note consolidated financial statement injanuarygenentechincgenentechinitiatedan risperdal arbitrationagainstucbcelltechcelltechseekingdamagesfor injanuaryjanssenpharmaceuticaincjanssennow allegedlycooperatingwithcentocornowjbitoimproperly janssenpharmaceuticalsincjpireceivedasubpoenafromthe terminateaprioragreementinwhichjbiwassublicensedunder officeoftheinspectorgeneraloftheunitedstatesofficeofper genentechscabillypatentsjbihasanindemnityagreementwith sonnelmanagementseekingdocumentsconcerningsalesandmar celltechandcelltechhasassertedthatjbiisliableforanydamage ketingofanyandallpaymentstophysiciansinconnectionwith celltechmayberequiredtopaygenentechinthatarbitrationtrial salesandmarketingofandclinicaltrialsforrisperdalfrom isscheduledforjune todocumentssubsequenttohavealsobeenrequeste bythedepartmentofjusticeanadditionalsubpoenaseekinginfor governmentproceeding mationaboutmarketingofandadversereactionstorisperdal likeothercompaniesinthepharmaceuticalandmedicaldevice wasreceivedfromtheunitedstatesattorneysofficefortheeast anddiagnosticsindustriesjohnsonjohnsonandcertainofits erndistrictofpennsylvaniainnovembernumeroussubpoe subsidiariesaresubjecttoextensiveregulationbynationalstate nasseekingtestimonyfromvariouswitnessesbeforeagrandjury andlocalgovernmentagenciesintheunitedstatesandothercoun werealsoreceivedjpicooperatedinrespondingtotheserequest triesinwhichtheyoperateasaresultinteractionwithgovernment fordocumentsandwitnessestheunitedstatesdepartmentof agenciesisongoingthemostsignificantlitigationbroughtbyand justiceandtheunitedstatesattorneysofficefortheeasterndis investigationsconductedbygovernmentagenciesarelistedbelow trictofpennsylvaniathegovernmentarecontinuingtoactively itispossiblethatcriminalchargesandsubstantialfinesandorcivil pursuebothcriminalandcivilactionsinfebruarythegovern penaltiesordamagescouldresultfromgovernmentinvestigation mentservedcivilinvestigativedemandsseekingadditionalinfor orlitigation mationrelatingtosalesandmarketingofrisperdalandsale andmarketingofinvegathefocusofthesemattersisthe averagewholesalepriceawplitigation allegedpromotionofrisperdalandinvegaforofflabeluse johnsonjohnsonandseveralofitspharmaceuticalsubsidiarie thegovernmenthasnotifiedjpithattherearealsopendingquitam thejjawpdefendantsalongwithnumerousotherpharmaceu actionsallegingofflabelpromotionofrisperdalthegovern ticalcompaniesaredefendantsinaseriesoflawsuitsinstateand mentinformedjpithatitwillinterveneinthesequitamactionsand federalcourtsinvolvingallegationsthatthepricingandmarketing fileasupersedingcomplaint ofcertainpharmaceuticalproductsamountedtofraudulentand discussionshavebeenongoinginanefforttoresolvecriminal otherwiseactionableconductbecauseamongotherthingsthe penaltiesunderthefooddrugandcosmeticactrelatedtothe companiesallegedlyreportedaninflatedaveragewholesaleprice promotionofrisperdalanagreementinprincipleonkeyissue awpforthedrugsatissuepayorsallegedthattheyusedthose relevanttoadispositionofcriminalchargespursuanttoasingle awpsincalculatingproviderreimbursementlevelsmanyofthese misdemeanorviolationofthefooddrugandcosmeticacthasbeen casesbothfederalactionsandstateactionsremovedtofederal reachedbutcertainissuesremainopenbeforeasettlementcanbe courtwereconsolidatedforpretrialpurposesinamultidistrict finalizedduringthecompanyaccruedamountstocoverthe litigationmdlintheunitedstatesdistrictcourtforthedistrict financialcomponentoftheproposedcriminalsettlement ofmassachusetts inadditiondiscussionswithstateandfederalgovernment theplaintiffsinthesecasesincludedthreeclassesofprivate representativestoresolvetheseparatecivilclaimsrelatedtothe personsorentitiesthatpaidforanyportionofthepurchaseofthe marketingofrisperdalandinvegaincludingthoseunderthe drugsatissuebasedonawpandstategovernmententitiesthat falseclaimsactthequitamactionsarestillongoingalthough mademedicaidpaymentsforthedrugsatissuebasedonawpin itstillremainsunclearwhetherasettlementcanbereachedwith juneafteratrialonthemeritsthemdlcourtdismissedthe respecttothefederalandstatecivilclaimstherehasbeenasub claimsoftwooftheplaintiffclassesagainstthejjawpdefen stantialnarrowingoftheissuesandpotentialliabilityandinthe dantsinmarchthecourtdismissedtheclaimsofthethird companyestablishedanaccrualtocovertheestimatedfinancial classagainstthejjawpdefendantswithoutprejudice componentofthepotentialfederalcivilsettlementifanegotiate awpcasesbroughtbyvariousattorneysgeneralhavepro resolutioncannotbereachedcivillitigationrelatingtotheallegation ceededtotrialagainstothermanufacturersseveralstatecase ofofflabelpromotionofrisperdalandorinvegaislikely againstcertainofjohnsonjohnsonssubsidiarieshavebeenset theattorneysgeneralofmultiplestatesincludingalaska tledincludingkentuckywhichhadbeensetfortrialinjanuary arkansaslouisianamassachusettsmississippimontananew kansasissetfortrialinmarchandotherstatecasesare mexicopennsylvaniasouthcarolinatexasandutahhavepende likelytobesetfortrialinadditionanawpcaseagainstthejj actionsagainstjanssennowjpiseekingoneormoreofthefollow awpdefendantsbroughtbythecommonwealthofpennsylvania ingremediesreimbursementofmedicaidorotherpublicfundsfor wastriedincommonwealthcourtinoctoberandnovember risperdalprescriptionswrittenforofflabelusecompensation thecourtfoundinthecommonwealthsfavorwithregardtocertain fortreatingtheircitizensforallegedadversereactionsto ofitsclaimsunderthepennsylvaniaunfairtradepracticesandcon risperdalcivilfinesorpenaltiesdamagesforoverpayment sumerprotectionlawutplenteredaninjunctionandawarded bythestateandothersviolationsofstateconsumerfraudstatutes millioninrestitutionandmillionincivilpenaltiesthe punitivedamagesorotherreliefrelatingtoallegedunfairbusiness courtfoundinthejjawpdefendantsfavoronthecommon practicescertainoftheseactionsalsoseekinjunctivereliefrelate wealthsclaimsofunjustenrichmentmisrepresentationfraudcivil tothepromotionofrisperdalinjanuaryjpiagreedto conspiracyandoncertainofthecommonwealthsclaimsunderthe settlealawsuitfiledbytheattorneygeneraloftexastrialinthe utplthejjawpdefendantshaveappealedthecommonwealth lawsuitbroughtbytheattorneygeneralofarkansasisschedule courtsutplrulingtothepennsylvaniasupremecourtthe tocommenceinmarchjpihasfiledmotionsforsummary companybelievesthatthejjawpdefendantshavestrongargu judgmentinthearkansasmatter mentssupportingtheirappealbecausethecompanybelievesthat theattorneygeneralofwestvirginiacommencedsuitin thepotentialforanunfavorableoutcomeisnotprobableithasnot againstjanssennowjpibasedonclaimsofallegedcon establishedanaccrualwithrespecttotheverdict sumerfraudastoduragesicaswellasrisperdaljpiwas johnson johnson annual reportfoundliableanddamageswereassessedatmillionjpifiledan mcneilconsumerhealthcare appealandinnovemberthewestvirginiasupremecourt startinginjunemcneilconsumerhealthcaredivisionof reversedthetrialcourtsdecisionindecembertheattorney mcneilppcincmcneilconsumerhealthcareandcertainaffili generalofwestvirginiadismissedthecaseasitrelatedto atesincludingjohnsonjohnsonthecompaniesreceivedgrand risperdalwithoutanypaymentthereafterjpisettledthecase jurysubpoenasfromtheunitedstatesattorneysofficefortheeast insofarasitrelatedtoduragesic erndistrictofpennsylvaniarequestingdocumentsbroadlyrelatingto intheattorneygeneraloflouisianafiledamulticount recentrecallsofvariousproductsofmcneilconsumerhealthcare complaintagainstjanssennowjpijohnsonjohnsonwaslater andthefdainspectionsofthefortwashingtonpennsylvaniaand addedasadefendantthecasewastriedinoctoberthe lancasterpennsylvaniamanufacturingfacilitiesaswellascertain issuetriedtothejurywaswhetherjohnsonjohnsonorjpihad documentsrelatingtorecentrecallsofasmallnumberofproduct violatedthestatesmedicaidfraudacttheactthroughmisrepre ofothersubsidiariesinadditioninfebruarythegovernment sentationsallegedlymadeinthemailingofanovemberdear servedmcneilppcincmcneilppcwithacivilinvestigative healthcareprofessionalletterregardingrisperdalthejury demandseekingrecordsrelevanttoitsinvestigationtodetermineif returnedaverdictthatjpiandjohnsonjohnsonhadviolatedthe therewasaviolationofthefederalfalseclaimsactthecompanie actandawardedmillionindamagesthetrialjudgesubse arecooperatingwiththeunitedstatesattorneysofficeinrespond quentlyawardedtheattorneygeneralcounselfeesandexpensesin ingtothesesubpoenas theamountofmillionjohnsonjohnsonsandjpismotionfor thecompanieshavealsoreceivedcivilinvestigativedemand anewtrialwasdeniedjohnsonjohnsonandjpihavefiledan frommultiplestateattorneysgeneralofficesbroadlyrelatingto appealandbelievethattheyhavestrongargumentssupportingthe themcneilrecallissuesthecompaniescontinuetocooperatewith appealthecompanybelievesthatthepotentialforanunfavorable theseinquiriesinjanuarytheoregonattorneygeneralfileda outcomeisnotprobableandthereforethecompanyhasnot civilcomplaintagainstjohnsonjohnsonmcneilppcand establishedanaccrualwithrespecttotheverdict mcneilhealthcarellcinstatecourtallegingcivilviolationsofthe intheofficeofgeneralcounselofthecommonwealth oregonunlawfultradepracticesactrelatingtoanearlierrecallofa ofpennsylvaniafiledalawsuitagainstjanssennowjpionamulti mcneilotcproductafteraremovaltofederalcourtthecasewa countcomplaintrelatedtojanssenssaleofrisperdaltothe remandedbacktostatecourtinoregonthecompaniesfileda commonwealthsmedicaidprogramthetrialoccurredinjune motiontodismissinfebruary thetrialjudgedismissedthecaseafterthecloseofthe inmarchtheunitedstatesfiledacomplaintforinjunctive plaintiffsevidencethecommonwealthsposttrialmotionswere reliefintheunitedstatesdistrictcourtfortheeasterndistrictof deniedthecommonwealthfiledanappealinapriltheoral pennsylvaniaagainstmcneilppcandtwoofitsemployeesalleg argumentisscheduledtotakeplaceinmay ingthatmcneilppcisinviolationoffdaregulationsregardingthe intheattorneygeneralofsouthcarolinafiledalawsuit manufactureofdrugsatthefacilitiesitoperatesinlancasterpenn againstjohnsonjohnsonandjanssennowjpionseveralcounts sylvaniafortwashingtonpennsylvaniaandlaspiedraspuerto inmarchthematterwastriedonliabilityonlyatwhichtime ricoonthesamedaythepartiesfiledaconsentdecreeofperma thelawsuitwaslimitedtoclaimsofviolationofthesouthcarolina nentinjunctionresolvingtheclaimssetforthinthecomplaintthe unfairtradepracticeactincludingamongothersquestionsof courtapprovedandenteredtheconsentdecreeonmarch whetherjohnsonjohnsonorjpiengagedinunfairordeceptive theconsentdecreewhichissubjecttoongoingenforcement actsorpracticesintheconductofanytradeorcommerceby bythecourtrequiresmcneilppctotakeenhancedmeasuresto distributingthenovemberdearhealthcareprofessional remediatethethreefacilitiesthefortwashingtonfacilitywhich letterregardingrisperdalorintheiruseoftheproduct wasvoluntarilyshutdowninaprilwillremainshutdownuntil fdaapprovedlabelthejuryfoundinfavorofjohnsonjohnson athirdpartyconsultantcertifiesthatitsoperationswillbeincom andagainstjpiinjunethecourtawardedcivilpenaltiesof pliancewithapplicablelawandthefdaconcurswiththethird approximatelymillionjpihasappealedthisjudgmentthe partycertificationthelancasterandlaspiedrasfacilitiesmay companybelievesthatjpihasstrongargumentssupportingan continuetomanufactureanddistributedrugsprovidedthatathird appealandthatthepotentialforanunfavorableoutcomeisnot partyreviewsmanufacturingrecordsforselectedbatchesofdrugs probablethereforethecompanyhasnotestablishedanaccrual releasedfromthefacilitiesandcertifiesthatanydeviation withrespecttotheverdict revieweddonotadverselyaffectthequalityoftheselectedbatche theattorneysgeneralofapproximatelyotherstateshave mcneilppchassubmittedaworkplantothefdaforremediation indicatedapotentialinterestinpursuingsimilarlitigationagainst ofthelancasterandlaspiedrasfacilitiesthatplanissubjectto jpiandhaveobtainedatollingagreementstayingtherunningofthe fdaapprovalthirdpartybatchrecordreviewmayceaseifthefda statuteoflimitationswhiletheypursueacoordinatedcivilinvesti hasstatedthatthefacilitiesappeartobeincompliancewithappli gationofjpiregardingpotentialconsumerfraudactionsinconnec cablelaweachfacilityissubjecttoafiveyearauditperiodbya tionwiththemarketingofrisperdal thirdpartyafterthefacilityhasbeendeemedbythefdatobein inthecompanyestablishedanaccrualwithrespectto apparentcompliancewithapplicablelaw theabovestatematter inthecompanysopiniontheultimateresolutionofanyof theaboverisperdalmattersisnotexpectedtohaveamaterial adverseeffectonthecompanysfinancialpositionalthoughthe resolutioninanyreportingperiodcouldhaveamaterialimpacton thecompanysresultsofoperationsandcashflowsforthatperiod note consolidated financial statement omnicare inseptemberjohnsonjohnsonreceivedasubpoenafrom injulysciosincsciosreceivedasubpoenafromtheunite theunitedstatesattorneysofficeforthedistrictofmassachusett statesattorneysofficeforthedistrictofmassachusettsseeke seekingdocumentsrelatedtothesalesandmarketingofeightdrug documentsrelatedtothesalesandmarketingofnatrecor toomnicareincomnicareamanagerofpharmaceuticalbene inaugustscioswasadvisedthattheinvestigationwouldbe fitsforlongtermcarefacilitiesinapriljohnsonjohnson handledbytheunitedstatesattorneysofficeforthenorthern andcertainofitspharmaceuticalsubsidiarieswereservedintwo districtofcaliforniainsanfranciscoinfebruarytwoquitam civilquitamcasesassertingclaimsunderthefederalfalseclaim complaintswereunsealedintheunitedstatesdistrictcourtfor actandrelatedstatelawclaimsallegingthatthedefendantspro thenortherndistrictofcaliforniaallegingamongotherthing videdomnicarewithrebatesandotherallegedkickbackscause improperactivitiesinthepromotionofnatrecorinjune omnicaretofilefalseclaimswithmedicaidandothergovernment theunitedstatesgovernmentintervenedinoneofthequitam programsinjanuarythegovernmentintervenedinbothof actionsandfiledacomplaintagainstsciosandjohnsonjohnson thesecasesnamingjohnsonjohnsonorthomcneiljanssen seekingreliefunderthefederalfalseclaimsactandassertinga pharmaceuticalsincnowjanssenpharmaceuticalsincjpi claimofunjustenrichmentthecivilcaseisproceedinganddiscovery andjohnsonjohnsonhealthcaresystemsincasdefendant isongoinginoctoberthecourtapprovedasettlementofthe subsequentlythecommonwealthofmassachusettsvirginiaand criminalcaseinwhichsciospledguiltytoasinglemisdemeanorvio kentuckyandthestatesofcaliforniaandindianaintervenedinthe lationofthefooddrugcosmeticactandpaidafineofmillion actionthedefendantsmovedtodismissthecomplaintsandin infebruaryjohnsonjohnsonvoluntarilydisclosedto februarytheunitedstatesdistrictcourtforthedistrictof theunitedstatesdepartmentofjusticedojandtheunite massachusettsdismissedonequitamcaseentirelyanddismisse statessecuritiesexchangecommissionsecthatsubsidiarie theothercaseinpartrejectingallegationsthatthedefendantshad outsidetheunitedstatesarebelievedtohavemadeimproperpay violatedtheirobligationtoreportitsbestpricetohealthcarepro mentsinconnectionwiththesaleofmedicaldevicesintwosmall gramofficialsthedefendantssubsequentlymovedthecourtto marketcountrieswhichpaymentsmayfallwithinthejurisdiction reconsideritsdecisionnottodismissthesecondcaseinitsentirety oftheforeigncorruptpracticesactfcpainthecourseof whichthecourtdeniedinmaytheclaimsoftheunitedstate continuingdialogueswiththeagenciesotherissuespotentially andindividualstatesremainpende risingtotheleveloffcpaviolationsinadditionalmarketswere innovemberalawsuitwasfiledundersealbyscott broughttotheattentionoftheagenciesbyjohnsonjohnsonin bartzaformeremployeeintheunitedstatesdistrictcourtforthe additioninfebruaryjohnsonjohnsonreceivedasubpoena easterndistrictofpennsylvaniaagainstjohnsonjohnsonandcer fromthesecrequestingdocumentsrelatingtotheparticipation tainofitspharmaceuticalsubsidiariesthejjdefendantsalong byseveralofitssubsidiariesintheunitednationsiraqoilforfood withcodefendantsmckessoncorporationmckessonandomni programinapriljohnsonjohnsonresolvedthefcpa careincthebartzcomplaintraisesmanyissuesincommonwith andoilforfoodmattersthroughsettlementswiththedojsec theomnicarerelatedlitigationdiscussedabovealreadypende andunitedkingdomseriousfraudofficethesesettlement beforetheunitedstatesdistrictcourtforthedistrictofmassachu requiredpaymentsofapproximatelymillioninfinancialpenal settssuchasbestpriceandanumberofkickbackallegationsafter tiesaspartofthesettlementwiththedojjohnsonjohnson investigationtheunitedstatesdeclinedtointervenethecasewa enteredintoadeferredprosecutionagreementthatrequire subsequentlyunsealedinjanuaryinfebruarytheplain johnsonjohnsontocompleteathreeyeartermofenhance tifffiledanamendedcomplaintwhichwasplacedunderseal compliancepractice thereafteronthejjdefendantsmotionthecasewastransferre injunejohnsonjohnsonreceivedasubpoenafrom totheunitedstatesdistrictcourtforthedistrictofmassachusetts theunitedstatesattorneysofficeforthedistrictofmassachu whereitiscurrentlypendinginapriltheamendedcomplaint settsrelatingtothemarketingofbiliarystentsbycordiscorpora wasorderedunsealedandallegesavarietyofcausesofactionunder tioncordiscordisiscurrentlycooperatinginrespondingtothe thefederalfalseclaimsactandcorrespondingstateandlocal subpoenainadditioninjanuaryacomplaintwasunsealedin statutesincludingthatthejjdefendantsengagedinvarious theunitedstatesdistrictcourtforthenortherndistrictoftexas impropertransactionsthatwereallegedlydesignedtoreportfalse seekingdamagesagainstcordisforallegedviolationsofthefederal prescriptiondrugpricestothefederalgovernmentinorderto falseclaimsactandseveralsimilarstatelawsinconnectionwith reducethejjdefendantsmedicaidrebateobligationsthecom themarketingofbiliarystentstheunitedstatesdepartmentof plaintfurtherallegesthatthejjdefendantsimproperlyretaliate justiceandseveralstateshavedeclinedtointerveneatthistimein againsttheplaintiffforhavingraisedtheseallegationsinternally apriltheunitedstatesdistrictcourtforthenortherndistrict bartzseeksmultipleformsofreliefincludingdamagesandrein oftexasdismissedthecomplaintwithoutprejudice statementtoapositionwiththesamesenioritystatus inoctobertheeuropeancommissionannouncedthat thejjdefendantssubsequentlymovedtodismissthecom itopenedaninvestigationconcerninganagreementbetween plaintinmayandoralargumentwasheldinaugustin janssencilagbvandsandozbvrelatingtothesupplyoffentanyl junebartzfiledanoticeofintenttovoluntarilydismiss patchesinthenetherlandstheinvestigationseekstodetermine mckessonandomnicarefromthecaseandaddedmckesson whethertheagreementinfringeseuropeancompetitionlaw specialtypharmaceuticalsllcasacodefendantthepartiesare inrecentyearsjohnsonjohnsonhasreceivednumerous awaitingarulingonthemotiontodismiss requestsfromavarietyofunitedstatescongressionalcommittee toproduceinformationrelevanttoongoingcongressionalinquirie itisjohnsonjohnsonspolicytocooperatewiththeseinquiriesby producingtherequestedinformation johnson johnson annual reportgenerallitigation merckcoincmerckandscheringploughconstituteda inseptemberplaintiffsinanemploymentdiscriminationliti changeofcontrolunderthetermsofthedistributionagreement gationinitiatedagainstjohnsonjohnsoninintheunite thatpermittedjbitoterminatetheagreementsinapril statesdistrictcourtforthedistrictofnewjerseymovedtocertify johnsonjohnsonjbiandmerckannouncedanagreementto aclassofallafricanamericanandhispanicsalariedemployeesof amendthedistributionagreementsthisagreementconclude johnsonjohnsonanditsaffiliatesintheunitedstateswhowere thearbitrationproceeding employedatanytimefromnovembertothepresentplaintiff pursuanttothetermsoftheamendeddistributionagree soughtmonetarydamagesfortheperiodthroughthepresent mentsonjulymerckssubsidiaryscheringploughireland includingpunitivedamagesandequitablereliefthecourtdenie relinquishedexclusivemarketingrightsforremicadeand plaintiffsclasscertificationmotionindecemberandtheir simponitojohnsonjohnsonsjanssenpharmaceuticalcompa motionforreconsiderationinaprilplaintiffssoughttoappeal niesinterritoriesincludingcanadacentralandsouthamericathe thesedecisionsandinaprilthecourtofappealsruledthat middleeastafricaandasiapacificrelinquishedterritoriesmerck plaintiffsappealofthedenialofclasscertificationwasuntimelyin retainedexclusivemarketingrightsthroughouteuroperussiaand julyplaintiffsfiledamotionforcertificationofamodifie turkeyretainedterritoriestheretainedterritoriesrepresent classwhichjohnsonjohnsonopposedthedistrictcourtdenie approximatelypercentofmercksrevenueofapproxi plaintiffsmotioninjulyandthecourtofappealsdenie matelybillionfromremicadeandsimponiwhilethe plaintiffsrequestforleavetoappealthedenialofcertificationofthe relinquishedterritoriesrepresentapproximatelypercentin modifiedclassinmaythecasewasdismissedwithprejudice additionasofjulyallprofitderivedfrommercksexclusive startinginjulyfivelawsuitswerefiledinunitedstate distributionofthetwoproductsintheretainedterritoriesisbee districtcourtforthedistrictofnewjerseybyvariousemployer equallydividedbetweenmerckandjbiunderthepriortermsofthe andemployeebenefitplansandfundsseekingtorecoveramount distributionagreementsthecontributionincomeprofitsplit theypaidforrisperdalforplanparticipantsingeneralplaintiff whichwasatpercenttomerckandpercenttojbiwouldhave allegethatjohnsonjohnsonandcertainofitspharmaceutical declinedformerckandincreasedforjbieachyearuntilwhen subsidiariesengagedinofflabelmarketingofrisperdalin itwouldhavebeenequallydividedjbialsoreceivedaonetime violationofthefederalandnewjerseyricostatutesinaddition paymentofmillioninaprilwhichisbeingamortize plaintiffsassertedvariousstatelawclaimsallofthecaseswere overtheperiodoftheagreement consolidatedintoonecaseseekingclassactionstatusbutshortly inaprilaputativeclassactionlawsuitwasfiledinthe thereafteroneactionwasvoluntarilydismissedindecember unitedstatesdistrictcourtforthenortherndistrictofcalifornia thecourtdismissedtheactionsofthefourremainingplain byrepresentativesofnursinghomeresidentsortheirestate tiffsinaprilthoseplaintiffsfiledanewconsolidatedclass againstjohnsonjohnsonomnicareincomnicareandother actionagainstjohnsonjohnsonandjanssenlpnowjanssen unidentifiedcompaniesorindividualsinfebruaryplaintiffs pharmaceuticalsincjpiandinmarchthatactionwasdis filedasecondamendedcomplaintassertingthatcertainrebate missedinapriloneofthoseplaintiffsfiledanoticeofappeal agreementsbetweenjohnsonjohnsonandomnicareincrease withtheunitedstatescourtofappealsforthethirdcircuitthat theamountofmoneyspentonpharmaceuticalsbythenurse appealwasdismissedinjuly homeresidentsandviolatedtheshermanactandthecalifornia inaprilorthoclinicaldiagnosticsincocdreceive businessprofessionscodethesecondamendedcomplaintalso agrandjurysubpoenafromtheunitedstatesdepartmentof assertedaclaimofunjustenrichmentplaintiffssoughtmultiple justiceantitrustdivisionrequestingdocumentsandinformation formsofmonetaryandinjunctivereliefjohnsonjohnsonmoved fortheperiodbeginningseptemberthroughthepresent todismissthesecondamendedcomplaintinmarchthecourt pertainingtoaninvestigationofallegedviolationsoftheantitrust grantedthemotioninitsentiretyinaugustdismissingall lawsinthebloodreagentsindustryocdcompliedwiththesub claimsassertedbyplaintiffsinoctoberthecourtdismisse poenainfebruaryocdreceivedaletterfromtheantitrust theactionwithprejudicetheplaintiffsfiledanoticeofappealin divisionindicatingthatithadcloseditsinvestigationinnovember novembertheappealispendingbeforetheunitedstate injunefollowingthepublicannouncementthatocd courtofappealsfortheninthcircuit hadreceivedagrandjurysubpoenamultipleclassactioncom startinginaprilanumberofshareholderderivativelaw plaintsseekingdamagesforallegedpricefixingwerefiledagainst suitswerefiledintheunitedstatesdistrictcourtforthedistrictof ocdthevariouscaseswereconsolidatedforpretrialpurpose newjerseyagainstcertaincurrentandformerdirectorsandofficer intheunitedstatesdistrictcourtfortheeasterndistrictof ofjohnsonjohnsonjohnsonjohnsonisnamedasanominal pennsylvaniadiscoveryisongoe defendanttheseactionswereconsolidatedinaugustintoone inmaycentocororthobiotechincnowjanssen lawsuitinrejohnsonjohnsonderivativelitigationanamendedcon biotechincjbicommencedanarbitrationproceedingbefore solidatedcomplaintwasfiledindecemberadditionallyin theamericanarbitrationassociationagainstscheringploughcor septemberanothershareholderderivativelawsuitwasfile porationanditssubsidiaryscheringploughirelandcompanycol innewjerseysuperiorcourtagainstcertaincurrentandformer lectivelyscheringploughjbiandscheringplougharepartiestoa directorsandofficersofjohnsonjohnsonjohnsonjohnsoni seriesofagreementsdistributionagreementsthatgrantschere namedasanominaldefendantinthisactionaswellthepartiesto ploughtheexclusiverighttodistributethedrugsremicadeand thisactionhavestipulatedthatitshallbestayeduntiltheinre simponiworldwideexceptwithintheunitedstatesjapan johnsonjohnsonderivativelitigationiscompletelyresolve taiwanindonesiaandthepeoplesrepublicofchinainclude hongkongjbidistributesremicadeandsimponithenext generationtreatmentwithintheunitedstatesinthearbitration jbisoughtadeclarationthattheagreementandmergerbetween note consolidate financial statement theseshareholderderivativeactionsaresimilarintheirclaim wasfiledindecemberinjanuaryjohnsonjohnson andcollectivelytheyassertavarietyofallegedbreachesoffiduciary movedtodismissorstaythestatelawsuitspendingresolutionof dutiesincludingamongotherthingsthatthedefendantsallegedly thefederallawsuitinadditionjohnsonjohnsonintendsto engagedinapprovedoforfailedtoremedyorpreventdefective movetodismissorstaythestatelawsuitsonthegroundsthatthe medicaldevicesimproperpharmaceuticalrebatesimproperoff plaintiffsfailedtomakeademandontheboardofdirectors labelmarketingofpharmaceuticalandmedicaldeviceproduct inseptembertwoadditionalshareholderderivativelaw violationsofcurrentgoodmanufacturingpracticeregulationsthat suitswerefiledintheunitedstatesdistrictcourtforthedistrictof resultedinproductrecallsandthattheyfailedtodisclosetheafore newjerseynamingjohnsonjohnsonscurrentdirectorsandone mentionedallegedmisconductinthecompanysfilingsunderthe formerdirectorasdefendantsandjohnsonjohnsonasthenominal securitiesexchangeactofeachcomplaintseeksavarietyof defendanttheselawsuitsallegethatthedefendantsbreachedtheir reliefincludingmonetarydamagesandcorporategovernance fiduciarydutiesintheirdecisionswithrespecttothecompensation reformsjohnsonjohnsonmovedtodismisstheseactionsonthe ofthechiefexecutiveofficerduringtheperiodfromthrough groundsinteraliathattheplaintiffsfailedtomakeademandupon thepresentandthatthedefendantsmademisleadingstatementsin theboardofdirectorsinseptemberinrejohnsonjohnson johnsonjohnsonsannualproxystatementsoneoftheselawsuit derivativelitigationwasdismissedwithoutprejudiceandwithleave hasbeenvoluntarilydismissedanamendedcomplainthasbeen tofileanamendedcomplaint filedintheotherindecemberjohnsonjohnsonmovedto johnsonjohnsonfiledareportintheinrejohnsonjohnson dismisstheremaininglawsuitonthegroundsthattheplaintifffailed derivativelitigationmatterinjulypreparedbyaspecialcom tomakeademandupontheboardofdirectors mitteeoftheboardofdirectorswhichinvestigatedtheallegation startinginmaymultiplecomplaintsseekingclassaction containedinthederivativeactionsandinanumberofshareholder certificationrelatedtothemcneilrecallshavebeenfiledagainst demandlettersthattheboardreceivedinraisingsimilar mcneilconsumerhealthcareandcertainaffiliatesinclude issuesthespecialcommitteewasassistedinitsinvestigationby johnsonjohnsonintheunitedstatesdistrictcourtfortheeast independentcounselthespecialcommitteesreportrecom erndistrictofpennsylvaniathenortherndistrictofillinoisthe mendedithatjohnsonjohnsonrejecttheshareholderdemands centraldistrictofcaliforniathesoutherndistrictofohioandthe andtakewhateverstepsarenecessaryorappropriatetosecuredi easterndistrictofmissouritheseconsumercomplaintsallegegen missalofthederivativelitigationandiithattheboardofdirector erallythatpurchasersofvariousmcneilmedicinesareowedmone createanewregulatoryandcompliancecommitteechargedwith tarydamagesandpenaltiesbecausetheypaidpremiumpricesfor responsibilityformonitoringandoversightofthecompanyshealth defectivemedicationsratherthanlessexpensivealternativemedica carecomplianceandqualitycompliancesystemsandissue tionsallbutonecomplaintseekscertificationofanationwideclass johnsonjohnsonsboardofdirectorsunanimouslyadoptedthe ofpurchasersofthesemedicineswhereasonecomplaintthehar specialcommitteesrecommendationsinaugusttwoshare veycaseseekscertificationofaclassofmotrinibpurchasers holderswhohadsubmittedshareholderdemandlettersin inmissouriinoctoberthejudicialpanelonmultidistrict filedshareholderderivativelawsuitsintheunitedstatesdistrict litigationjpmlconsolidatedalloftheconsumercomplaints courtforthedistrictofnewjerseynamingvariouscurrentand exceptfortheharveycasewhichwasconsolidatedinmarch formerofficersanddirectorsasdefendantsandchallengingthe forpretrialproceedingsintheunitedstatesdistrictcourtforthe boardsrejectionoftheirdemandsinnovemberthecourt easterndistrictofpennsylvaniainjanuarytheplaintiffsin consolidatedthesetwocasesjohnsonjohnsonhassecuredan allofthecasesexcepttheharveycasefiledaconsolidate extensionoftimetorespondtothecomplaintandwillifnecessary amendedcivilconsumerclassactioncomplaintcacname movetoterminatetheselawsuitsonthebasisoftheboard additionalpartiesandclaimsinjulythecourtgrante decisiontoadoptthespecialcommitteesrecommendation johnsonjohnsonsmotiontodismissthecacwithoutprejudice twoadditionalshareholderderivativelawsuitswerefiledin butpermittedtheplaintiffstofileanamendedcomplaintwithinthirty mayintheunitedstatesdistrictcourtforthedistrictofnew daysofthedismissalorderinaugusttheplaintiffsfileda jerseyandtwoothershareholderderivativelawsuitswerefiledin secondamendedcivilconsumerclassactioncomplaintsac newjerseysuperiorcourtinmayandaugustall johnsonjohnsonmovedtodismissthesacinseptember namingjohnsonjohnsonscurrentdirectorsasdefendantsand thissecondmotiontodismissispending johnsonjohnsonasthenominaldefendantthecomplaintsallege separatelyinseptemberjohnsonjohnson breachesoffiduciarydutiesrelatedtothecompanyscompliance johnsonjohnsonincandmcneilconsumerhealthcaredivision withtheforeigncorruptpracticesactandparticipationinthe ofjohnsonjohnsonincreceivedanoticeofcivilclaimfiledin unitednationsiraqoilforfoodprogramthatthecompanyhas thesupremecourtofbritishcolumbiacanadathecanadiancivil suffereddamagesasaresultofthoseallegedbreachesandthatthe claimthecanadiancivilclaimisaputativeclassactionbrought defendantsfailedtodisclosetheallegedmisconductinthe onbehalfofpersonswhoresideinbritishcolumbiaandwhopur companysfilingsunderthesecuritiesexchangeactofplain chasedvariousmcneilchildrensoverthecountermedicine tiffsseekmonetarydamagesandoneplaintiffalsoseekscorporate duringtheperiodbetweenseptemberandthepresent governancereformsthefederallawsuitswereconsolidatedinjuly thecanadiancivilclaimallegesthatthedefendantsviolatedthe andanamendedconsolidatedcomplaintwasfiledinaugust canadianbusinesspracticesandconsumerprotectionactand inoctoberjohnsonjohnsonmovedtodismissthe othercanadianstatutesandcommonlawsbysellingmedicines consolidatedfederallawsuitonthegroundsthattheplaintiffsfaile thatdidnotcomplywithcanadiangoodmanufacturingpractice tomakeademandupontheboardofdirectorsthestatelawsuit wereconsolidatedinnovemberandaconsolidatedcomplaint johnson johnson annual reportinseptemberashareholderronaldmonkfiledalawsuit restructuring intheunitedstatesdistrictcourtforthedistrictofnewjersey inthefiscalsecondquarterofcordiscorporationasubsidiary seekingclasscertificationandallegingthatjohnsonjohnsonand ofjohnsonjohnsonannouncedthediscontinuationofitsclinical certainindividualsincludingexecutiveofficersandemployeesof developmentprogramforthenevosirolimuselutingcoronary johnsonjohnsonfailedtodisclosethatanumberofmanufactur stentandcessationofthemanufactureandmarketingofcypher ingfacilitieswerefailingtomaintaincurrentgoodmanufacture andcypherselectplussirolimuselutingcoronarystentsby practicesandthatasaresultthepriceofjohnsonjohnson theendofthecompanywillfocusonothercardiovascular stockhasdeclinedsignificantlyplaintiffseekstopursueremedie therapieswheresignificantpatientneedsexist underthesecuritiesexchangeactoftorecoverhisalleged asaresultoftheabovementionedrestructuringplan economiclossesindecemberjohnsonjohnsonsmotionto announcedbycordiscorporationthecompanyrecorde dismisswasgrantedinpartanddeniedinpartplaintiffhasmove millioninrelatedpretaxchargesofwhichapproximately thecourttoreconsiderpartofthedecemberrulingdefen millionofthepretaxrestructuringchargesrequirecashpay dantsfiledanswerstotheremainingclaimsoftheamende mentsthemillionofrestructuringchargesconsistsofasset complaintinfebruary writeoffsofmillionandmillionrelatedtoleaseholdand inaprilomjpharmaceuticalsincomjprfileda contractobligationsandotherexpensesthemillionofasset lawsuitagainsttheunitedstatesinunitedstatesdistrictcourtfor writeoffsrelatetopropertyplantandequipmentofmillion thedistrictofpuertoricoallegingoverpaymentoffederalincome intangibleassetsofmillionandinventoryofmillion taxesforthetaxyearsendednovemberandnovember recordedincostofproductssoldthecordisrestructuring omjprallegesthattheinternalrevenueserviceerro programhasbeensubstantiallycomplete neouslycalculatedomjprstaxcreditsundersectionofthe thecompanyrecordedanaccrualforrestructuringinthe taxcodediscoveryisongoing fourthquarterofwhichwassubstantiallycompletedin inaugustanarbitrationpanelruledthatmitsubishi foradditionalinformationontherestructuringasitrelatesto tanabepharmacorporationtanabejanssenbiotechincsjbis thesegmentsseenote distributorofremicadeinjapancouldseektomodifythepropor tionofnetsalesrevenuethattanabemustremittojbiinexchange fordistributionrightsandcommercialsupplyofremicadethe supplypricetanabecommencedthearbitrationagainstcentocor orthobiotechincnowjbiinpursuanttothepartie distributionagreementwhichgrantstanabetherighttodistribute remicadeinjapanandcertainotherpartsofasiajbihascoun terclaimedforanincreaseinthesupplypriceahearingwasheldin novembertodeterminetheappropriatesplitofrevenueanda decisionisanticipatedinthesecondhalfof johnsonjohnsonoritssubsidiariesarealsopartiestoanum berofproceedingsbroughtunderthecomprehensiveenvironman talresponsecompensationandliabilityactcommonlyknownas superfundandcomparablestatelocalorforeignlawsinwhichthe primaryreliefsoughtisthecostofpastandorfutureremediation note consolidated financial statement reportofindependentregisteredpublicaccountingfirm totheshareholdersandboardofdirectorsofjohnsonjohnson andevaluatingthedesignandoperatingeffectivenessofinternal controlbasedontheassessedriskourauditsalsoincludedper inouropiniontheaccompanyingconsolidatedbalancesheetsand formingsuchotherproceduresasweconsiderednecessaryinthe therelatedconsolidatedstatementsofearningsstatementsof circumstanceswebelievethatourauditsprovideareasonable equityandstatementsofcashflowspresentfairlyinallmaterial basisforouropinion respectsthefinancialpositionofjohnsonjohnsonanditssub acompanysinternalcontroloverfinancialreportingisa sidiariesthecompanyatjanuaryandjanuary processdesignedtoprovidereasonableassuranceregardingthe andtheresultsoftheiroperationsandtheircashflowsforeachof reliabilityoffinancialreportingandthepreparationoffinancial thethreeyearsintheperiodendedjanuaryinconformity statementsforexternalpurposesinaccordancewithgenerally withaccountingprinciplesgenerallyacceptedintheunitedstates acceptedaccountingprinciplesacompanysinternalcontrolover ofamericaalsoinouropinionthecompanymaintainedinall financialreportingincludesthosepoliciesandproceduresthati materialrespectseffectiveinternalcontroloverfinancialreporting pertaintothemaintenanceofrecordsthatinreasonabledetail asofjanuarybasedoncriteriaestablishedininternal accuratelyandfairlyreflectthetransactionsanddispositionsofthe controlintegratedframeworkissuedbythecommitteeofspon assetsofthecompanyiiprovidereasonableassurancethattrans soringorganizationsofthetreadwaycommissioncosothe actionsarerecordedasnecessarytopermitpreparationoffinancial companysmanagementisresponsibleforthesefinancialstate statementsinaccordancewithgenerallyacceptedaccountingprin mentsformaintainingeffectiveinternalcontroloverfinancial ciplesandthatreceiptsandexpendituresofthecompanyarebeing reportingandforitsassessmentoftheeffectivenessofinternal madeonlyinaccordancewithauthorizationsofmanagementand controloverfinancialreportingincludedintheaccompanye directorsofthecompanyandiiiprovidereasonableassurance managementsreportoninternalcontroloverfinancialreport regardingpreventionortimelydetectionofunauthorizedacquisi ingourresponsibilityistoexpressopinionsonthesefinancial tionuseordispositionofthecompanysassetsthatcouldhavea statementsandonthecompanysinternalcontroloverfinancial materialeffectonthefinancialstatement reportingbasedonourintegratedauditsweconductedouraudit becauseofitsinherentlimitationsinternalcontroloverfinan inaccordancewiththestandardsofthepubliccompanyaccounte cialreportingmaynotpreventordetectmisstatementsalsopro oversightboardunitedstatesthosestandardsrequirethatwe jectionsofanyevaluationofeffectivenesstofutureperiodsare planandperformtheauditstoobtainreasonableassuranceabout subjecttotheriskthatcontrolsmaybecomeinadequatebecauseof whetherthefinancialstatementsarefreeofmaterialmisstatement changesinconditionsorthatthedegreeofcompliancewiththe andwhethereffectiveinternalcontroloverfinancialreportingwa policiesorproceduresmaydeteriorate maintainedinallmaterialrespectsourauditsofthefinancialstate mentsincludedexaminingonatestbasisevidencesupportingthe amountsanddisclosuresinthefinancialstatementsassessingthe accountingprinciplesusedandsignificantestimatesmadeby managementandevaluatingtheoverallfinancialstatementpresen tationourauditofinternalcontroloverfinancialreportingincluded obtaininganunderstandingofinternalcontroloverfinancialreport newyorknewyork ingassessingtheriskthatamaterialweaknessexistsandtesting february report independent register public accounting firmmanagementsreportoninternalcontroloverfinancialreporting undersectionofthesarbanesoxleyactofmanage establishedbythecommitteeofsponsoringorganizationsofthe mentisrequiredtoassesstheeffectivenessofthecompanysinter treadwaycommissioncosoininternalcontrolintegrate nalcontroloverfinancialreportingasoftheendofeachfiscalyear frameworkthesecriteriaareintheareasofcontrolenvironment andreportbasedonthatassessmentwhetherthecompany riskassessmentcontrolactivitiesinformationandcommunication internalcontroloverfinancialreportingiseffective andmonitoringthecompanysassessmentincludedextensive managementofthecompanyisresponsibleforestablishing documentingevaluatingandtestingthedesignandoperating andmaintainingadequateinternalcontroloverfinancialreporte effectivenessofitsinternalcontrolsoverfinancialreporte thecompanysinternalcontroloverfinancialreportingisdesigne basedonthecompanysprocessesandassessmenta toprovidereasonableassuranceastothereliabilityofthecompany describedabovemanagementhasconcludedthatasofjanuary financialreportingandthepreparationofexternalfinancialstate thecompanysinternalcontroloverfinancialreporting mentsinaccordancewithgenerallyacceptedaccountingprinciple waseffective internalcontrolsoverfinancialreportingnomatterhowwell theeffectivenessofthecompanysinternalcontrolover designedhaveinherentlimitationsthereforeinternalcontrolover financialreportingasofjanuaryhasbeenauditedby financialreportingdeterminedtobeeffectivecanprovideonly pricewaterhousecoopersllpanindependentregisteredpublic reasonableassurancewithrespecttofinancialstatementprepara accountingfirmasstatedintheirreportwhichappearsherein tionandmaynotpreventordetectallmisstatementsmoreover projectionsofanyevaluationofeffectivenesstofutureperiodsare subjecttotheriskthatcontrolsmaybecomeinadequatebecauseof changesinconditionsorthatthedegreeofcompliancewiththe policiesorproceduresmaydeteriorate thecompanysmanagementhasassessedtheeffectivenessof williamcweldon dominicjcaruso thecompanysinternalcontroloverfinancialreportingasofjanuary chairmanboardofdirector vicepresidentfinance inmakingthisassessmentthecompanyusedthecriteria andchiefexecutiveofficer andchieffinancialofficer management report internal control financial reporting summaryofoperationsandstatisticaldata dollarsinmillionsexceptpersharefigure salestocustomersus salestocustomersinternational totalsale costofproductssold sellingmarketingandadministrativeexpense researchanddevelopmentexpense purchasedinprocessresearchanddevelopment interestincome interestexpensenetofportioncapitalize otherincomeexpensenet restructure earningsbeforeprovisionfortaxesonincome provisionfortaxesonincome netearning percentofsalestocustomer dilutednetearningspershareofcommonstock percentreturnonaverageshareholdersequity percentincreasedecreaseoverpreviousyear salestocustomer dilutednetearningspershare supplementaryexpensedata costofmaterialsandservice totalemploymentcost depreciationandamortization maintenanceandrepairs totaltaxexpense supplementarybalancesheetdata propertyplantandequipmentnet additionstopropertyplantandequipment totalasset longtermdebt operatingcashflow commonstockinformation dividendspaidpershare shareholdersequitypershare marketpricepershareyearendclose averagesharesoutstandingmillionsbasic diluted employeesthousand alsoincludedincostofmaterialsandservicescategory includestaxesonincomepayrollpropertyandotherbusinesstaxe summary operation statistical datashareholderreturnperformancegraphs yearcumulative totalshareholderreturn johnson johnson spindex sppharmaceutical index sphealthcare equipmentindex yearcagr jj sp sppharm sp hc equip johnsonjohnson spindex sp pharmaceutical index sphealthcareequipmentindex yearcumulative totalshareholderreturn johnson johnson spindex sppharmaceutical index sp health care equipment index yearcagr jj sp sppharm sp hc equip johnsonjohnson spindex sppharmaceuticalindex sp healthcare equipment index shareholder return performance graph reconciliationofnongaapfinancialmeasure thetablesbelowareprovidedtoreconcilecertainfinancialdisclosuresinthelettertoshareholderspage vs vs dollarsinmillionsexceptpersharedata change change earningsbeforeprovisionfortaxesonincomeasreporte netlitigationsettlementslossgain productliabilityexpense restructuringexpense depuyasrhiprecallprogram adjustmenttothevalueofthecurrencyoptionandcostsrelatedtoplannedacquisitionofsynthesinc inprocessresearchanddevelopment earningsbeforeprovisionfortaxesonincomeasadjuste netearningsasreported netlitigationsettlementslossgain productliabilityexpense restructuringexpense depuyasrhiprecallprogram adjustmenttothevalueofthecurrencyoptionandcostsrelatedtoplannedacquisitionofsynthesinc inprocessresearchanddevelopment netearningsasadjuste dilutednetearningspershareasreported netlitigationsettlementslossgain productliabilityexpense restructuringexpense depuyasrhiprecallprogram adjustmenttothevalueofthecurrencyoptionandcostsrelatedtoplannedacquisitionofsynthesinc inprocessresearchanddevelopment dilutednetearningspershareasadjuste vs vs dollarsinmillion change change netcashflowsfromoperatingactivities additionstopropertyplantandequipment freecashflow thecompanyprovidesearningsbeforeprovisionfortaxesonincomenetearningsnetearningspersharedilutedandnetcashflow fromoperatingactivitiesonanadjustedbasisbecausemanagementbelievesthatthesemeasuresprovideusefulinformationtoinvestor amongotherthingsthesemeasuresmayassistinvestorsinevaluatingthecompanysresultsofoperationsperiodoverperiodinvarious periodsthesemeasuresmayexcludesuchitemsassignificantcostsassociatedwithacquisitionsrestructuringlitigationandchangesin applicablelawsandregulationsincludingsignificantaccountingortaxmattersthesespecialitemsmaybehighlyvariabledifficultto predictandofasizethatsometimeshassubstantialimpactonthecompanysreportedresultsofoperationsforaperiodmanagement usesthesemeasuresinternallyforplanningforecastingandevaluatingtheperformancesofthecompanysbusinessesincludingallocate resourcesandevaluatingresultsrelativetoemployeeperformancecompensationtargetsunlikeearningsbeforeprovisionfortaxeson incomenetearningsnetearningspersharedilutedandnetcashflowsfromoperatingactivitiespreparedinaccordancewithgaap adjustedearningsbeforeprovisionfortaxesonincomeadjustednetearningsadjustednetearningspersharedilutedandfreecashflow maynotbecomparablewiththecalculationofsimilarmeasuresforothercompaniesthesenongaapfinancialmeasuresarepresente solelytopermitinvestorstomorefullyunderstandhowmanagementassessestheperformanceofthecompanythelimitationsofuse thesenongaapfinancialmeasuresasperformancemeasuresarethattheyprovideaviewofthecompanysresultsofoperationswithout includingalleventsduringaperiodsuchastheeffectsofanacquisitionrestructuringlitigationandchangesinapplicablelawsand regulationsincludingsignificantaccountingortaxmattersanddonotprovideacomparableviewofthecompanysperformancetoother companiesinthehealthcareindustryinvestorsshouldconsidernongaapfinancialmeasuresinadditiontoandnotasreplacementsfor orsuperiortomeasuresoffinancialperformancepreparedinaccordancewithgaap reconciliation nongaap financial measuresprincipal office common stock johnson johnson web johnson johnson plaza list new york stock exchange company website wwwjnjcom new brunswick new jersey stock symbol jnj online annual report shareholder relation contact wwwinvestorjnjcomannualreport annual meeting douglas k chia annual meeting shareholder corporate secretary blog wwwjnjbtwcom place april hyatt regency new brunswick albany street new brunswick history blog wwwkilmerhousecom investor relation contact new jersey meeting convene louise mehrotra shareholder cordially invite attend vice president investor relation wwwfacebookcomjnj formal notice meet proxy statement proxy send shareholder jnjcomm jnjstorie jnjvideo jnjhistory corporate governance transfer agent registrar copy company annual report question stock holding wwwyoutubecomjnjhealth quarterly report form certificate replacementtransfer dividend q current report form k address change direct security exchange commission proxy computershare trust company na statement annual report available scan code royall street online wwwinvestorjnjcomsecfilingscfm smartphone view canton shareholders charge write multimedia version request secretary company report outside principal address call wwwcomputersharecom addition company corporate dividend reinvestment plan governance website wwwinvestorjnjcom plan allow partial governancematerialscfm shareholder dividend reinvestment additional monthly view company principle corporate cash investment year governance charter audit committee johnson johnson common stock compensation benefit committee brokerage commission service charge nominate corporate governance stock purchase interested committee policy business conduct participate plan need authoriza employee code business conduct tion form andor information ethic member board director computershare trust company na executive officer copy document available shareholder outside charge write request secretary company principal address hear impaired shareholder inquiry company require file exhibit stockrelate matter communicate directly fiscal year certification computershare trust company na section sarbanesoxley act telecommunications device tdd sign chief executive officer telephone number service chief financial officer addition outside company require submit certification paper publication sign chief executive officer postconsumer recycle fiber new york stock exchange day electronic delivery notification forest stewardship council certify follow annual meeting shareholder register shareholder wish receive chain custody manufacture copy certification file previous electronic notice online access future green energy credit purchase electricity year post company corporate annual report proxy material instead generate renewableenergy source governance website future certification paper copy register online wind lowimpact hydro resource post promptly file wwwcomputersharenacomgreen beneficial johnson johnson shareholders shares broker bank register online delivery material go httpenrollicsdeliverycomjnj johnson johnson annual report contain valuable trademark trade name own johnson johnson family company united states internationally distinguish product service outstanding quality johnson johnson corporate shareholder informationone johnson johnson plaza new brunswick new jersey